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Abkürzungsverzeichnis 
AA   Arachidonic acid 
ALA   α-Linolenic acid 
ANGPTL4  Angiopoietin-like 4 
BCL   B-cell lymphoma 
BRCA   Breast cancer 
CCL   CC-chemokine ligand 2 
CEFT  Peptidpool aus Cytomegalovirus, Epstein-Barr Virus, Influenza 
Virus und Tetanus Toxin 
CD   Cluster of differentiation 
C/EBP   CCAAT/Enhancer binding protein 
ChIP   Chromatin immunoprecipitation 
CPT1A  Carnitine palmitoyltransferase I 
CXCL   Chemokine (C-X-C motif) ligand 
DHA   Docosahexaenoic acid 
EAE   Experimentelle autoimmune Enzephalomyelitis 
EBI3   Epstein-barr virus induced gene 3 
ECM   Extracellular matrix 
EMSA   Elektrophoretic mobility shift assay 
ENPP2  Ectonucleotide pyrophosphatase/phosphodiesterase 2 
EPA   Eicosapentaenoic acid 
FACS   Flourescent activated cell sorting 
GM-CSF  Granulocyte-macrophage colony-stimulating factor 
H3K4me3  Trimethylation of lysine 4 on histone H3 
H3K27ac  Acetylation of lysine 27 on histone H3 
H3K27me3  Trimethylation of lysine 27 on histone H3 
HGSOC  High grade serous ovarian carcinoma 
(Serös-papilläres Zystadenokarzinom) 
ICSBP Interferon consensus sequence binding protein 
IDO  Indolamin-2,3-Dioxygenase 
IkB  Inhibitor of nuclear factor kB 
IFN   Interferon  
IFNGR   Interferon-gamma Rezeptor 
IL   Interleukin 
IPA   Ingenuity Pathway Analysis 
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IRF   Interferon regulatory factor 
ISG15   Interferon-stimulated gene 15 
JAK   Januskinase 
LA   Linolsäure, Linoleic acid 
LPA   Lysophosphatidic acid 
LC-MS/MS  Liquid chromatography–mass spectrometry/mass spectrometry 
LPS   Lipopolysaccharid 
LRP5   Low-density lipoprotein receptor-related protein 5 
LTB4   Leukotrien B4 
MCP   Monocyte chemotactic protein 
MDC   Myeloid dendritic cell 
MDM   Monocyte-derived macrophage 
MSDM   Mendelian susceptibility to mycobacterial disease 
MMP   Matrix-Metalloproteinase 
mRNA   Messenger ribonucleic acid 
NFAT   Nuclear factor of activated T-cells 
NF-κB   Nuclear factor kappa-light-chain-enhancer of activated B cells 
NK   Natürliche Killer 
NKT   Natürliche Killer-T 
PD-1   Programmed cell death protein 1 
PDK4   Pyruvat Dehydrogenase Kinase 4 
PDC   Plasmacytoid dendritic cell 
PG   Prostaglandin 
PPAR   Peroxisome proliferator-activated receptor 
PPRE   PPAR response element 
PUFA   Polyunsaturated fatty acid 
RHD   REL-homology domain 
RXR   Retinoid-X-Rezeptor 
STIC   Serous tubal intraepithelial carcinoma 
STAT   Signal transducer and activator of transcription 
TAM   Tumor-assoziierte Makrophagen 
TGF   Transforming growth factor 
TH   T-Helfer 
TLR   Toll-like Rezeptor 
TP53   Tumor Protein 53 
TNF   Tumor necrosis factor 
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TNFSF  Tumor necrosis factor superfamily 
TSS   Transcription start site 
TYK   Tyrosinkinase 
VCAM   Vascular cell adhesion molecule 
VEGF   Vascular endothelial growth factor 
WT   Wildtyp 
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1 Summary 
Since high grade serous ovarian cancer is one of the deadliest cancers in women, 
efforts to establish new therapies are of great interest. Undoubtedly, the reversion of the 
suppressive and protumorigenic functions of tumor-associated immune cells would be a 
significant therapeutic approach.  
The interactive network of tumor-associated immune cells and metastatic tumor 
cells, especially macrophages, is determined to a large extend by the secretome of the 
peritoneal fluid, which occurs at advanced stages as a malignancy-associated effusion, 
termed ascites. Published data have shown a correlation of high concentrations of IL-10, 
IL-6 or TGFb in ascites with a poor prognosis.  
In this thesis, high concentrations of polyunsaturated fatty acids, such as linoleic 
acid or arachidonic acid, were identified in the ascites as natural agonists of the lipid 
sensor PPARb/d, a member of the nuclear receptor superfamily. In tumor-associated 
macrophages, high concentrations of these fatty acids, which are stored in intracellular 
lipid droplets, result in the constitutive overexpression of PPARb/d specific target genes. 
Consistent with this finding, these cells were found to be refractory to synthetic PPARb/d 
agonists in vitro but repressible by inhibitory PPARb/d ligands. Expression of ANGPTL4, 
one of the major target genes of PPARb/d, with functions in metastasis, is associated 
with a reduced relapse free survival of the patients, underscoring the potential clinical 
significance of our results. 
In human macrophages from healthy donors, we identified two fundamentally 
different mechanisms of agonist-induced transcriptional regulation of PPARb/d target 
genes. On the one hand, there is the canonical, cell-type-independent induction of 
different target genes of lipid and glucose metabolism (including ANGPTL4) by specific 
synthetic agonists. On the other hand, a macrophage-specific inverse regulation, which 
does not require direct PPARb/d chromatin binding and mainly affects the regulation of 
immune functions, could be identified. PPARb/d agonists mainly lead to the repression 
of proinflammatory genes, which might be relevant in view of the predominantly anti-
inflammatory effect of the ascites. However, antiinflammatory genes are also repressed 
by the same ligands. This suggests the induction of a specific, hitherto not described 
polarisation state of macrophages that is regulated by PPARb/d. 
In order to gain a better understanding of the protumorigenic macrophages within 
the tumor microenvironment, the regulation of IL-12, a central cytokine responsible for 
the proinflammatory functions of macrophages, was investigated in detail. IL-12 is not 
expressed in TAMs, and is not inducible by Interferon-g (IFNg) and lipopolysaccharide in 
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ascites-treated macrophages from healthy donors. However, the observed reversibility 
of ascites-mediated suppression by subsequent ascites withdrawal or 
IFNg supplementation is potentially interesting from a therapeutical view. 
One of the major roles of IL-10 is to repress transcription of IL12B, which encodes 
for the limiting subunit of the IL-12 heterodimer. IL-10 is known to impinge on nuclear 
translocation of the NF-kB subunits c-REL and RELA/p65. Since IL12B has been 
described as an NF-kB target gene, we hypothesized that NF-kB signaling is an 
important target of ascites-mediated suppression of IL12B induction via IL-10. This 
hypothesis could not be confirmed. The ascites-mediated suppression of IL12B indeed 
coincided with a markedly reduced translocation of c-REL and p65/RELA in primary 
human macrophages in vitro. Surprisingly, however, chromatin binding by these factors 
to a newly identified upstream regulatory binding site was largely unaltered. These 
findings suggest that besides a possible role for NF-kB, other regulatory mechanisms 
play an essential role in the suppression of IL12B transcription. This conclusion is 
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Zusammenfassung 
Da das seröse Ovarialkarzinom einer der tödlichsten Tumorerkrankungen bei 
Frauen darstellt, sind neue Therapieansätze von erheblichem Interesse. Eine Reversion 
der Suppression und protumorigenen Funktionen Tumor-assoziierter Immunzellen wäre 
dabei zweifellos ein bedeutender therapeutischer Ansatz. 
Das interaktive Netzwerk aus Tumor-assoziierten Immunzellen und 
metastasierenden Tumorzellen, insbesondere Makrophagen, wird maßgeblich über das 
Sekretom des Aszites bestimmt. Publizierte Daten zeigten bereits eine Korrelation hoher 
Konzentrationen von IL-10, IL-6 oder TGFb im Aszites mit einer schlechten Prognose.  
Im Rahmen dieser Arbeit konnten mehrfach ungesättigte Fettsäuren wie 
Linolsäure oder Arachidonsäure im Aszites als natürliche Agonisten des als Lipidsensor 
fungierenden Kernrezeptors PPARb/d identifiziert werden. In Tumor-assoziierten 
Makrophagen des Aszites führen hohe Konzentrationen dieser Fettsäuren, die in 
intrazellulären Lipidtröpfchen gespeichert werden, zu einer konstitutiven Überexpression 
PPARb/d-spezifischer Zielgene. Im Einklang mit diesem Befund erwiesen sich diese 
Zellen als refraktär gegenüber synthetischen PPARb/d Agonisten in vitro, allerdings 
reprimierbar durch inhibitorische PPARb/d-Liganden. Die Expression von ANGPTL4, 
eines der wichtigsten Zielgene von PPARb/d mit Funktionen bei der Metastasierung ist 
mit einem verkürztem rezidivfreien Überleben der Patientinnen korreliert, was die 
mögliche klinische Bedeutung unserer Ergebnisse unterstreicht. 
In humanen Makrophagen gesunder Spender konnten wir zwei grundsätzlich 
unterschiedliche Mechanismen einer Agonisten-induzierten transkriptionellen 
Regulation von PPARb/d Zielgenen identifizieren. Zum einen existiert eine kanonische, 
zelltypunabhängige Induktion verschiedener Zielgene des Lipid- und 
Glukosemetabolismus (einschließlich ANGPTL4) durch spezifische synthetische 
Agonisten. Zum anderen konnte eine Makrophagen-spezifische inverse Regulation 
identifiziert werden, die keiner direkten PPARb/d-Chromatinbindung bedarf und 
hauptsächlich die Regulation von Immunfunktionen betrifft. Hierbei führen PPARb/d 
Agonisten hauptsächlich zu einer Repression proinflammatorischer Gene, was im 
Hinblick auf die vorrangig antiinflammatorische Wirkung des Aszites relevant sein 
könnte. Allerdings werden durch dieselben Liganden auch antiinflammatorische Gene 
reprimiert. Dies spricht für die Induktion eines spezifischen, bislang nicht beschriebenen 
PPARb/d-regulierten Polarisierungsstatus der Makrophagen. 
Um ein besseres Verständnis der protumorigenen Makrophagen innerhalb des 
Tumormikromilieus zu erhalten wurde die Regulation von IL-12, einem für die 
Zusammenfassung 
 
   8 
proinflammatorische Funktion von Makrophagen zentralen Zytokin, näher untersucht. IL-
12 ist in TAM nicht exprimiert und ist in Aszites-behandelten Makrophagen gesunder 
Spender nicht durch proinflammatorische Stimuli, wie Interferon-g (IFNg) und 
Lipopolysaccharid induzierbar. Andererseits könnte die beobachtete Reversibilität der 
Aszites-vermittelten Suppression durch nachfolgenden Aszitesentzug oder IFNg 
Supplementation aus therapeutischer Sicht interessant sein.  
Eine wichtige Rolle von IL-10 ist die Repression der Transkription von IL12B, das 
für die limitierende p40 Untereinheit des IL-12 Heterodimers kodiert. IL-10 hemmt 
bekanntermaßen die Kerntranslokation der NF-kB-Untereinheiten c-REL und p65/RELA. 
Da IL12B als NF-kB-Zielgen beschrieben wurde, liegt die Vermutung nahe, dass der NF-
kB-Signalweg ein zentrales Ziel der durch Aszites vermittelten, von IL-10 abhängigen 
Suppression der IL12B-Induktion ist. Diese Hypothese konnte allerdings nicht bestätigt 
werden. Die Behandlung primärer Makrophagen mit Aszites in vitro supprimierte zwar 
die Stimulus-abhängige Transkription von IL12B und ging mit einer deutlich 
verminderten Translokation von c-REL und p65/RELA einher. Überraschenderweise 
erwies sich jedoch die Chromatinbindung dieser Faktoren an eine neu identifizierte, der 
TSS vorgelagerten Bindestelle des IL12B Lokus, als weitgehend unbeeinflusst. Diese 
Befunde legen nahe, dass neben einer Rolle für NF-kB andere 
Regulationsmechanismen eine essentielle Rolle bei der Suppression der IL12B-
Transkription spielen. Diese Schlussfolgerung wird bestärkt durch den Befund, dass ein 
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2 Einleitung 
2.1 Ovarialkarzinom 
Das Ovarialkarzinom ist die Haupttodesursache aller gynäkologischen 
Erkrankungen weltweit (Parkin et al. 2005), (Lengyel 2010), (Jemal et al. 2009). Es 
betrifft meist Frauen über dem 50. Lebensjahr (Pignata et al. 2011) und beträgt je nach 
Fortschritt der Erkrankungen zum Zeitpunkt der Diagnose eine 5-Jahres-Überlebensrate 
von 17-95 % (American Cancer Society, 2017).  
Die Besonderheit des Ovarialkarzinoms, im Gegensatz zu anderen 
Tumorentitäten, liegt darin, dass sich der Tumor sehr leicht über die peritoneale 
Flüssigkeit ausbreiten kann und es somit zu einer schnellen Progression und 
Metastasierung kommt. Aufgrund der sich erst in fortgeschrittenem Stadium 
bemerkbaren Symptome, wird der Krebs in 75 % aller Fälle erst sehr spät diagnostiziert 
und die Überlebenschancen sinken auf nur 30 % (Lengyel 2010). 
Die Klassifizierung des Ovarialkarzinoms unterliegt vielfältigen Faktoren und wird 
in mehr als fünf verschieden histologische Subtypen unterteilt. Diese unterscheiden sich 
stark in der Schwere ihrer Ausprägung. Zu den prominentesten Subtypen zählen das 
Klarzellkarzinom, das endometroide Karzinom, das muzinöse Zystadenokarzinom, das 
am häufigsten diagnostizierte seröse-papilläre Zystadenokarzinom (high grade serous 
ovarian carcinoma, HGSOC) und das seröse tubare intraepitheliale Karzinom (serous 
tubal intraepithelial carcinoma, STIC). Letzteres besitzt ähnliche Eigenschaften wie das 
HGSOC und wird häufig als Vorläuferstufe des HGSOCs angesehen (Matulonis et al. 
2016).  
Nebst Punktmutationen von TP53 (in über 90% aller Fälle) und somatischen 
Mutationen von BRCA1 und BRCA2 spielt die chromosomale Instabilität im HGSOC eine 
große Rolle. In etwa der Hälfte aller Tumore besteht ein Defekt in der homologen 
Rekombination (Network 2011).  
Die Therapie des HGSOC besteht hauptsächlich in der chirurgischen Entfernung 
des Tumors mit anschließender Platin-basierter Chemotherapie (Pignata et al. 2011). 
Der Tumor wirkt zunächst sehr sensitiv gegenüber der Therapie, entwickelt jedoch eine 
zunehmende Resistenz, welche in den meisten Fällen zu einem Rezidiv der Erkrankung 
und zu einer niedrigen 5-Jahres-Überlebensrate führt (Bowtell et al. 2015). 
2.1.1 Aszites des Ovarialkarzinom 
Das Ovarialkarzinom ist gekennzeichnet durch das schnelle Wachstum und die  
Dissemination des Tumors in den Peritonealraum aufgrund der Akkumulation maligner 
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Aszitesflüssigkeit (Lengyel 2010). Unter physiologischen Bedingungen werden zwei 
Drittel der Peritonealflüssigkeit in das lymphatische System reabsorbiert (Feldman and 
Knapp 1974). Die vermehrte Ansammlung des Aszites im Ovarialkarzinom entsteht 
höchstwahrscheinlich durch die Dissemination des Tumors und der damit 
einhergehenden verstärkten Mikrovaskularisierung (Sherer, Eliakim, and Abulafia 2000). 
Aufgrund der physiologischen Strömung und Verteilung des Aszites im Peritoneum 
erfolgt die Metastasierung hauptsächlich an drei Regionen: dem großen Omentum, dem 
rechten subphrenischen Raum und dem Douglas Raum (Buy et al. 1988).  
Neben den Tumorzellen beherbergt der Aszites ein großes Reservoir an löslichen 
Faktoren, dazu zählen diverse Chemokine, Zytokine, Wachstumsfaktoren und 
Extrazelluläre Matrix (ECM) Bestandteile (Matte et al. 2012), (G. B. Mills et al. 1988), 
aber auch Phospholipide wie Lysophosphatidsäure (LPA) (Mukherjee et al. 2012) und 
dessen Derivate (Shen et al. 2001) sind in hohen Konzentrationen vorhanden. Die 
Konzentrationen verschiedener Zytokine, darunter IL-10, IL-6 (Reinartz et al. 2014) und 
Leptin (Matte et al. 2012) korrelieren mit einer schlechten Prognose der Patientinnen. 
Auch die Expression von Vascular endothelial growth factor (VEGF) korreliert mit einer 
schlechten Prognose aufgrund erhöhter Metastasierung des Tumors (Santin et al. 1999). 
Hier gibt es bereits erste Erfolge in der Therapie mittels eines humanisierten Antikörpers, 
Bevacizumab, der mittlerweile standardmäßig in der Therapie angewendet wird (Ferriss 
et al. 2015). 
Neben den löslichen Faktoren besteht der Aszites aus vielen Zellen, die dem 
Immunsystem entspringen (Worzfeld et al. 2017). Darunter befinden sich Tumor-
assoziierte CD4+ / CD8+ T-Zellen, regulatorische T-Zellen (Leffers et al. 2009), natürliche 
Killerzellen (NK-Zellen) und natürliche Killer-T-Zellen (NKT-Zellen) (Bamias et al. 2007) 
sowie Zellen monozytären Ursprungs, hauptsächlich Tumor-assoziierte Makrophagen 
(TAM) (Mantovani et al. 2002), aber auch CCL2-produzierende plasmacytoide 
dendritische Zellen (PDC) sind in geringer Anzahl vorhanden. Mittels eines anti-CCL2 
Antikörpers konnte bereits die Anzahl der regulatorischen T-Zellen, die mit einer 
schlechten Prognose korrelieren (Giuntoli et al. 2009) minimiert werden (Curiel, Coukos, 
et al. 2004). Hingegen sind IL-12 produzierende myeloide dendritische Zellen (MDC) 
nicht im Aszites vorhanden. In vivo konnte gezeigt werden, dass durch die Produktion 
von IL-12 der MDC die Angiogenese gehemmt wird. Der Aszites favorisiert demnach die 
Anwesenheit von PDC im Gegensatz zu MDC (Curiel, Cheng, et al. 2004). 
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2.2 Makrophagen  
Makrophagen werden den Zellen des angeborenen Immunsystem zugeordnet und 
entstehen aus hämatopoetischen Vorläuferzellen des Knochenmarks. Eine weitere 
Population von Makrophagen sind die Gewebsmakrophagen. Diese entstehen sehr früh 
während der Embryonalentwicklung aus Vorläuferzellen im Dottersack und sind in der 
Lage sich im Gewebe ständig selbst zu erneuern (Gomez Perdiguero et al. 2014). 
Makrophagen stellen einen divergenten, adaptiven und plastischen Zelltyp mit 
vielfältigen Funktionen in der Immunregulation, Gewebshomöostase, Wundheilung, 
allergischen und chronischen Entzündungsprozessen, der daraus bedingten 
Krankheitspathogenese und Krebs dar (Sica and Mantovani 2012), (C. D. Mills and Ley 
2014). Aus diesem Grund verliert die gängige, binäre Klassifizierung in M1 und M2 
Makrophagen, also pro- und antiinflammatorische Makrophagen zunehmend an 
Bedeutung. Makrophagen werden vielmehr in ein Netzwerk anhand ihrer Herkunft, ihrer 
Aktivatoren und Marker eingeteilt und koexistieren oft in unterschiedlichen 
Aktivierungszuständen (Murray et al. 2014), (Sica and Mantovani 2012). In vitro werden 
Makrophagen jedoch häufig in zwei Aktivierungszustände eingeteilt. Mit Hilfe der 
Zytokine Interleukin-4 (IL-4) und Interleukin-13 (IL-13) werden sie zu einem alternativen 
Aktivierungszustand und mit Lipopoysacchariden (LPS) und Interferon gamma zu einem 
starken proinflammatorischen Phänotyp polarisiert (Martinez, Helming, and Gordon 
2009), (Chanput et al. 2013). Humane Makrophagen können kein Stickstoffmonoxid als 
Mechanismus der unspezifischen Immunantwort produzieren (Gross et al. 2014). Somit 
leiten sie eine starke proinflammatorische Antwort ein, indem sie proinflammatorische 
Zytokine, wie IL-12 freisetzen und damit eine zytotoxische Antwort von NK- und T-Zellen 
auslösen (Trinchieri 1995).  
2.2.1 Tumor-assoziierte Makrophagen (TAM) 
Die Mikroumgebung solider Tumore und die damit verbundenen 
Entzündungsprozesse spielen in der Tumorigenese eine zentrale Bedeutung und sind 
Teil der „Hallmarks of cancer“ (Cavallo et al. 2011). Tumor-assoziierte Makrophagen 
dienen oft der Verbindung von Entzündungsprozessen und Kanzerogenese. Sie sind in 
der Lage die Tumorzellproliferation und Angiogenese zu steigern, fördern die 
Matrixreorganisation und reprimieren die Immunantwort. Sie stellen somit ein sehr 
interessantes therapeutisches Ziel in der Bekämpfung diverser Krebserkrankungen, 
darunter dem Ovarialkarzinom, dar (Solinas et al. 2009), (Mantovani and Locati 2013), 
(Mantovani et al. 2002). 
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Die Hauptsignalwege und Transkriptionsfaktoren, welche in Korrelation mit einem 
protumorigenen Phänotyp von TAM stehen sind NF-kB, STAT1, STAT3, STAT6, IRF3 
und C/EBPb (Antonio Sica and Bronte 2007). In TAM wird ein funktioneller STAT1/ IRF3 
Signalweg beschrieben, der zu einer hohen Expression von IL-10 im Fibrosarkom Modell 
führt (Subhra K. Biswas et al. 2006). Des Weiteren kommt es in Mäusen zu einem 
verstärkten Tumorwachstum nach Stat1 Depletion (Kaplan et al. 1998)  und einer STAT1 
vermittelten funktionellen T-Zell Antwort in TAM (Kusmartsev and Gabrilovich 2005). 
Im Ovarialkarzinom konnte gezeigt werden, dass es aufgrund einer hohen 
Expression der Zytokine IL-10 und transforming growth factor-ß (TGF-ß) oder Arginase-
1 von TAM zu einer immunsuppressiven Mikroumgebung des infiltrierenden Tumors 
kommt (Hao et al. 2012), (Santin et al. 2001). Im HGSOC nehmen Tumor-assoziierten 
Makrophagen einen gemischten Polarisierungszustand ein, bei dem die Anzahl dieser 
Makrophagen im Aszites, bzw. die hohe Expression antiinflammatorischer Marker wie 
CD163 und IL-10 negativ mit dem rückfallfreien Überleben der Patientinnen korrelieren 
(Reinartz et al. 2014). 
Jedoch wurde in weiteren eigenen Studien gezeigt, dass TAM im Ovarialkarzinoms 
ein ähnliches Transkriptom und Polarisierungsmarker wie peritoneale Makrophagen von 
Patientinnen mit benignen Erkrankungen besitzen. Der einzige Unterschied konnte in 
der Expression von Genen festgestellt werden, die die extrazelluläre Matrix und somit 
Wundheilung und Tumorigenese betreffen (Finkernagel et al. 2016).  
TAM des HGSOC können anhand der Expression einer Interferon-regulierten 
Gruppe von Genen in zwei distinkte Gruppen unterteilt werden. Die Gruppe mit 
verstärktem IFN Signaling zeigte einen deutlich verbesserten klinischen Verlauf im 
Vergleich zu einer Gruppe mit niedriger IFN-Antwort (Adhikary et al. 2017). Des Weiteren 
konnte bereits gezeigt werden, dass unter 32 Zytokinen allein IFNg in der Lage ist den 
immunsuppressiven, protumorigenen IL-12low, IL-10high Phänotyp zu revertieren (Duluc 
et al. 2009), (Adhikary et al. 2017). Zusammengefasst lässt dies vermuten, dass TAM 
antiinflammatorischen Peritonealmakrophagen ähneln, wie sie bei nicht an Tumoren 
erkrankten Patienten anzutreffen sind, und zumindest ein Teil der Population die 
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2.3 NF-kB 
NF-kB ist einer der wichtigsten Regulatoren in Immunfunktionen und 
Entzündungsprozessen. NF-kB wurde 1986 erstmals erwähnt von Sen und Baltimore, 
als k- light chain bindendes Protein in B-Zellen im Elektrophoretic-mobility-shift-Assays 
(EMSA) (Sen and Baltimore 1986). Heutzutage ist jedoch allgemein bekannt, dass die 
meisten der fünf Mitglieder der NF-kB Familie ubiquitär exprimiert werden. Zu diesen 
zählen NF-kB1 (p50), NF-kB2 (p52) und die zugehörigen Vorläuferproteine p105, bzw. 
p100, RELA (p65), c-REL und RELB (Liou and Baltimore 1993). Allen 
Familienmitgliedern gemeinsam ist eine REL-homology domain (RHD). Diese Region 
dient der Heterodimerisierung mit anderen Familienmitgliedern, der Homodimersierung, 
der Translokation in den Kern und DNA-Bindung sowie der Interaktion mit den 
inhibitorischen Proteinen, den IkBs. Darüber hinaus besitzen REL Proteine 
Transaktivierungsdomänen, die zur Transkription diverser proinflammatorischer 
Zielgenen führen können (Thanos and Maniatis 1995). 
NF-kB unterliegt nicht der Regulation durch de novo Synthese, sondern liegt als 
primärer Faktor inaktiv im Zytoplasma vor und wird nach Aktivierung aufgrund der 
Ubiquitinierung und proteasomalen Degradierung der inhibitorischen Proteine in den 
Nukleus an responsive Zielgene transportiert und bindet dort an die Konsensussequenz 
5’GGGRAYYYYY-3’ (Baeuerle 1994). 
Die IkB Familie lässt sich in zwei Gruppen einteilen. Die klassischen, 
zytoplasmatischen Mitglieder IkBa, IkBb, IkBe und die atypischen, kernständigen 
Proteine BCL-3, IkBz,  IkBNS, IkBh und IkBL (Annemann et al. 2016). Jeder dieser 
Faktoren besitzt sich wiederholende Ankyrin Elemente, diese dienen der Proteinstabilität 
der REL-Proteine und der Interaktion mit der DNA-Bindungsdomäne der NF-kB-Proteine 
und halten diese in einem transkriptionell inaktiven Zustand. p105 und p100 besitzen als 
Vorläuferproteine ebenfalls Ankyrin Elemente und sind somit eigene Inhibitoren der 
aktiven Spaltprodukte p50 und p52 (Hoesel and Schmid 2013).  
Da RELA eine hohe „Turn-over“ Rate besitzt, was als Sicherheitsmechanismus 
gegen einen Verlust des Signalweges gedeutet werden kann, besitzt NF-kB neben 
seiner Funktion in der zellulären Immunität eine entscheidende Rolle als 
Überlebensfaktor, vor allem auch in Tumorzellen. Aus diesem Grund ist ein kompletter 
Ausfall des Signalweges für die Zelle nicht von Vorteil und somit meist nicht vorhanden 
(Piva, Belardo, and Santoro 2006), (Wagner et al. 2015), (Ashall et al. 2009).  
Der NF-kB Signalweg ist auch einer der wichtigsten Signalwege während der 
Polarisierung Tumor-assoziierter Makrophagen zu einem protumorigenen Phänotyp (S. 
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K. Biswas and Lewis 2010). In vielen Tumoren wurde dieser Gruppe von 
Transkriptionsfaktoren eine entscheidende Rolle bei der Entstehung von Krebs 
zugeschrieben. Die Hauptursache scheint ein deregulierter Signalweg zu sein, (Subhra 
K. Biswas et al. 2006), der über die Überexpression des inhibitorischen p50 Proteins 
erfolgt und zu einer verminderten IL-12p40 und TNFa Expression (A. Saccani et al. 
2006) und erhöhten STAT1-Phosphorylierung führt (Subhra K. Biswas et al. 2006). Aber 
auch der konstitutive Erhalt des NF-kB Weges könnte von Bedeutung sein (Hagemann 
et al. 2008). Auch die physikalischen Interaktionen der NF-kB-Transkriptionsfaktoren 
und die Wechselwirkungen des Signalweges mit anderen Transkriptionsfaktoren wie 
STAT3 oder p53 ist von zentraler Bedeutung (Hoesel and Schmid 2013).  
Im Gegensatz dazu führt die Aktivierung des NF-kB Weges im Ovarialkarzinom 
zur Aktivierung von NK Zellen aufgrund einer erhöhten Expression von löslichem 
Interleukin-18 (Bellora et al. 2014). Eine Antitumorresponsivität und Reversibilität 
protumorigener TAM wurde erzeugt durch eine kombinierte Behandlung von CpG 
Oligonukleotiden, die eine TLR9 Antwort auslösen, und einem antagonistisch wirkenden 
anti-IL-10 Rezeptor spezifischen Antikörper (Guiducci et al. 2005). 
2.4 Interleukin 12 (IL-12) 
Schon während der Entdeckung des Zytokins IL-12 im Jahr 1989 erkannte man 
seine Besonderheit. Bis dato war es das erste und einzige Zytokin, dass als Heterodimer 
(IL-12p70), bestehend aus den zwei Untereinheiten p40 und p35, vorlag. Es wurde als 
NK-Zell-stimulierendes Protein beschrieben und führt zur IFNg Produktion durch 
Zielzellen (Kobayashi et al. 1989). Erst nach mehr als zehn Jahren wurde bekannt, dass 
IL-12 zu einer Gruppe von vier heterodimerisierenden Zytokinen gehört.  
Die IL-12 Familie besitzt eine zentrale Rolle in der Immunregulation. Neben seiner 
Funktion in der Regulation verschiedener T-Zell Populationen hat IL-12 Einfluss auf die 
Entwicklung dieser Zellen. Während IL-12 und IL-23 allgemein proinflammatorische 
Zytokine induzieren und die Entwicklung der proinflammatorischen TH1 und TH17 Zellen 
regulieren, üben IL-27 und IL-35 eher eine suppressive Funktion auf das Immunsystem 
aus indem sie die Polarisierung zu regulatorischen T-Zellen fördern (Vignali and Kuchroo 
2012). 
IL-23 besteht aus der Untereinheit p19, welche allein biologisch inaktiv ist, und der 
Untereinheit p40. IL-23 besitzt zwar strukturelle Ähnlichkeiten zu IL-12, hat aber eine 
differentielle Rolle in der Immunabwehr (McKenzie, Kastelein, and Cua 2006). IL-23 ist 
der Hauptmediator der IL-17 Produktion von Gedächtnis T-Zellen, führt allerdings nicht 
zu deren Differenzierung (Bettelli et al. 2006). Exogen überexprimiertes IL-23 führt über 
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Gedächtnis-T-Zellen zu einem anti-tumoralen Effekt, wohingegen eine endogene 
Expression von IL-23 die Tumorinzidenz und das Tumorwachstum fördert (Langowski et 
al. 2006).  
STAT3 ist in vielen Tumoren aufgrund verstärkter DNA-Bindung konstitutiv aktiv 
(Yu and Jove 2004). Über immunsuppressive Faktoren, wie IL-10, wird STAT3 aktiviert 
und führt zu einem antiinflammatorischen Effekt, indem es die Produktion 
proinflammatorischer Mediatoren wie IL-12 unterbindet, jedoch die Induktion von IL-23 
fördert. Dies funktioniert hauptsächlich über die Aktivierung von IL-23p19 durch RelA. Im 
Gegensatz dazu wird die durch c-Rel induzierte Expression von IL-12p35 in Tumor-
assoziierten dendritischen Zellen von Stat3 verhindert (Kortylewski et al. 2009).  
IL-12 wird von antigen-präsentierenden Zellen, hauptsächlich von Makrophagen 
und dendritischen Zellen aufgrund diverser Stimuli, darunter LPS und IFNg sezerniert. 
Die Signalkaskade wird von IL-12 durch dessen Bindung an Transmembranrezeptoren 
ausgeübt. Die p35 Untereinheit von IL-12 bindet an den IL-12 Rezeptor IL-12Rb2, p40 
an den IL-12Rb1. Neben der Proliferation von NK- und T-Zellen führt die Aktivierung von 
STAT4 über IL-12 zu der Generierung und Aktivierung von zytotoxischen T-Zellen. Einer 
der wichtigsten regulatorischen Signalwege der IL-12 (Sanjabi et al. 2000), (Grumont et 
al. 2001) und IL-23 (Carmody et al. 2007) Transkription ist NF-kB und im speziellen der 
Transkriptionsfaktor c-Rel (Rahim et al. 2005). Sanjabi et al konnten zeigen, dass im 
Gegensatz zu p65 knockout Mäusen c-Rel knockout Mäuse drastisch reduzierte Il12b 
mRNA und Proteinlevel aufzeigten (Sanjabi et al. 2000). Auch konnte für die Expression 
von p35 in CD8+ dendritischen Zellen die Abhängigkeit von c-Rel-Komplexen aufgezeigt 
werden (Grumont et al. 2001). Neben c-Rel gilt das Interferon-Konsensus-Sequenz-
bindende Protein (Icsbp/Irf8) als weiterer wichtiger Faktor für die Il12b Expression, da in 
Irf8 knockout Mäusen weder Il12b Transkription noch Promotoraktivität in 
Reportergenassays nachgewiesen werden konnte und dies vollständig durch ektopische 
Irf8 Expression aufgehoben wurde (Wang et al. 2000). 
Um eine maximale IL-12p70 Antwort zu erreichen werden jedoch weitere 
aktivierende Faktoren wie STAT1, IRF1 (Liu et al. 2003) und IRF8 (Wang et al. 2000) 
benötigt (Wagner et al. 2015). Über einen positiven Rückkopplungsmechanismus wird 
die IL-12 Antwort zusätzlich gesteigert. Die von IL-12 induzierte IFNg Produktion durch 
T-Zellen erhöht die Produktion von IL-12 in antigen-präsentierenden Zellen und verstärkt 
zusätzlich die TH1 Antwort (Becskei and Grusby 2007). Im Gegensatz dazu konnte 
mittels siRNA Experimenten gegen TYK2, einer Tyrosinkinase der Januskinase (JAK) 
Familie und RELB eine erhöhte IL-12 Sekretion gemessen werden (Wagner et al. 2015). 
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Die bedeutende Rolle des IFNg-Signalweges in der IL-12 Regulation zeigten auch 
Studien der „Mendelian susceptibility to Mycobacterial disease“ (MSDM). Die erhöhte 
Anfälligkeit gegenüber mykobakteriellen Infektionen konnte u.a. auf genetische Defekte 
in IFNGR1, IFNGR2, STAT1, IL12B und IL12RB1, ISG15 und IRF8 zurückgeführt 
werden (Bustamante et al. 2014).  
Neben pathogenspezifischen Stimuli, welche die IL-12 Signalkaskade aktivieren, 
gibt es auch endogene Signale wie den CD40 Liganden, die zur Aktivierung des 
Signalweges führen. CD40L alleine führt allerdings zur Induktion von IL-10. Erst in 
Kombination mit weiteren Stimuli wie GM-CSF, IL-4 und IFNg kommt es zu einer IL-12 
Induktion (Conzelmann et al. 2010). 
IL-12p70 besitzt eine herausragende Rolle in der Vernetzung des angeborenen 
und adaptiven Immunsystems. Letztendlich führt die Sekretion des Proteins zu einer TH1 
Differenzierung und zytotoxischen Aktivität von NK- und T-Zellen (Trinchieri 1995). IL-12 
spielt in der antitumoralen-Aktivität eine bedeutende Rolle. Viele Arbeiten in Maus-
Tumormodellen zeigten ein teils komplett inhibiertes Tumorwachstum nach 
peritumoraler Injektion von IL-12 in subkutane Renca Tumore (Brunda et al. 1993). In 
klinischen Studien zeigte IL-12 jedoch noch keine Erfolge aufgrund systemischer 
Toxizitäten und einer geringen Wirksamkeit, hervorgerufen durch dominantere, 
immunsuppressive Faktoren im Tumormilieu (Beyer and Schultze 2006), (Portielje et al. 
2003),  (Haicheur et al. 2000). 
IL12-p40 kann als Monomer oder Homodimer (IL-12p80) eine antagonistische 
Wirkung auf IL-12 haben und immunsuppressiv wirken, indem es kompetitiv an den IL-
12 Rezeptor bindet und so einen negativen Rückkopplungsmechanismus ausübt 
(Cooper and Khader 2007). 
Die Synthese von IL-10 und IL-12 unterliegt in vivo einem Kreislauf und 
gegenseitiger Kontrolle. Kommt es jedoch zu einem Ungleichgewicht, hat dies 
gravierende Folgen auf die Polarisierung und Reaktion von Makrophagen auf das 
Immunsystem (Segal, Dwyer, and Shevach 1998), (Xiaoyu Hu, Chakravarty, and 
Ivashkiv 2008). 
Wie bereits erwähnt inhibiert IL-10 über STAT3 die Synthese von IL-12. Dies 
erfolgt durch die Suppression von IL12B und IL12A auf transkriptioneller Ebene. Diese 
inhibitorische Aktivität von IL-10 auf die Expression von p40 kann durch Cycloheximid, 
einem Translationsinhibitor unterbunden werden. Dies trifft allerdings nicht auf p35 zu. 
Die transkriptionelle Regulation der Untereinheiten von IL-12, p35 und p40 scheint nicht 
identisch zu sein. Da der Translationsblocker in LPS oder S.aureus behandelten Zellen 
lediglich das IL12B und nicht das IL12A mRNA Level und die Transkription vollständig 
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inhibieren konnte, wird p35 vermutlich über bereits vorhandene Transkriptionsfaktoren 
reguliert, wohingegen die Regulation der IL12B Transkription einer de novo 
Proteinsynthese unterliegt (Aste-Amezaga et al. 1998).  
Auch Adenosin führt zu einer Suppression von IL-12 über A2A Rezeptor 
abhängige und unabhängige Mechanismen. In einer Studie wurde gezeigt, dass 
Adenosin zu einer verstärkten IL-10 Produktion in Maus Makrophagen führt, die 
Suppression von IL-12 hier jedoch unabhängig von IL-10 erfolgt (HASKO 2000). 
2.5 Peroxisomen-Proliferator-aktivierte Rezeptoren (PPAR) 
Makrophagen sind nicht nur zentrale Regulatoren von Immunreaktionen durch 
Sekretion proinflammatorischer Zytokine, sondern besitzen als residente Zellen eine 
sehr wichtige Rolle in der Wundheilung und im Metabolismus. In diesen alternativ 
aktivierten Makrophagen steht die Regulation der Homöostase im Vordergrund. Kang 
und Odegaard et. al beschrieben den Kernrezeptor PPARb/d als maßgeblichen 
Regulator der alternativen Aktivierung von Makrophagen in Kupffer Zellen der Leber und 
im Fettgewebe (Kang et al. 2008b), (Odegaard et al. 2008). 
Peroxisomen-Proliferator-aktivierte Rezeptoren (PPAR) sind lipidregulierte 
Kernrezeptoren und wurden ursprünglich als Regulatoren der b-Oxidation in 
Peroxisomen identifiziert (Issemann and Green 1990). PPARs umfassen drei Isoformen: 
PPARa, PPARb/d und PPARg (Desvergne and Wahli 1999). Allen gemeinsam ist ihre 
Rolle im Lipid- und Glukosemetabolismus. PPARa wird hauptsächlich in der Leber, im 
braunen Fettgewebe und Geweben mit hohem Fettsäurekatabolismus wie Herz, Niere, 
Dünndarmarm und Skelettmuskel exprimiert. PPARb/d ist ein ubiquitär exprimierter 
Faktor, gehäuft kommt er jedoch in Hirn, Gastrointestinaltrakt und Dickdarm vor (Escher 
et al. 2001), (Braissant et al. 1996). PPARg wird sowohl im Dickdarm, in der Retina, in 
den Skelettmuskeln und lymphoiden Organen als auch verstärkt in weißem und braunem 
Fettgewebe exprimiert (Rosen and Spiegelman 2001). 
PPAR bindet zusammen mit dem Heterodimerisierungspartner Retinoid-X-
Rezeptor (RXR) an die PPAR Responsiven Elemente (PPREs) in Kontrollregionen der 
entsprechenden Zielgene. Durch PPARb/d kommt es entweder zu einer Liganden-
unabhängigen Repression, zu einer Liganden-abhängigen Aktivierung bzw. 
Derepression oder zu einer Liganden-unabhängigen Aktivierung der Zielgen-
Transkription (Adhikary et al. 2011).  
Mehrfach ungesättigte Fettsäuren wie Arachidonsäure und Linolsäure wirken als 
Agonisten aller drei Subtypen. Eicosanoide wie Leukotrien B4 (LTB4) oder 8S-HETE 
sind physiologische Liganden von PPARa. Prostaglandin J2 ist ein physiologischer 
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Agonist für  PPARg (Barry M. Forman et al. 1995) und 15-HETE ist ein 
PPARb/d selektiver Agonist (Naruhn et al. 2009), (Kostadinova, Wahli, and Michalik 
2005).  
Aufgrund der Korrelation erhöhter Fettsäurewerte mit Adipositas, Diabetes, 
Arteriosklerose und Blutdochdruck, stellen PPARs einen wichtigen Regulator und auch 
therapeutisch vielversprechende Zielstrukturen in der Bekämpfung metabolischer 
Erkrankungen dar (B M Forman, Chen, and Evans 1997). 
Neben physiologischen Liganden wurden in den letzten Jahren auch selektive 
synthetische Agonisten hergestellt. Hierzu zählen Rosiglitazon und Pioglitazon, selektiv 
für PPARg, die bereits erfolgreich in der Behandlung von Diabetes Mellitus Typ 2 
eingesetzt werden. Fibrate wie Bezafibrat und Gemfibrozil für PPARa, die zur 
Behandlung von Dislipidämien verabreicht werden (Kostadinova, Wahli, and Michalik 
2005) und die selektiven Agonisten GW501516, L165,041, GW0742 und GW2433 für 
PPARb/d (Sznaidman et al. 2003), (Peraza et al. 2006), (Sen and Baltimore 1986). 
Neben dem Einsatz PPAR selektiver Liganden ist auch der Einsatz inverser 
Agonisten von therapeutischem Interesse. Inverse Agonisten führen im Vergleich zu 
Agonisten zur transkriptionellen Repression kanonischer PPAR-Zielgene. Der inverse 
PPARb/d Agonist ST247 ist hochaffin zu PPARb/d und führt zu dessen verstärkter 
Interaktion mit Korepressoren und reprimiert so die basale Expression von PPARb/d-
spezifischen Zielgenen wie ANGPTL4 (Naruhn et al. 2011). Des Weiteren vermindert er 
durch kompetetive Bindung Agonisten-induzierte transkriptionelle Aktivität. Eine 
verbesserte Bioverfügbarkeit bietet jedoch der der strukturell ähnliche inverse Agonist 
PT-S264 (Toth et al. 2016). 
2.5.1 PPARb/d als Immunmodulator 
PPARb/d besitzt neben seiner Funktion im Glukose- und Lipidmetabolismus, vor 
allem in der Fettsäureoxidation, zusätzliche Funktionen in der Karzinogenese (T. 
Adhikary et al. 2013), der Differenzierung und Apoptose und auch eine zentrale Rolle in 
der Immunregulation, indem er den inflammatorischen Status in Makrophagen 
kontrolliert (Müller 2017).  
Die proinflammatorische Rolle des Rezeptors konnte zum einen in Pparb/d 
knockout Makrophagen gezeigt werden, in denen die proinflammatorischen Zytokine IL-
1ß, MMP9 und das Chemoattraktant MCP-1 durch den spezifischen Agonisten 
GW501516 herunterreguliert werden (C.-H. Lee 2003). Auch in Psoriasis, einer 
Autoimmunerkrankung der Haut, waren PPARD mRNA und Proteinlevel drastisch erhöht 
(Westergaard et al. 2003), (Romanowska et al. 2010). 
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Auf der anderen Seite besitzt PPARb/d allerdings auch eine antiinflammatorische 
Rolle, was in mehreren Studien gezeigt werden konnte. 
In eigenen Analysen konnte ein Zusammenhang von PPARb/d und anti- bzw. 
proinflammatorischen Signalwegen wie TGFb und IL-1b gezeigt werden (Kaddatz et al. 
2010), (Stockert et al. 2013, 2011). Des Weiteren verringerten PPAR Agonisten die 
VCAM1 Expression und reduzierten drastisch die p65 Translokation in endothelialen 
Zellen (Rival et al. 2002). Auch die Aktivierung von PPARb/d in Fibroblasten führte zu 
einer Inhibition des IL-1 Signalweges (Chong et al. 2009). Die Expression von TH2 
Zytokinen wie IL-13 und IL-4 antiinflammatorischer Adipozyten führte in Kokultur über 
PPARb/d zu einer alternativen Polarisierung adipozytärer Gewebsmakrophagen (Kang 
et al. 2008a). PPARb/d Agonisten mindern außerdem die experimentelle autoimmune 
Enzephalomyelitis (EAE) im Mausmodell, indem sie die IFNg und IL-17 Produktion der 
TH1 und TH17 Zellen blockieren, IL-12 und IL-23 inhibieren und gleichzeitig die IL-4 und 
IL-10 Produktion steigern (Kanakasabai et al. 2010). 
 
2.6 Ziel der vorliegenden Arbeit  
Bis zum heutigen Zeitpunkt ist die Rolle löslicher Mediatoren der 
Tumormikroumgebung bei der Immunsuppression und pro-tumorigenen Polarisierung 
von Tumor-assoziierten Makrophagen im menschlichen Ovarialkarzinom nur 
ansatzweise verstanden. Besonders proinflammatorische Signalwege wie der NF-kB 
Signalweg werden kontrovers in diesem Zusammenhang diskutiert. 
Ziel der vorliegenden Arbeit war es den Einfluss spezifischer Faktoren des Aszites 
auf zwei zentrale Transkriptionsfaktoren zu untersuchen, und zwar den lipidresponsiven 
Kernrezeptor PPARβ/δ sowie den zytokinregulierten Transkriptionsfaktor NF-kB. Dabei 
sollten auch die Regulation von Immunfunktionen durch PPARβ/δ sowie die Rolle von 
spezifischen Mitgliedern der NF-kB-Familie bei der Regulation von IL-12, ein für die 
Funktion inflammatorischer Makrophagen zentrales Zytokin, näher untersucht werden. 
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3 Ergebnisse 
3.1 Deregulation of PPARβ/δ target genes in tumor-associated 
macrophages by fatty acid ligands in the ovarian cancer 
microenvironment 
Tim Schumann*, Till Adhikary*, Annika Wortmann *, Florian Finkernagel, Sonja 
Lieber, Evelyn Schnitzer, Nathalie Legrand, Yvonne Schober, W. Andreas Nockher,  
Philipp M. Toth, Wibke E. Diederich, Andrea Nist, Thorsten Stiewe, Uwe Wagner,  
Silke Reinartz, Sabine Müller-Brüsselbach and Rolf Müller (2015) Oncotarget 6(15):  
13416-33 
* These authors contributed equally to the paper as first authors. 
 
Eine der häufigsten Begleiterscheinungen des Ovarialkarzinoms ist ein maligner 
Aszites, der neben Tumorzellen und antiinflammatorischen Mediatoren eine große 
Anzahl an Immunzellen, insbesondere Tumor-assoziierte Makrophagen beinhaltet. Eine 
hohe Anzahl an Tumor-assoziierten Makrophagen korreliert mit einer schlechten 
Überlebensprognose der Patientinnen. Aufgrund sezernierter Chemokine, Zytokine und 
weiterer antiinflammatorischer Mediatoren besitzt dieser Zelltyp eine hohe Plastizität und 
einen gemischten pro- als auch antiinflammatorischen Phänotyp.   
In dieser Publikation konnte nach Lipidomanalysen gezeigt werden, dass sich im 
Aszites eine Reihe mehrfach ungesättigter Fettsäuren befinden. Diese Lipide, 
vorangestellt Linolsäure, wirken als physiologische Liganden für den 
Transkriptionsfaktor PPARβ/δ, ein Typ II Kernrezeptor, der neben wichtigen Aufgaben 
im Fettsäuremetabolismus maßgeblich an der Makrophagenpolarisation beteiligt ist. 
 
Tumor-assoziierte Makrophagen besitzen einen divergenten, eher 
antiinflammatorischen Phänotyp, mit einer hohen Expression des scavenger rezeptor 
CD163 und einer niedrigen Expression der Matrixmetalloprotease MMP9 (Abbildung 
1A). Mikroskopisch auffällig ist, dass dieser Phänotyp einem durch einen synthetischen 
Agonisten (L165,041) für PPARβ/δ induzierbaren Phänotyp in Makrophagen gleicht und 
nicht durch zusätzliche Gabe des synthetischen Liganden L165,041 verändert wird 
(Abbildung 1B). 
Als in vitro Modellsystem zur Aufklärung der Ligandenfunktion in TAM eignen sich 
hervorragend Monozyten-abgeleitete Makrophagen (MDM), da sie eine vergleichbar 
hohe messbare DNA-Bindung von PPARβ/δ und seinem Heterodimerisierungspartner 
RXR an den genomischen PDK4 Enhancer Bereich besitzen. Im Gegensatz dazu 
besitzen frisch isolierte Monozyten eine deutlich reduzierte Anwesenheit von PPARβ/δ 
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und RXR an dieser Region und wurden demzufolge als Modellsystem ausgeschlossen 
(Abbildung 2A). Im Einklang hiermit war die geringe Expression von PPARD in 
Monozyten. 
Zur globalen Analyse der Liganden-abhängigen Effekte von PPARβ/δ in 
Makrophagen oder Tumor-assoziierten Makrophagen wurden genomweite Studien 
mittels RNA Sequenzierung durchgeführt. Es konnten direkte, durch Agonisten 
induzierte oder durch inverse Agonisten reprimierte Zielgene in MDM als auch in Aszites 
kultivierten TAM identifiziert werden. Hierbei zeigte sich erneut, dass TAM im Vergleich 
zu MDM nicht responsiv auf synthetische Agonisten sind. Des Weiteren wurde in TAM 
eine größere Anzahl an Genen gefunden, die durch inverse Agonisten reprimiert werden. 
Diese Ergebnisse verdeutlichten, dass der Aszites vermutlich hohe Spiegel an 
physiologischen PPARβ/δ Agonisten beinhaltet (Abbildung 2B, C). Auch ChIP 
Sequenzierungsdaten unterstützten diese Erkenntnis, da es eine große 
Übereinstimmung der Bindungsstellen von PPARβ/δ und RXR in MDM und in Aszites 
kultivierten TAM gab (Abbildung 2E, F). Somit scheint die erhöhte Expression direkter 
PPARβ/δ-Zielgene in TAM nicht durch veränderte DNA-Bindung des Rezeptors 
verursacht zu sein. Um zu überprüfen, ob der Verlust der Ligandenregulation in TAM 
durch Aszites stabil ist, wurden TAM in herkömmlichem Medium kultiviert und der 
Ligandeneffekt analysiert. Hierbei zeigte sich, dass es lediglich zu einer gering 
gesteigerten Induktion kanonischer Zielgene von PPARβ/δ (PDK4 und ANGPTL4) in 
TAM kam. Somit veranlasst der Aszites eine sehr stabile Veränderung der Makrophagen 
im Hinblick auf die Responsivität synthetischer PPARβ/δ Liganden (Abbildung 2D).  
Etwa die Hälfte aller induzierten Gene in kultivierten TAM zeigten auch eine 
erhöhte und durch Agonisten unbeeinflussbare Expression in ex vivo TAM (Abbildung 
3A, B, C). Diese Deregulation betraf unter anderem die Expression der kanonischen 
PPARβ/δ Zielgene PDK4, ANGPTL4 und CPT1A (Abbildung 3D) und die 
Proteinexpression von PDK4 (Abbildung 3E). ANGPTL4 ist in diesem Zusammenhang 
besonders hervorzuheben, da dessen Expression mit einer schlechten Prognose der 
Patientinnen mit HGSOC korreliert (Abbildung 3F, G) und es eine zentrale Rolle während 
der Metastasierung und Invasion spielt. 
Weitere Funktionen der induzierten Transkripte in ex vivo TAM konnten mittels IPA 
(Ingenuity Pathway Analysis) überwiegend dem Glukose- und Lipidmetabolismus, 
Entzündungsfunktionen, Zellmigration als auch dem Überleben zugeordnet werden 
(Abbildung 4A). Deren wichtigste identifizierte Regulatoren sind die PPAR Liganden 
Bezafibrat, Eicosapentaensäure (EPA), Lipopolysaccharide (LPS), Rosiglitazon und 
Pirinixinsäure (Abbildung 4B). 
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Zur Verifizierung der Aszites vermittelten Deregulation von PPARβ/δ Zielgenen in 
TAM wurden MDM gesunder Spender in Aszites kultiviert und die Expression mehrerer 
PPARβ/δ Zielgene untersucht. Die in Abbildung 5A und 5B dargestellten Gene zeigten 
eine deutlich erhöhte Expression nach Aszitesbehandlung (ähnlich der Induktion durch 
L165,041) im Vergleich zur Kontrollgruppe. Auch hatte die zusätzliche Stimulation mit 
L165,041 im Aszites keinen Einfluss mehr (Abbildung 5B).  
Um zu zeigen, dass die Deregulation der Zielgene im Aszites vornehmlich 
PPARβ/δ vermittelt ist, wurden Luziferase-Reportergenassays am PDK4 Enhancer 
durchgeführt, die der Kontrolle von mutierten oder funktionsfähigen PPREs unterliegen. 
Hierbei zeigte sich, dass die durch Aszites induzierte Luziferaseaktiviät bei mutierten 
PPREs deutlich vermindert wurde, wohingegen der Aszites bei den Wildtyp-PPRE-
Sequenzen eine sehr starke Reportergenaktivität verursachte (Abbildung 5C).  
Nicht nur in humanen Makrophagen, sondern auch in Maus-
Knochenmarksmakrophagen konnte eine Aszites vermittelte Deregulation der Pparβ/δ 
Zielgene Pdk4 und Angptl4 nachgewiesen werden. In Mäusen mit Pparβ/δ knockout kam 
es zu einem Verlust dieser Regulation (Abbildung 5D).  
Alle bisher bekannten PPARβ/δ Agonisten sind Fettsäuren oder Fettsäurederivate. 
Da diese in Makrophagen in intrazelluläre Lipidtröpfchen eingelagert werden und auch 
noch mehrere Tage nach Wegnahme des Aszites oder der gesondert zugeführten 
mehrfach ungesättigten Fettsäuren (PUFAs) noch nachweisbar sind, scheint die 
Deregulation in Makrophagen sehr stabil zu sein (Abbildung 7A-F). Zur genaueren 
Identifikation der Fettsäuren im Aszites wurden Lipidomanalysen mittels LC-MS/MS 
durchgeführt. Die gemessene Fettsäure mit der höchsten Konzentration ist Linolsäure 
(LA), gefolgt von Arachidonsäure (AA), Docosahexaensäure (DHA) und 
Eicosapentaensäure (EPA). Bis auf EPA und alpha-Linolensäure (ALA) führte jede 
dieser Fettsäuren zu einer starken Induktion von PDK4 in humanen Makrophagen in vitro 
(Abbildung 6A, B). Sowohl LA als auch dessen konjugierte Formen konnten bereits 
innerhalb einer dreistündigen Behandlung dosisabhängig PDK4 in MDM induzieren 
(Abbildung 6C). LA induzierte mehrere PPARβ/δ spezifische Zielgene ähnlich stark wie 
der synthetische Agonist L165,041 und dies lässt sich durch inverse PPARβ/δ Agonisten 
wie PT-S264 kompetitiv verhindern (Abbildung 6E), was möglicherweise Hinweise auf 






   23 
Der Eigenanteil zur Erstellung dieser Publikation umfasst die Beteiligung an Versuchsplanung, 
Durchführung und Datenanalyse zu Abbildung 1A, 2A, D-F, Abbildung 3D, 5A, B, Abbildung 6C, 
E, Abbildung 7C, Abbildung S3, S4, Tabelle S1  
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ChIP Sequenzierung wurden durchgeführt von Andrea Nist und Thorsten Stiewe aus der 
Genomics Core Facility. Patientenproben wurden zur Verfügung gestellt von Uwe 
Wagner und Silke Reinartz, Klinik für Gynäkologie, Gynäkol. Onkologie und 
Endokrinologie.  
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3.2 The transcriptional PPARβ/δ network in human macrophages 
defines a unique agonist-induced activation state 
Till Adhikary*, Annika Wortmann *, Tim Schumann*, Florian Finkernagel*, Sonja 
Lieber, Katrin Roth, Phil ipp M. Toth, Wibke E. Diederich, Andrea Nist, Thorsten 
Stiewe, Lara Kleinesudeik, Silke Reinartz, Sabine Müller-Brüsselbach and Rolf  
Müller (2015) Nucleic Acids Research. 43(10): 5033–5051 
* These authors contributed equally to the paper as first authors. 
 
Die Rolle von PPARβ/δ in der Immunregulation ist bis zum heutigen Stand der 
Forschung noch weitgehend ungeklärt. Bereits bekannt ist jedoch, dass PPARβ/δ 
spezifische Agonisten eine antiinflammatorische Immunantwort in Makrophagen 
auslösen können (Daniel S. Straus and Glass 2007). Im Gegensatz dazu führt die 
Überexpression von PPARβ/δ in der Epidermis zur Psoriasis und erfüllt somit eine 
proinflammatorische Funktion (Westergaard et al. 2003), (Romanowska et al. 2010).  
In dieser hier dargestellten Publikation konnten erstmals immunregulatorische 
Gene identifiziert werden, die durch PPARβ/δ selektive Agonisten über einen nicht-
kanonischen Weg reprimiert werden. Demhingegen konnte auch eine durch Liganden 
geförderte Regulation proinflammatorischer Gene beobachtet werden. Daraus lässt sich 
ein besonderer Liganden-gesteuerter Phänotyp humaner Makrophagen postulieren. 
 
Zur Untersuchung PPARβ/δ Liganden-abhängiger Effekte wurden von humanen 
Monozyten abgeleitete Makrophagen gesunder Spender verwendet, die sowohl eine gut 
messbare PPARD Genexpression, als auch PPARβ/δ Proteinlevel besitzen (Abbildung 
1 A, B, Abbildung S1). In diesen Zellen ist die Ligandenregulation, messbar an der 
PPARβ/δ Zielgenexpression von PDK4 (Abbildung 1C), gut sichtbar. Die 
Chromatinbindung von PPARβ/δ und dem Heterodimerisierungspartner RXR an der 
PDK4 Enhancer Region (Abbildung S2) legt nahe, dass die Induktion abhängig von 
direkter DNA-Bindung des Heterodimers ist.   
Um eine genauere Einsicht in das durch PPARβ/δ Liganden regulierte 
Transkriptom und Cistrom zu bekommen wurden genomweite Studien mittels RNA und 
ChIP Sequenzierung in humanen Makrophagen durchgeführt. Im Transkriptom zeigten 
sich neben den kanonischen, durch den Agonisten L165,041 induzierte und inverse 
Agonisten reprimierte Gene (Abbildung 2A) auch eine große Anzahl an invers regulierten 
Genen, die durch Agonisten reprimiert und durch inverse Agonisten induziert werden 
(Abbildung 2B). Nach IPA Diseases and Functions Annotation Analyse konnten die 
durch Agonisten induzierten Gene hauptsächlich der Inhibition des Zelltodes von 
Immunzellen und der Suppression von Immunzellfunktionen zugeordnet werden. 
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Allerdings gab es auch eine Gruppe von Genen die durch L165,041 induziert wurden 
und maßgeblich an der Entstehung von Entzündungsfunktionen wie der Colitis beteiligt 
sind (Abbildung 2C). Durch die Analyse der Upstream Regulatoren mittels IPA konnten 
zwei durch L165,041 regulierte Klassen unterschieden werden. Zum einen werden 
kanonische Zielgene durch bereits bekannte Regulatoren des Lipidmetabolismus wie 
Pirinixinsäure und Rosiglitazon induziert, zum anderen werden allerdings auch nicht 
kanonische Zielgene von Immunmodulatoren wie TLR4, LPS, TNF, IFNG, IL1B, IL4, und 
STAT3 reprimiert (Abbildung 2E).  
Um auszuschließen, dass die inverse Regulation aus einem off target Effekt 
resultiert, wurden Knochenmarksmakrophagen (BMDM) von Wildtyp (WT) und Pparβ/δ 
knockout Mäusen mit dem PPARβ/δ Agonisten GW501516 behandelt. Die kanonischen 
Zielgene Angptl4 und Pdk4 wurden lediglich in WT-Mäusen durch den Agonisten 
induziert. Auch die inversen Zielgene Ccl24, Tnfsf15 und Serpinb2 wurden nur in WT-
Mäusen durch den Agonisten reprimiert. Zwei weitere Gene (Ccl8 und Enpp2) die einer 
inversen Regulation in humanen Makrophagen unterlagen, wurden in diesem System 
nicht durch den Agonisten reguliert, was mutmaßlich an der differentiellen Regulation in 
Maus und Mensch liegt.  
ChIP-Seq Analysen in humanen Makrophagen zeigten eine Anreicherung von 
PPARβ/δ und RXR an 3372 Regionen innerhalb des Genoms. 130 mit diesen 
genomischen Regionen assoziierte Transkripte unterliegen der Regulation durch 
L165,041. Die Bindung von PPARβ/δ und RXR erfolgte an annotierten 
Transkriptionsstarts, innerhalb von Introns oder vorgelagerten Bereichen (Abbildung 3A-
C). Die Funktionen dieser kanonisch regulierten Gene liegen hauptsächlich im 
Lipidmetabolismus, der Zellmigration, aber auch in der Immunregulation (Abbildung 3E, 
Abbildung S4, Tabelle 1, Abbildung S6).  
Im Gegensatz zur direkten Bindung von PPARβ/δ und RXR an den kanonischen 
Zielgenen konnte in den nicht kanonisch durch L165,041 reprimierten Genen lediglich 
eine sehr schwache Bindung von PPARβ/δ und RXR an den entsprechenden Loci 
nachgewiesen werden (Abbildung 4A, B).  
Die Hauptregulatoren dieser inversen Zielgene sind Modulatoren 
proinflammatorischer Zytokin-Signalwege (Abbildung 4C, Tabelle 1). Einige dieser Gene 
werden durch STAT1, STAT3, NF-kB, BCL6 und p300 reguliert (Abbildung 4D). Einen 
weiteren Hinweis für eine Rolle des NF-kB Weges gab einer Behandlung von 
Makrophagen mit dem Proteasominhibitor MG132 in Kombination mit L165,041. MG132 
hemmt den Abbau der inhibitorischen Faktoren des NF-kB Weges, der IkBs. Bei 
gleichzeitiger Behandlung mit L165,041 wurde die invers regulierte Repression der 
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Gene, bis auf IL8, teilweise aufgehoben. Da die Repression jedoch nicht vollständig 
aufgehoben wird, sind höchstwahrscheinlich noch andere Signalwege an dieser 
Regulation beteiligt (Abbildung 4E). 
Morphologisch betrachtet ähneln L165,041-differenzierte Makrophagen sehr stark 
einem IL-4 erzeugten, M2 polarisiertem Phänotyp. Die Funktion dieses Phänotyps 
entspricht auch einer verminderten Phagozytoserate der mit L165,041 behandelten 
Makrophagen (Abbildung 6F). Entgegengesetzt entsprechen in Gegenwart von LPS und 
IFNg differenzierte, M1-artige Makrophagen eher einem morphologischen Phänotyp der 
durch inverse Agonisten wie PT-S264 induziert wird (Abbildung 6, Abbildung S5).  
Funktionelle Netzwerk-Analysen wie in Abbildung 5 dargestellt zeigen zum einen 
eine Reihe durch Liganden reprimierte Immunfunktionen aber auch einige Liganden 
erzeugten proinflammatorische Eigenschaften. Zum Beispiel kommt es zu einer 
gesteigerten T-Zellaktivität, gemessen an IFNg produzierenden CD8+ T-Zellen nach 
Kokultur L165,041-differenzierter MDM, die zuvor einem CEFT Peptidpool ausgesetzt 
wurden (Abbildung 7A).  
IDO1 als geschwindigkeitsbestimmendes Enzym im Aminosäureabbau von 
Tryptophan zu Kynurenin wurde als inverses Zielgen identifiziert. Eine erhöhte IDO 
Aktivität führt generell zur Suppression der T-Zell Aktivität. L165,041 führt jedoch in 
Makrophagen zu einer verminderten IDO Expression, IDO Proteinlevel und 
Kynureninlevel und somit generell zu einer proinflammatorischen Antwort (Abbildung 7B-
D, Abbildung S7). In diesem Fall reichte die verminderte Kynureninkonzentration 
dennoch aus um die T-Zell-Aktivierung zu vermindern. Auch die Expression des PD-1 
Liganden (CD274) und des Fcg-Rezeptors FCGR2B (CD32B) wurden deutlich durch 
L165,041 reprimiert (Abbildung 7F-H).  
Zur Übertragung der gewonnen Erkenntnisse über die inverse Regulation durch 
L165,041 auf andere Zelltypen wurden zunächst die Trankriptom und Cistrom Daten mit  
denen der Myofibroblastenzelllinie WPMY-1 und der Brustzellkrebszellinie  MDA-MB231 
verglichen. Es kam zur Übereinstimmung von 129 regulierten Genen in allen drei 
Zelltypen, die hauptsächlich im Intermediärstoffwechsel zu finden sind (Abbildung 9A). 
Allerdings kam es zu keiner Übereinstimmung der invers regulierten Gene (Abbildung 
9B). Auch sind diese Zellen refraktär gegenüber der Regulation von CD52 und LRP5, 
die in Makrophagen durch L165,041 induziert werden (Abbildung 9C, Abbildung S4). 
Somit gibt es zusammengefasst eine kanonische Regulation bestimmter Transkripte die 
zelltypunabhängig oder Makrophagen spezifisch ist und eine Makrophagen selektive 
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Der Eigenanteil zur Erstellung dieser Publikation umfasst die Beteiligung an Versuchsplanung, 
Durchführung und Datenanalyse zu Abbildung 3A-C, Abbildung 4A, B, E, Abbildung 7D, 
Abbildung 9C, Abbildung S2, Abbildung S4, Abbildung S6 
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3.3 Chromatin Binding of c-REL and p65 Is Not Limiting for 
Macrophage IL12B Transcription During Immediate 
Suppression by Ovarian Carcinoma Ascites  
Annika Unger, Florian Finkernagel, Nathalie Hoffmann, Felix Neuhaus, Barbara 
Joos, Andrea Nist, Thorsten Stiewe, Alexander Visekruna, Uwe Wagner, Silke 
Reinartz, Sabine Müller-Brüsselbach, Rolf Müller and Till Adhikary (2018), Front.  
Immunol. 9:1425. doi: 10.3389/fimmu.2018.01425 
  
 
IL12p40, kodiert durch IL12B, ist der limitierende Faktor für funktionelles IL-12 und 
einer proinflammatorischen Immunantwort. Tumor-assoziierte Makrophagen des 
Ovarialkarzinoms sind refraktär gegenüber proinflammatorische Stimuli (Gordon and 
Freedman 2006) und sezernieren p40 nach Stimulation mit LPS und IFNg nicht oder nur 
in geringen Mengen (Finkernagel et al. 2016). Sowohl das Verständnis über die 
Mechanismen der IL12B Suppression, als auch die Reversibilität dieses Zustandes sind 
für therapeutische Ansatzpunkte maßgeblich und sind somit von höchster Priorität in der 
Aufklärung immunsuppressiver Mechanismus im Ovarialkarzinom.  
 
In dieser Arbeit wurde zunächst der ex vivo Zustand von Tumor-assoziierten 
Makrophagen des Ovarialkarzinoms in Bezug auf die Fähigkeit der IL12B Expression 
untersucht. Es konnte keine IL12B mRNA (Abbildung 1A) und auch kein Protein 
(Abbildung 1B) detektiert werden. Nach zwei Tagen Kultivierung in Aszites, mit 
zusätzlicher IFNg Supplementation oder normalem Kulturmedium (R5) konnte in einem 
Teil der Spenderinnen der supprimierende Effekt signifikant aufgehoben werden 
(Abbildung 1A). Dies zeigt, dass TAM potentiell reaktivierbar sind und IL12B induzieren 
können. Höchstwahrscheinlich sind lösliche Faktoren im Aszites für die Suppression 
verantwortlich. 
Um herauszufinden, welcher lösliche Faktor des Aszites die IL-12 Suppression in 
Makrophagen hervorruft, wurde aufgrund vieler Hinweise in der Literatur der Einfluss von 
IL-10 untersucht (Segal, Dwyer, and Shevach 1998), (Xiaoyu Hu, Chakravarty, and 
Ivashkiv 2008). IL-10 führte zu einer Reduktion der im Überstand gemessenen IL12p40 
Konzentrationen um ca. 50 % (von 10 auf 5 ng/ml, Abbildung 7B), konnte jedoch nicht 
den Effekt des Aszites einer vollständigen Suppression von IL12p40 erreichen (Inhibition 
um mehr als 80 % Abbildung 2B). 
In weiteren Versuchen ließ sich klären ob der Aszites über Kurzzeitmechanismen 
die Suppression hervorruft oder ob die Differenzierung der Zellen eine Rolle spielt. 
Erstaunlicherweise reicht eine kurze Exposition der MDM gegenüber dem Aszites aus 
um eine vollständige Suppression von IL-12 zu erreichen (Abbildung 2B). Dieser Effekt 
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ist auf RNA-Ebene durch eine Depletion des Aszites und Ersetzen durch normales 
Kulturmedium (+ 1 d R5) wieder reversibel (Abbildung 2A). Der Effekt lässt sich auf 
Proteinebene nur partiell erkennen und ist aufgrund der Spenderdiversität sehr variabel 
und nicht signifikant (Abbildung 2B). Die durch Langzeitexposition des Aszites 
vermittelte Suppression führt in einem Teil der Spender zu einer verbesserten IL12B 
Expression und Sekretion nach Aszitesdepletion für einen längeren Zeitraum (Abbildung 
2C, D).  
Da die TAM einiger Patientinnen durch Stimulation mit IFNg im Aszites die 
Fähigkeit besitzen IL12B zu induzieren (5 von 8 TAM Proben, Abbildung 1A, B), stellte 
sich die Frage ob eine Veränderung ihrer Polarisation für diesen Zustand verantwortlich 
ist. Umgekehrt stellte sich die Frage ob die Veränderung des Phänotyps, bzw. die 
Expression verschiedener makrophagenspezifischer Marker erheblich für die IL12B 
Suppression ist. In Abbildung S3 sind FACS Messungen der Makrophagenmarker 
CD163 (Abbildung S3A) und CD206 (Abbildung S3B) dargestellt, die sehr stark in 
antiinflammatorischen Makrophagen exprimiert sind. Generell ist der Aszites 
verantwortlich für die hohe Expression dieser Marker in gesunden Spendermakrophagen 
nach Differenzierung. Allerdings ändert sich die Expression von CD163 nur geringfügig 
in Gegenwart von Aszites und IFNg-differenzierten Zellen, bzw. erhöht sich die 
Expression nicht maßgeblich nach kurzer Aszites Exposition. Dies bedeutet, dass die 
Reinduzierbarkeit von IL12B keine Reduktion der antiinflammatorischen Marker, bzw. 
die Suppression von IL-12 durch den Aszites keine Induktion von CD163 bedingt. 
Aufgrund der aktuellen Literaturlage, die den NF-kB Weg, speziell c-REL als 
maßgeblichen Regulator der IL12B Induktion beschreibt, untersuchten wir die 
Involvierung des NF-kB Weges in unserem experimentellen System der Aszites 
induzierten IL-12 Suppression.  
Die Translokation von c-REL und RELA in Aszites differenzierten Zellen war in 
einem Großteil der Spenderinnen komplett inhibiert, da sehr geringe bis keine 
detektierbaren nukleären Proteinkonzentrationen gemessen wurden (Abbildung 3A, C). 
Auch in Zellen, die nur für einen Tag mit Aszites kultiviert wurden ist die Translokation 
deutlich verringert (Abbildung 3B, D). Diese ist nach Aszites Wegnahme im Vergleich 
zur Langzeitexposition jedoch teils revertierbar (vergleiche A/C mit B/D).  
Aufgrund dieser Ergebnisse untersuchten wir die Funktionalität der 
zytoplasmatischen NF-kB Inhibitoren, IkBa, IkBb und IkBe. Entgegen der Annahme 
einer Stabilität dieser Faktoren welche die reduzierte Translokation verursacht, konnte 
man einen funktionellen Abbau von IkBb und IkBe im Aszites feststellen (Abbildung S4A, 
S5B, C). IkBa unterliegt generell einer schnelleren Abbau-Kinetik und ist zu dem 
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betrachteten Zeitpunkt in Medium-differenzierten Makrophagen durch positive 
Rückkopplung stärker exprimiert (Abbildung S4A, S5A).  
Um zu überprüfen, ob der Aszites neben IL12B auch noch andere NF-kB Zielgene 
supprimiert, wurde die Induktion von CXCL10 nach Aszites-Differenzierung oder 
Kurzzeitbehandlung untersucht. Erstaunlicherweise verursachte der Aszites keine 
Suppression des c-REL Zielgens CXCL10 (Abbildung S6A, B).  
Um einen genaueren Einblick in die Aszites-vermittelte Regulation der REL und 
p65 induzierten Zielgene zu gewinnen wurden ChIP Experimente durchgeführt. 
ChIP Sequenzierungen in ex vivo TAM gaben Hinweise auf regulatorische 
Bereiche des IL12B Lokus. Ein Enhancer mark, Histon H3 Lysin4 Monomethylierung 
(H3K4me1) wurde an vier Regionen innerhalb eines 25 kbp großen Abschnitts des IL12B 
Lokus detektiert (Abbildung 4A). 1200 bp stromaufwärts der Transkriptionsstartstelle 
(TSS) befindet sich ein Element mit an Lysin 4 trimethyliertem Histon H3 (H3K4me3), 
welches im Allgemeinen direkt an TSSs gefunden wird (Abbildung 4A, B). Etwa 20 kbp 
stromabwäts des annotierten TSS konnte eine H3K27me3-markierte Region gefunden 
werden (Abbildung 4A, D), die auf die Anwesenheit repressiver Faktoren wie dem 
Polycomb repressive complex 2 deutet. Die Besonderheit der H3K4me3 Marks an einer 
der TSS vorgelagerten Region, nicht aber an der TSS selbst, zeigte sich auch in anderen 
c-REL Zielgenen, wie CXCL10 und IL-2 (Abbildung S9).  
Da die Sequenzierungsdaten zwei eigentlich konträre Marks (H3K4me3 und 
H3K27me3) an einem Lokus zeigen, kann man die Besonderheit einer stabilen 
Repression und gleichzeitig schnellen Aktivierungsmöglichkeit dieser 
proinflammatorischen Gene vermuten.  
Im weiteren Schritt sollte herausgefunden werden, ob der Aszites einen Einfluss 
auf die Chromatin-Bindung der NF-kB Transkriptionsfaktoren hat. Es wurde gezeigt, 
dass Aszites-differenzierte Zellen eine verminderte durch LPS/IFNg induzierte Bindung 
von REL und RELA ausschließlich am vorgelagerten TSS (-1200 bp) von IL12B 
aufweisen (Abbildung 5A). Kurzzeit-Aszites behandelte Makrophagen (R5 differentiation 
+ 1 d ascites) wiesen jedoch kein deutlich verändertes Anreicherungsmuster im 
Vergleich zu den Kontrollzellen auf, und die Bindung der beiden Transkriptionsfaktoren 
an zwei regulatorische Bereiche des CXCL10-Lokus war in keiner der Zellpopulationen 
nach Stimulation verändert (Abbildung 7D, E). Auch konnten keine wesentlichen 
Histonmodifikations- Unterschiede innerhalb dieser drei unterschiedlich differenzierten, 
bzw. behandelten Makrophagengruppen am IL12B (Abbildung 4E-G) oder am CXCL10 
Lokus (Abbildung S9 C, D) festgestellt werden. Dies zeigte, dass trotz verminderter 
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Translokation der beiden Faktoren, eine ausreichende und funktionelle DNA-Bindung 
von REL und p65 vorhanden war. 
Die Vermutung, dass c-REL zwar an der Regulation von IL12B beteiligt ist, aber 
nicht ausschließlich für die Induktion verantwortlich ist zeigte sich auch in siRNA 
Versuchen in humanen Makrophagen und knockout Zellen in BMDM. Trotz verminderter 
c-REL oder RELA Proteinkonzentration oder einem kompletten Verlust von c-Rel in 
knockout Mäusen, kam es lediglich zu einer reduzierten IL12B oder p40 Induktion 
(Abbildung 6A, B, S7).  
 
Der Eigenanteil zur Erstellung dieser Publikation umfasst die Beteiligung an Versuchsplanung, 
Durchführung und Datenanalyse zu Abbildung 1, 2, 3, 4E-G, 5, Abbildung S2, S3, S4, S5, S6, 
S7, S8, S9C, D, S10 
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Genomics Core Facility. FACS Phänotypisierung von Silke Reinartz, Klinik für 
Gynäkologie, Gynäkol. Onkologie und Endokrinologie, Patientenproben wurden zur 
Verfügung gestellt von Uwe Wagner und Silke Reinartz, Klinik für Gynäkologie, Gynäkol. 
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4 Diskussion 
Aszites vermittelte Deregulation PPARb/d-spezifischer Zielgene 
Die Suppression inflammatorischer Immunzellen in der Mikroumgebung des 
Ovarialkarzinoms ist einer der bedeutendsten Mechanismen dieses Tumors um einen 
protumorigenen Phänotyp zu generieren und zu erhalten. Eine äußerst wichtige Rolle 
spielt in diesem Prozess die Akkumulation des Aszites, als Reservoir von Tumor- und 
Stromazellen, antiinflammatorischer Immunzellen, löslicher Faktoren und vor allem 
Lipiden. 
Lipide haben einen großen Einfluss auf die Tumorigenese und wie in neuesten 
Studien gezeigt werden konnte, vor allem auf die Metastasierung des Tumors (Pascual 
et al. 2017). Die innerhalb dieser Arbeit durchgeführten Lipidomanalysen des Aszites 
von Ovarialkarzinompatientinnen ergaben teils sehr hohe Konzentrationen an mehrfach 
ungesättigten Fettsäuren, wie Linolsäure, Arachidonsäure, oder Docosahexaensäure. 
Einer der Hauptregulatoren des Fettsäuremetabolismuses ist der Lipidsensor PPARb/d. 
Da die im Aszites vorhandenen Fettsäuren natürliche Liganden dieses Kernrezeptors 
darstellen, wurde deren Einfluss auf die PPARb/d spezifische Zielgenregulation in 
Makrophagen gesunder Spender und Tumor-assoziierten Makrophagen des 
Ovarialkarzinom untersucht.  
Neben morphologischer Ähnlichkeiten des durch PPARb/d selektive Agonisten 
erzeugten antiinflammatorischen Phänotyps von MDM und ex vivo TAM zeigten RNA 
Seq Daten eine Überlappung der Agonisten-induzierten Zielgene in MDM und 
unbehandelten ex vivo TAM, was auf eine Deregulation der Zielgene in TAM hinwies.  
 
PPARb/d im Immunsystem 
Die Funktionen der deregulierten, durch PPARb/d-Agonisten induzierten Zielgene 
konnten neben den bekannten, klassischen Metabolismus- und Migrationsaufgaben 
auch dem Überleben und Entzündungs- bzw. Immunfunktionen zugeordnet werden. Bei 
Letzteren wurde LPS als Hauptmediator der Zielgene mit proinflammatorischer Funktion 
identifiziert. 
Immunmodulatorische Funktionen der PPARs wurden bisher überwiegend für 
PPARa und PPARg beschrieben. In Makrophagen wurde vor allem die Interaktion 
Agonisten-abhängiger Effekte mit den Transkriptionsfaktoren NF-kB, STAT, Aktivator 
Protein 1 (AP1) und NFAT (nuclear factor of activated T-cells) beschrieben (Daynes and 
Jones 2002). PPARa interagiert durch Transrepressions-Mechanismen  beispielsweise 
mit der RHD von p65 und dem Aminoterminus von JUN (Philippe Delerive et al. 1999) 
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oder kontrolliert die Dauer der Immunantwort indem Agonisten die verstärkte 
Transkription und Proteinsynthese des inhibitorischen NF-kB Proteins IkBa induzieren 
(P. Delerive et al. 2000). Der selektive PPARg Agonist 15d-PGJ2 inhibiert die IkB 
Komplex Kinase (IKK) und dadurch die NF-kB DNA Bindung (D S Straus et al. 2000), 
wodurch es zu einer Hemmung proinflammatorischer Transkripte kommt. Über den 
Einfluss von PPARb/d auf die Immunregulation gibt es bisher nur wenige Informationen, 
(Rival et al. 2002), (Stockert et al. 2013), (Daynes and Jones 2002), die im Rahmen 
dieser Arbeit, insbesondere in humanen Makrophagen genauer charakterisiert werden.  
 
Makrophagen-spezifische inverse Regulation inflammatorischer Gene 
durch PPARb/d-Agonisten 
Anhand der gewonnenen Erkenntnisse über PPARb/d  spezifische Funktionen in 
humanen Makrophagen wurden neue, transkriptionelle Mechanismen der 
PPARb/d spezifischen Zielgenregulation gefunden, die durch die selektiven Agonisten 
erzeugt werden. PPARb/d Agonisten besitzen nicht nur die Fähigkeit die Expression 
kanonischer Zielgene zu induzieren, sondern führen auch zu einem nicht-kanonischen 
Mechanismus, der keine oder nur eine sehr schwache direkte PPARb/d DNA Bindung 
benötigt und zur Repression dieser Gene führt. Diese inverse Regulation ist 
zelltypspezifisch und betrifft hauptsächlich die Regulation in Makrophagen. Nicht 
verwunderlich ist aufgrund dieser Tatsache, dass die reprimierten Gene überwiegend an 
der Immunregulation beteiligt sind und vor allem über NF-kB reguliert werden. Mittels 
gleichzeitiger Behandlung des Agonisten L165,041 und dem Proteasominhibitor MG132, 
der die Agonisten-induzierte Repression verschiedener NF-kB Zielgene aufhebt, konnte 
ein Einfluss des NF-kB Weges auf die inverse Regulation durch PPARb/d Agonisten 
vermutet werden. Zu beachten ist allerdings, dass MG132 kein selektiver IKK-Inhibitor 
ist und der Einfluss anderer Signalwege nicht ausgeschlossen werden kann.  
Zusätzlich zur bisher beschriebenen Agonisten-induzierten antiinflammatorischen 
Rolle von PPARb/d in Makrophagen konnte im Rahmen dieser Arbeit auch eine 
proinflammatorische Funktion von PPARb/d aufgezeigt werden, was zur allgemein 
kontrovers diskutierten Rolle von PPARb/d passt. Beispielsweise wird die T-
Zellaktivierung durch Agonistenbehandlung gefördert, indem IDO1, das 
geschwindigkeitsbestimmende Enzym im Tryptophanabbau, und auch das Endprodukt 
der enzymatischen Kette Kynurenin, in Makrophagen reduziert werden. Des Weiteren 
kam es zu einer Agonisten vermittelten Anreicherung IFNg+ positiver CD8 Zellen und 
einer Reduktion der Expression des T-Zell inhibitorischen Faktors CD274 (PD-1).  
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Die Expression der PPARb/d spezifischen Zielgene unterliegt somit einer 
einzigartigen Regulation, die von hoher klinischer Bedeutung ist. Ein therapeutisch 
wichtiger Aspekt ist in diesem Zusammenhang die dosisabhängige Repression 
verschiedener Aszites-induzierbarer Zielgene in MDM durch den inversen Agonisten PT-
S264. Durch bereits niedrige Konzentrationen des inversen Agonisten in Gegenwart von 
Aszites kann die Transkription von z.B. ANGPTL4, dessen Expression mit einer 
schlechten Prognose der Patientinnen korreliert, in vitro deutlich verringert werden. Der 
Einsatz inverser Agonisten stellt somit einen therapeutischen Ansatzpunkt in der 
Reversion des protumorigenen, immunsuppressiven Mikromilieus in ein funktionelles, 
antitumorales Netzwerk diverser Immunzellen dar. 
 
Der Einfluss von PPARs auf die Induktion des proinflammatorischen 
Zytokins IL-12 
Die detaillierte Beschreibung der Involvierung der PPARs, vor allem von PPARb/d 
auf viele weitere essentielle proinflammatorische Transkripte in humanen Makrophagen 
wie IL12B wurde bisher jedoch wenig untersucht. IL-12 ist eines der wichtigsten 
proinflammatorischen Zytokine, die durch NF-kB reguliert werden und ist in TAM nicht 
exprimiert. Bereits bekannt ist, dass PPARb/d Agonisten die Expression von IL-12 
supprimieren und somit die experimentelle autoimmune Enzephalomyelitis (EAE) im 
Mausmodell schwächen (Kanakasabai et al. 2010). PPARg Agonisten supprimieren die 
Produktion der limitierenden Untereinheit von funktionellem IL-12, IL-12p40 in LPS-
stimulierten Mikrogliazellen (Xu and Drew 2007) und modulieren die CD40 induzierte 
Sekretion von Il-12 in murinen dendritschen Zellen (Faveeuw et al. 2000). Der PPARa 
Agonist Fenofibrat inhibiert die Sekretion von IL-12p40 und IL12p70 (Xu, Racke, and 
Drew 2007).  
 
Reversibilität der IL12B Suppression in TAM  
U.a. aufgrund des Einflusses von PPARb/d Agonisten auf den NF-kB Signalweg 
im Ovarialkarzinom wurde die transkriptionelle Induktion von IL12B im Hinblick auf die 
Aszites-vermittelte Suppression des Zytokins hin untersucht. 
Zunächst stellte sich die Frage, ob der Aszites, bzw. lösliche Faktoren im Aszites 
für die Suppression in TAM oder auch in Aszites differenzierten Zellen für die 
Suppression verantwortlich ist. Da TAM nach einer Kultivierung von zwei Tagen in 
normalem Kulturmedium (R5) wieder in der Lage sind auf transkriptioneller Ebene IL12B 
zu induzieren, spricht dies für eine mögliche Reversibilität dieser Zellen in einen 
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proinflammatorischen Status. Die Suppression wird daher überwiegend durch lösliche 
Faktoren des Aszites hervorgerufen.  
Des Weiteren konnte der immunsuppressive IL-10high, IL-12low Phänotyp der TAM 
sowohl in dieser, als auch in anderen Studien durch IFNg revertiert werden (Duluc et al. 
2009), (X Hu, Chakravarty, and Ivashkiv 2008). Auch konnten Arbeiten der eigenen 
Gruppe zeigen, dass die Prognose von Ovarialkarzinompatientinnen mit verstärktem 
Interferon signaling deutlich besser ist im Vergleich zu Patientinnen mit weniger stark 
ausgeprägter Interferonantwort (Adhikary et al. 2017). 
 
Der Einfluss von IL-10 auf IL-12 
Als einer der Hauptverursacher der IL12B Repression kam IL-10 in Frage, da 
dieses Zytokin eine erheblich Rolle in der Differenzierung zu einem 
antiinflammatorischen Phänotyp einnimmt und eine proinflammatorische Antwort 
unterbindet (Ito and Ansari 1999), (A. Sica et al. 2000), (Williams et al. 2004). Zusätzlich 
korreliert eine hohe IL-10 Konzentration im Aszites mit einer schlechten Prognose der 
Patientinnen mit HGSOC (Reinartz et al. 2014). Gezeigt wurde auch, dass sich die IL-
10 und IL-12 Expression gegenseitig reguliert und ein Ungleichgewicht dieses 
Mechanismus zu der Entstehung diverser Erkrankungen führt (Segal, Dwyer, and 
Shevach 1998). Da TAM im Aszites hohen Konzentrationen an IL-10 ausgesetzt sind, 
war die Annahme, dass dies zu einer Suppression von IL12B über eine NF-kB Inhibition 
in Makrophagen gesunder Spender führt. In unserem System hingegen konnte jedoch 
keine vollständige Suppression von IL12B durch IL-10 gezeigt werden, was auf die 
Präsenz weiterer antiinflammatorischer Faktoren im Aszites hindeutet, die die 
Suppression bedingen.  
 
Die Rolle von NF-kB in der Regulation von IL-12 
Da c-REL als  Hauptregulator von IL-12p40 beschrieben ist (Sanjabi et al. 2000) 
wurde die Funktionalität der Translokation dieses Faktors, als auch die Translokation 
von RELA nach Aszitesbehandlung untersucht. Die Aszitesbehandlung, parallel zur 
Stimulation und auch die Differenzierung in Aszites führte zu drastisch verminderten 
kernständigen REL und RELA Proteinkonzentrationen, welche durch Aszitesentzug 
teilweise wieder erhöht werden konnten. Aufgrund dieser Tatsache wurde die Stabilität 
der NF-kB Inhibitoren (IkBs) überprüft. Hierbei ist zu erwähnen, dass die NF-kB Antwort 
in zwei zeitliche Einheiten eingeteilt wird, zum einen kommt es zu einer sehr schnellen 
Aktivierung des Signalweges, welche als primäre Antwort gesehen wird und zum 
anderen gibt es eine sekundäre Antwort mit einer verzögerten Kinetik, die Zielgene 
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dieser Gruppe langsamer induziert. Zu diesen Genen zählt auch IL12B. Für diese 
verspätete Induktion der Zielgene ist vermutlich die Bindung der Transkriptionsfaktoren, 
die eine Chromatinveränderung bedingt, verantwortlich (S. Saccani, Pantano, and Natoli 
2001), (Schultze 2017). Da IkBa, als Inhibitor des NF-kB Signalweges, vielen schnell 
induzierbaren Zielgenen zugeordnet wird, und für einen negativen 
Rückkopplungsmechanismus verantwortlich ist (Brown et al. 1993), lässt sich seine 
verstärkte Proteinsynthese zum Betrachtungszeitpunkt nach LPS und IFNg Stimulation 
in unseren Versuchen erklären. Weiterhin lässt sich aus diesen Ergebnissen schließen, 
dass ein IkBa Abbau vermutlich nicht essentiell für die Induktion von IL12B ist, obwohl 
interessanterweise IL-10 zu einer Stabilisierung von IkBa und der somit verminderten 
Translokation von RELA führt (Rahim et al. 2005), (Shames et al. 1998). Eine 
Involvierung, bzw. nicht funktioneller IkB Abbau der zwei anderen zytoplasmatischen 
inhibitorischen Faktoren IkBb und IkBe konnte in dieser Arbeit weitgehend 
ausgeschlossen werden, da der Abbau nach Aktivierung des Signalweges deutlich 
sichtbar und somit funktionell ist.  
Allerdings kann eine Involvierung anderer, atypischer IkBs nicht ausgeschlossen 
werden. Nennenswert ist hier IκBζ, welches als Regulator der H3K4 Trimethylierung  und 
als Induktor des transkriptionellen Präinitiationskomplexes nach Nukleosomumbau 
beschrieben wurde (Annemann et al. 2016) und durch Bindung an den Il12b Promoter 
dessen Aktivität reguliert (Kayama et al. 2008).  
Trotz der sehr geringen kernständigen Konzentrationen von REL und RELA kam 
es lediglich in Aszites differenzierten aber nicht in Kurzzeit-Aszites-exponierten Zellen 
zu einer verminderten DNA Bindung an einen in dieser Arbeit neu identifizierten, dem 
Transkriptionsstart vorgelagerten, erweiterten Promotorbereich. An der annotierten TSS 
konnte keine NF-kB Bindung detektiert werden. 
Auch am CXCL10-Lokus konnte eine der TSS vorgelagerte Bindungsstelle von 
REL und RELA identifiziert werden. Hier kam es zu keiner Aszites vermittelten Änderung 
in der Anreicherung der beiden Transkriptionsfaktoren. Dies bedeutet, dass eine 
verminderte DNA-Bindung nach Langzeitexposition des Aszites vermutlich 
genspezifisch ist. Möglicherweise fehlt ein Komplex-stabilisierender Bindungspartner 
oder es kommt zu einer Blockierung der Bindung durch einen Repressor. Auch könnten 
posttranslationale Modifikationen der Transkriptionsfaktoren für die Regulation 
bedeutend sein. 
ChIP Sequenzierungen von ex vivo TAM ließen eine repressive Modifikation, 
H3K27me3 an einem Bereich ca. 20 kbp stromabwärts der annotierten TSS erkennen. 
In Aszites kultivierten Makrophagen konnte an diesem Bereich allerdings keine 
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Veränderung der Histonmodifikation im Vergleich zu Makrophagen in normalem 
Kulturmedium festgestellt werden.  
Zusammengefasst bedeutet dies, dass die Induktion von IL12B zwar eine REL 
und/oder RELA DNA Bindung benötigt, (erkennbar auch an eigenen RNAi Daten von 
von REL und RELA und knockout Daten von Rel), die Suppression jedoch aufgrund der 
noch vorhandenen DNA Bindung der NF-kB Faktoren vermutlich noch durch andere 
Faktoren reguliert wird.  
 
Potentielle Beteiligung weiterer Signalwege an der IL-12 Suppression  
Da eine volle Induktion von IL-12 nur durch eine Kombination der TLR4 oder 
CD40L und IFNg gesteuerten Signalwege erreicht wird (Liu et al. 2003), (Conzelmann et 
al. 2010) und eine STAT1 Defizienz zu einer Suppression des TLR Signaling führt, 
welche die Aktivierung STAT3 regulierter Zielgene fördert (H. S. Kim et al. 2015), könnte 
eine verminderte oder veränderte Funktion von STAT1 maßgeblich an der durch Aszites 
induzierten Suppression von IL-12 beteiligt sein.  
Auch weitere Faktoren wie Prostaglandin E2 (van der Pouw Kraan 1995), 
(Mitsuhashi et al. 2004), Arachidonsäure (Zhang and Fritsche 2004), Adenosin (HASKO 
2000) und die Phosphatidylserin vermittelte Phagozytose vermitteln einen 
antiinflammatorischen Status, der die Inhibition der Synthese von IL-12 mit sich zieht (S. 
Kim, Elkon, and Ma 2004), (Birge et al. 2016). 
In Magen, Darm oder auch Leberkrebs konnte zum einen eine physikalische 
Interaktion von STAT3 und dem NF-kB-Signalweg festgestellt werden. Zum anderen 
konkurrieren die Transkriptionsfaktoren um die Bindung an Promotor und 
Enhancerbereiche. Des Weiteren wird durch NF-kB die Expression von STAT3 
Inhibitoren induziert (Grivennikov and Karin 2010), (Hoentjen et al. 2005). Da STAT3 in 
Makrophagen im Ovarialkarzinom durch Phosphorylierung konstitutiv aktiv vorliegt (Saini 
et al. 2017) und auch STAT3 Zielgenprodukte wie IL-6 in hohen Konzentrationen im 
Aszites vorhanden sind (Reinartz et al. 2014), die im Mausmodell die Interleukin-12 
Produktion über die Inhibition der Phosphorylierung von c-Rel supprimieren (E. J. Lee et 
al. 2016), liegt es nahe, dass dieser Signalweg, höchst wahrscheinlich in Kooperation 
mit NF-kB, einen großen Einfluss auf die protumorigenen Eigenschaften der TAM 
ausübt. Da der NF-kB Weg als alleiniger Hauptregulator der IL-12 Induktion 
ausgeschlossen werden kann, sollte in erweiterten Studien die Rolle anderer beteiligter 
Signalwege und deren Mediatoren auf die IL-12 Suppression hin überprüft werden um 
zukünftige therapeutische Maßnahmen für eine funktionelle zytokinvermittelte 
proinflammatorische Immunantwort zu generieren. Hierbei ist auf die hohe Diversität der 
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Makrophagen einzelner Spenderinnen zu achten, die auch in den hier dargestellten 
Experimenten häufig vorhanden war und von höchstem therapeutischem Interesse ist. 
Nur durch die genaue Charakterisierung der Zellen einzelner Spenderinnen kann eine 
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ABSTRACT
Peroxisome proliferator-activated receptor !/"
(PPAR!/") is a lipid ligand-inducible transcription
factor with established metabolic functions, whereas
its anti-inflammatory function is poorly understood.
To address this issue, we determined the global
PPAR!/"-regulated signaling network in human
monocyte-derived macrophages. Besides cell type-
independent, canonical target genes with metabolic
and immune regulatory functions we identified a
large number of inflammation-associated NF#B and
STAT1 target genes that are repressed by agonists.
Accordingly, PPAR!/" agonists inhibited the ex-
pression of multiple pro-inflammatory mediators
and induced an anti-inflammatory, IL-4-like mor-
phological phenotype. Surprisingly, bioinformatic
analyses also identified immune stimulatory effects.
Consistent with this prediction, PPAR!/" agonists
enhanced macrophage survival under hypoxic stress
and stimulated CD8+ T cell activation, concomitantly
with the repression of immune suppressive target
genes and their encoded products CD274 (PD-1
ligand), CD32B (inhibitory Fc$ receptor IIB) and
indoleamine 2,3-dioxygenase 1 (IDO-1), as well as
a diminished release of the immune suppressive
IDO-1 metabolite kynurenine. Comparison with
published data revealed a significant overlap of the
PPAR!/" transcriptome with coexpression modules
characteristic of both anti-inflammatory and pro-
inflammatory cytokines. Our findings indicate that
PPAR!/" agonists induce a unique macrophage ac-
tivation state with strong anti-inflammatory but also
specific immune stimulatory components, pointing
to a context-dependent function of PPAR!/" in
immune regulation.
INTRODUCTION
Macrophages display an enormous degree of plastic-
ity and react to their microenvironment by profoundly
different phenotypes, with classically activated, pro-
inflammatory macrophages [e.g. by tumor necrosis factor-!
(TNF!) or interleukin-1" (IL-1")] and anti-inflammatory
macrophages [e.g. by interleukin 4 or 10 (IL-4 or IL-10)]
as the extremes, originally designated as M1 and M2
macrophages (1). However, the macrophage phenotype
is highly dynamic, depending on the precise environ-
mental cues (2). Consequently, a spectrum of defined
activation/polarization states has recently been proposed
(3). A protein involved in the regulation of macrophage
activation and polarization is the nuclear receptor per-
oxisome proliferator-activated receptor "/# (PPAR"/#).
PPAR"/# is a ligand-inducible transcription factor with
established functions in intermediary metabolism and a
less well-defined anti-inflammatory role in immune regu-
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lation (4–7). Thus, PPAR"/# deficiency exacerbated the
inflammatory response to topical O-tetradecanoylphorbol-
13-acetate in mice (8). Furthermore, PPAR"/# dampened
the inflammatory response in a human model of dermal
wound healing by stimulating the secretion of IL-1 receptor
antagonist in dermal fibroblasts (9). Anti-inflammatory
effects of PPAR"/# agonists have also been observed in
mouse models of intestinal inflammation (10) and exper-
imental allergic encephalomyelitis, the latter involving an
inhibition of interferon $ (IFN$ ) and IL-17 production by
Th1 and Th17 cells (11). An anti-inflammatory function
of PPAR"/# in macrophages has been demonstrated
in two studies reporting that M2 polarization of murine
macrophages in adipose tissue and liver is dependent on the
induction of PPAR"/# expression by IL-4 or IL-13 (12,13).
The precise mechanism of anti-inflammatory macrophage
polarization by PPAR"/# remains, however, unclear.
Moreover, inconsistent with a purely anti-inflammatory
function, PPAR"/# is overexpressed in human psoriasis
(14) and ligand activation induces a proinflammatory
psoriasis-like response in a mouse model (15,16), even
though the molecular mechanisms underlying the latter
observation and its relevance for the human system remain
unclear.
PPAR"/# regulates its direct target genes through bind-
ing to PPAR response elements (PPREs) as a heterodimer
with a retinoid X receptor (RXR) (17). Genome-wide anal-
yses have identified PPRE-mediated repression as a major
mechanism of transcriptional regulation in the absence of
a PPAR"/# agonist and showed that an agonist-mediated
switch induces a subset of these genes (18). PPRE-mediated
repression is enhanced by inverse agonists, which establish a
repressor complex that apparently is different from the unli-
ganded receptor complex (19). Besides this canonical mech-
anism, agonist-bound PPAR"/# can also repress genes by
interacting with specific transcription factors without es-
tablishing direct DNA contact. For example, PPAR"/# in-
teracts with the p65 subunit of the nuclear factor kappa B
(NF%B) dimer in different cell types (14,20,21), PPAR"/#
ligands decrease NF%B activity via crosstalk with other sig-
naling pathways, including ERK in adipocytes (22) and
BCL-6 in macrophages (23). BCL-6 is a transcriptional re-
pressor of inflammatory genes, many of which are targets of
NF%B (24). Deletion ofPpard or application of a PPAR"/#
ligand abolishes the sequestration of BCL-6 by PPAR"/#,
resulting in the repression of BCL-6 target genes (23).
PPAR"/# serves as a receptor for a broad range
of natural agonists with function in inflammatory pro-
cesses, including unsaturated fatty acids (25) and 15-
hydroxyeicosatetraenoic acid (15-HETE) (26). The func-
tion of prostaglandin I2 (prostacyclin) as a PPAR"/# ag-
onist is controversial (27,28), which might be due to its
extreme instability at pH values below 7.8 (29), making
the microenvironment an essential determinant in this con-
text. Owing to the association of PPAR"/# with major hu-
man diseases a number of PPAR"/#-specific agonists have
been developed, several of which are well characterized and
have been used in numerous preclinical studies (30,31). Fur-
thermore, several synthetic inhibitory ligands for PPAR"/#
have been described over the past years. These include the
PPAR"/#-specific GSK0660 (32) and its improved deriva-
tive ST247 (33,34). These ligands inhibit the basal expres-
sion of PPAR"/# target genes by enhancing the recruitment
of transcriptional corepressors, classifying them as inverse
agonists (33).
To date, genome-wide studies addressing the tran-
scriptional PPAR"/# signaling network in primary
macrophages have not been performed. Recently published
transcriptome data for myeloid leukemia THP-1 cells,
induced to differentiation toward macrophage-like cells
by phorbol ester exposure, do not reflect the situation in
normal primary macrophages (35). However, such studies
are urgently required to understand the multi-faceted role
of PPAR"/# in immune regulation. In the present study,
we applied next-generation sequencing technologies to
determine the PPAR"/#-regulated transcriptome and the
PPAR"/#-RXR cistrome in human monocyte-derived
macrophages (MDMs) with the goal to establish the
PPAR"/#-controlled regulatory network in these cells.
MATERIALS AND METHODS
Ligands
L165,041 was purchased from Biozol (Eching, Germany)
and GW501516 from Axxora (Lo¨rrach, Germany). ST247
was synthesized as described (33,34). The inverse PPAR"/#
agonist PT-S264 is a novel derivative of ST247 with im-
proved plasma stability (Toth, P.M. et al., submitted for
publication). Ligands were used at a concentration of 1 &M
in all experiments.
Cell culture
MDA-MB-231 cells were purchased from Caliper Life Sci-
ence (MDA-MB-231-luc2). WPMY-1 cells were obtained
from the ATCC. Cells were maintained in Dulbecco’s mod-
ified Eagle’s medium supplemented with 10% fetal bovine
serum, 100 U/ml penicillin and 100 &g/ml streptomycin in
a humidified incubator at 37◦C and 5% CO2.
Isolation of CD14+ cells
Peripheral blood mononuclear cells were obtained from
healthy adult volunteers for MDM stimulation. Mononu-
clear cells were isolated by Lymphocyte Separation
Medium 1077 density gradient centrifugation (PromoCell
GmbH, D-69126 Heidelberg, Germany) and further
purified by adherent cell positive selection.
Cell culture and cytokine treatment of MDMs
CD14+ monocytes were cultured either in RPMI1640 with
10% fetal calf serum (FCS) (R10 medium) or in serum-
free macrophage X-VIVO 10 medium (Biozym Scientific
GmbH, Hessisch Oldendorf, Germany; subsequently re-
ferred to as XV0medium).MDMswere differentiated from
CD14+ monocytes of healthy volunteers for 5–7 days at 1
× 106 cells/ml. In some experiments MDMs were treated
with 20 ng/ml IL-4 (Biozol, Eching, Germany), 100 ng/ml
(lipopolysaccharide (LPS); Escherichia coli 0111:b4 L4391;
Sigma Aldrich, Steinheim, Germany) or 10 ng/ml IFN$
(Biomol, Hamburg, Germany) during differentiation for
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5–7 days. Isolation of murine bone marrow cells (BMCs),
differentiation to macrophages (BMDMs) by granulocyte-
macrophage colony stimulating factor (GM-CSF) and lig-
and treatment were carried out as described (36).
Propidium iodide uptake under hypoxia
MDMs were treated with ligands as indicated and kept un-
der 1% oxygen starting directly after isolation of mono-
cytes. Propidium iodide (Sigma Aldrich, Steinheim, Ger-
many) was added to a 1 ml cell suspension containing 1–
2 × 106 MDMs to yield a final concentration of 1 &g/ml.
Cells were kept at ambient temperature in the dark for 1 h
followed by fluorescence-activated cell sorting (FACS) anal-
ysis using an FACS Canto cytometer and BD FACSDiva
software (BD Biosciences, Heidelberg, Germany).
Phagocytosis assay
Phagocytosis assaywas performedwith d6MDMsusing 0.5
mg/ml fluorescein isothiocyanate (FITC) dextran (Sigma
Aldrich, Steinheim, Germany). Cells were kept under stan-
dard culture conditions for 1 h. Negative control cells were
incubated for 1 h at 4◦C. Following the incubation, cells
were washed three times and analyzed by FACS.
FACS phenotyping
Cells were pretreated and stained for macrophage mark-
ers as previously described (37). In addition, FITC-labeled
anti-human CD86 (Miltenyi Biotech, Bergisch Gladbach,
Germany), FITC-labeled anti-CD32A (Clone IV.3, Stem-
cell Technologies, Cologne, Germany) and allophycocyanin
(APC)-labeled anti-CD274 (BD Biosciences) were used. In-
tracellular staining of permeabilized cells with anti-CD32B
(Clone C2C3, Genetex, Irvine, CA, USA) and FITC-
labeled secondary antibody (eBioscience, Frankfurt a.M.,
Germany) was performed as published (37). Isotype con-
trol antibodies were purchased from BD Biosciences, Mil-
tenyi Biotech and eBioscience. Cells were analyzed using an
FACS Canto cytometer and BD FACSDiva software (BD
Biosciences). Results were calculated as mean fluorescence
intensities.
T cell activation
For antigen-specific T cell activation, autologous CD14+
monocytes from buffy coats of healthy donors were dif-
ferentiated to MDMs in the presence of different stim-
uli for 5–7 days and used as antigen-presenting cells for
antigen-specific T cell activation. Eighty thousand MDMs
per 96 well culture plate were loaded with 1 &g/ml
cytomegalovirus, Epstein-Barr virus, influenza virus and
tetanus toxoid (CEFT) peptide pool of 27 peptides (jpt
Peptide Technologies, Berlin, Germany) for 24 h (37◦C,
5% CO2). After washing with phosphate buffered saline,
peptide-pulsed MDMs were cocultured with 4 × 105 au-
tologous lymphocytes (CD14− fraction after MACS se-
lection of buffy coats) at a 5:1 ratio of lymphocytes to
MDMs in XV0 medium. MDMs pulsed with dimethylsul-
foxide (DMSO; 0.2% final concentration) were used as un-
stimulated controls for antigen-specific T cell activation.
For polyclonal T cell stimulation, 4 × 105 lymphocytes
were incubated in 96 well culture plates coated with mouse
anti-human CD3 mAb (500 ng/well; clone OKT3, Biole-
gend, San Diego, CA, USA) in the absence of autologous
MDMs. Experimental controls included non-stimulated
lymphocytes cultured without anti-CD3 mAb. Polyclonal
and peptide-specific T cell stimulation were performed at
37◦C and 5%CO2 for a total of 18 h with 5 &g/ml Brefeldin
A (Sigma Aldrich, Steinheim, Germany) for the last 16
h. Activated lymphocytes were harvested and stained with
surface markers anti-human CD8 APC (Miltenyi Biotec,
BergischGladbach, Germany). After permeabilization (BD
Cytofix/Cytoperm Kit, BD Bioscience, Heidelberg, Ger-
many) anti-human IFN$ FITC (eBioscience, Frankfurt
a.M., Germany) was added according to themanufacturer’s
instructions. Frequencies of activated T cells were measured
by flow cytometry (FACS Canto, BD Bioscience, Heidel-
berg, Germany) and expressed as IFN$+/CD8+ cells af-
ter subtracting background staining of corresponding non-
stimulated controls.
Immunoblotting
Immunoblots were performed according to standard proto-
cols using the following antibodies: !-PPAR"/# (sc-74517;
Santa Cruz, Heidelberg, Germany); !-IDO-1 (MAB10009;
Millipore, Darmstadt, Germany), !-LDH (sc-33781; Santa
Cruz, Heidelberg, Germany), !-rabbit IgGHRP-linked AB
and!-mouse IgGHRP-linkedAB (cs7074, cs7076; Cell Sig-
naling, NEB, Frankfurt, Germany). Imaging and quantifi-
cationwas done using the ChemiDocMP system and Image
Lab software version 5 (Bio-Rad, Mu¨nchen, Germany).
Kynurenine assay
Kynurenine was measured according to a published pro-
cedure (38). Supernatant of MDM cultures (360 &l) was
incubated with 180 &l of 30% trichloroacetic acid (TCA)
for 30 min at 50◦C. After centrifugation at 3000 × g
for 10 min, the supernatant was collected, mixed with an
equal volume of freshly prepared Ehrlich Reagent (2% p-
dimethylaminobenzaldehyde in glacial acetic acid) and in-
cubated for 12–30 min at ambient temperature. The ab-
sorbance was measured at 492 nm and compared to a cal-
ibration curve obtained with L-kynurenine (Santa Cruz,
Heidelberg, Germany).
Reverse transcription quantitative polymerase chain reaction
(RT-qPCR)
cDNA isolation and qPCR analyses were performed as de-
scribed (33). L27 was used for normalization. Primer se-
quences are listed in Supplementary Table S1.
RNA sequencing
RNA was extracted with TRIfast (Peqlab, Erlangen, Ger-
many) according to the manufacturer’s instructions. Ge-
nomic DNA was removed by incubation with RNase-free
DNase (Macherey-Nagel, Du¨ren, Germany) for 15 min at
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room temperature. After column-based purification (Qi-
agen Minelute, Hilden Germany), 0.1–0.5 &g of DNA-
depleted RNA was used for library preparation accord-
ing to the manufacturer’s instructions (ScriptSeq Com-
plete Gold Kit, Human/Mouse/Rat-Low Input, Epicen-
tre,Madison,WI, USA) utilizing QiagenMinelute columns
and Beckman Coulter Agencourt AMpure XP beads. Sam-
ples were sequenced on an Illumina HiSeq 1500.
Chromatin immunoprecipitation (ChIP) sequencing
ChIP was performed and evaluated as described (18,19)
using the following antibodies: IgG pool, I5006 (Sigma-
Aldrich, Steinheim, Germany); !-PPAR"/#, sc-7197; !-
RXR, sc-774 (Santa Cruz, Heidelberg, Germany). For pre-
cipitation, a mixture of Dynabeads Protein A (10002D) and
Dynabeads Protein G (10004D; both from Life Technolo-
gies, Carlsbad, CA, USA) was blocked with 1 g/l bovine
serum albumin overnight, and 50 &l was used per immuno-
precipitation (IP). DNA was purified using Qiagen Mine-
lute columns. Preceding the PE washing step, the mem-
branes were washed twice with pure methanol in order
to remove contaminating DNA-binding lipids that inhibit
subsequent low-temperature enzymatic modification steps,
which we found to be present in samples from primary
macrophages. Libraries were synthesized from 1–2 ng of ge-
nomic DNA using the MicroPlex kit (Diagenode, Seraing,
Belgium). Samples were sequenced on an Illumina Hi-Seq
1500 (Illumina, San Diego, CA, USA).
Mapping of ChIP sequencing reads and peak calling
ChIP sequencing (ChIP-Seq)mapping and peak calling was
performed as described (18,19) except that (i) Subread (ver-
sion 1.4.3-p1) (39) was used for alignment, (ii) reads were
filtered to a maximum of five mismatches and five repeti-
tions of each read start site (deduplication) and (iii) updated
versions of Ensembl (v74) and MACS (1.4.0rc2 20110214)
were employed. The number of usable reads was 46 299 322
(PPAR"/#), 39 483 674 (RXR) and 42 750 342 (IgG con-
trol). Peaks were filtered for at least 15 deduplicated tags,
a fold change (FC) over IgG of ≥2 (normalized total read
counts) and at most 60 deduplicated IgG tags. Venn dia-
grams for peak overlaps were calculated by building the in-
terval union and testing each resulting interval for overlaps
with the initial peak sets. Genes were associated with peaks
based on the closest transcription start site (TSS) from the
peak summit and all TSSswithin 50 kb of the summit (inter-
nal TSSs were considered). A peak could thus be assigned
to multiple genes.
RNA sequencing analysis
RNA sequencing (RNA-Seq) data were aligned to Ensembl
v74 using STAR (version STAR 2.3.1z13 r470) (40). Gene
read counts were established as read count within merged
exons of protein coding transcripts (for genes with a pro-
tein gene product) or within merged exons of all transcripts
(for non-coding genes). FPKM (fragments per kb per mil-
lion) were calculated based on the total gene read counts
and length of merged exons. Raw read counts were quantile
normalized within each comparison and logFC values were
calculated (after adding 1/60 to the normalized FPKM val-
ues to avoid undefined values). Genes were considered regu-
lated if they had a logFC of at least 0.7 (∼1.62-fold), a min-
imum FPKM of 0.3 in any condition and at least 50 raw
reads.
Comparisons with published ChIP-Seq data
For comparison of the PPAR bound gene sets, signal trans-
ducer and activator of transcription 1 (STAT1) data were
retrieved from (41) and gene IDs updated to Ensembl
v74. STAT3 data were retrieved from Supplementary Ta-
ble S1 in (42), updated to Ensembl v74 and translated from
mouse to human via Ensembl Compara. NF%B bound re-
gions (24) were retrieved from Gene Expression Omnibus
(GSM61116,GSM61117, union), lifted frommm9 tomm10
using UCSCs liftOver utility and associated with the mouse
gene with the closest transcription start site (internal TSSs
were considered). Translation to human genes was again by
Ensembl Compara. BCL6 bound sites from the same publi-
cation (24) (GSE16723, top level data file) were treated iden-
tically. P300 associated genes were extracted from (43) (Sup-
plementary Table S1), assigned to mouse stable IDs using
the ‘Official Gene Symbol’ column and Ensembl v64, up-
dated to Ensembl v74 and translated to human genes via
Ensembl Compara.
Comparisons with published stimulus-specific MDM tran-
scriptomes
Raw microarray data (3) (GSE46903, ‘GSE46903 non-
normalized.txt.gz’) quantile normalized using the lumi Bio-
conductor package annotated using Supplementary Ta-
ble S1B in (3) were used to calculate logFC values ver-
sus basal (M0) condition based on expression values av-
erages within each condition. Only GM-CSF stimulated
macrophage samples were analyzed. WGCNA output (49
modules; Supplementary Table S2B in (3)) was translated
to Ensembl stable gene IDs using Illumina Human-HT-
12 v3 annotation (‘HumanHT-12 V3 0 R3 11283641 A’).
Translation was preferentially based on Entrez IDs with
gene symbols as a fall back. Overlaps between modules and
L165,041 regulated genes were assessed by Fisher’s exact
test. For Figure 8, a directional score for overlapping genes
was calculated as follows: the number of genes regulated in
the same direction by L165,041 and a given stimulus mi-
nus the number of genes regulated in the opposite direc-
tion. Only genes showing an at least 1.5-fold induction by
the respective stimulus [3] and 1.62-fold by L165,041 (Sup-
plementary Table S2) were included.
Comparison with published genomic PPAR!/" data for
other cell types
For comparisons based on peaks, original sequencing data
(18,19) were reanalyzed as described in section ‘Mapping of
ChIP-Seq reads and peak calling’. Microarray based tran-
scription assay results were retrieved from supplementary
tables of the aforementioned publications and their gene
stable IDs updated to the Ensembl revision used. In com-
parisons depicting both RNA-Seq and microarray data,
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genes were filtered to those occurring on both microarray
chip types used (Agilent-028004 and Agilent-014850).
Databases
All genomic sequence and gene annotation data were re-
trieved from Ensembl release 74, genome assembly hg19.
Our full analysis scripts and computational pipeline are
available upon request.
Statistical analysis of experimental data
Data are presented as the average of biological replicates
(n ≥ 3; precise numbers for each experiment indicated in
the figure legends)± standard deviations (error bars). Com-
parative data were statistically analyzed by Student’s t-test
(two-sided, equal variance) using GraphPad Prism 6.0. Re-
sults were expressed as follows: *P < 0.05, **P < 0.01 and
***P < 0.001. When appropriate, correction for multiple
hypothesis testing was done by Benjamini–Hochberg ad-
justment, as indicated.
Functional annotations, networks and pathway analyses
RNA-Seq data were analyzed using the Ingenuity Pathway
Analysis (IPA) application and knowledge database (Qia-
gen Redwood City, CA, USA). The functions ‘Upstream
Regulators, Diseases and Bio Functions and Networks’
were applied using the default settings. Results were sorted
according to P-value of overlap (minimum 10−5) and acti-
vation z-scores (≤−2.0 or ≥+2.0 required).
RESULTS
Induction of PPAR!/" during differentiation of human
monocytes to MDMs
First, we sought to identify an experimental system suitable
for studying the PPAR"/# cistrome and ligand-regulated
transcriptome. Human monocytes were differentiated to
MDMs in RPMI1640 with 10% FCS medium (R10) and
characterized with respect to PPAR"/# expression and
activity. RT-qPCR analysis showed increasing PPARD
mRNA levels after initiation of cultures reaching a maxi-
mum around day 5 (Figure 1A), which was paralleled by
a strong increase in PPAR"/# protein expression (Figure
1B and Supplementary Figure S1) and ligand inducibility
of the well-established target gene PDK4 (Figure 1C), both
reaching maximum levels around day 6. Chromatin-bound
PPAR"/# and RXR were detected by ChIP at the PPAR-
responsive PDK4 enhancer already on day 0 (monocytes;
Figure 1D), which explains the ligand responsiveness of the
PDK4 gene at early time points (Figure 1C). Re-ChIP anal-
yses showed that PPAR"/# and RXR formed complexes
on the PDK4 enhancer, as expected (Supplementary Fig-
ure S2). The induction of PPAR"/# expression and activity
during differentiation was paralleled by an increased sur-
face expression of the macrophage markers CD32, CD63,
CD86, CD206 and HLA-DR and an induction of intracel-
lular CD68 (Supplementary Figure S3). MDMs thus ap-
pear to be suitable for investigating effects of PPAR"/# lig-
ands onmacrophage activation and/or polarization, in par-
ticular since plastic adherence partially activates monocytes
and macrophages (44–48), including increased STAT1 and
NF%B signaling (49,50), thus allowing for a potential mod-
ulation by agonists or inverse agonists in either direction.
We therefore chose day-6 MDMs for the subsequent stud-
ies.
The transcriptome of PPAR!/" ligand-regulated genes in
human MDMs
We used this experimental system to identify ligand-
responsive genes as well as PPAR"/# and RXR bind-
ing sites in macrophages by deep sequencing technologies.
RNA-Seq data obtained with MDMs cultured either in
R10 or serum-free synthetic X-VIVO 10 medium (XV0)
revealed a total of 285 protein-coding genes upregulated
by PPAR"/# agonist L165,041 and 246 genes downregu-
lated by the inverse agonists ST247 or PT-S264; logFC ≥
0.7; FPKM ≥ 0.3), 29.6% of the latter (n = 73) overlap-
ping with the agonist-induced gene set (Figure 2A; Supple-
mentary Table S2). Our RNA-Seq also identified a large
fraction of genes repressed by the agonist L165,041 (n =
388) and upregulated by the inverse agonist ST247 (n =
174), with 40 genes (10.3%) overlapping (Figure 2B; Sup-
plementary Table S2). Diseases and functions annotation
of the L165,041-induced gene set showed a strong asso-
ciation with the inhibition of cell death of immune cells
and suppression of immune cell functions, including mi-
gration, inflammatory response, activation, homing, ad-
hesion, chemotaxis and phagocytosis (Figure 2C; Supple-
mentary Table S3). The gene set representing inflammation
clearly overlapped with cell survival, migration/movement,
adhesion and recruitment/infiltration/ chemotaxis (Fig-
ure 2D), suggesting that these to a large extent repre-
sent genes with functions in immune regulation. Interest-
ingly, ‘Inflammation of intestine’ and ‘Colitis’ showed a
positive activation z-score (Figure 2C), providing a first
hint that the response to L165,041 may not be strictly
anti-inflammatory. Likewise, lipidmetabolism (‘Concentra-
tion of acylglycerol’) was upregulated, consistent with the
known metabolic role of PPAR"/#. Finally, analysis of
the known upstream regulators of these genes (signaling
molecules and transcription factors) identified two groups:
canonically regulated (L165,041-induced) genes known to
be activated by PPARagonists (pirixinic acid, fibrates, glita-
zones) were upregulated by L165,041, while genes induced
by pro-inflammatory signaling via LPS, TNF!, IFN$ , IL-
1", STAT3 or TLR4 were downregulated (inverse target
genes).
To rule out the possibility that inverse regulation may
be due to PPAR"/#-independent off-target mechanisms we
analyzed the regulation of target genes in bone marrow-
derived macrophages (BMDMs) from wild-type and Ppard
null mice. As shown in Figure 2F, Ccl24, Tnfsf15 and Ser-
pinb2 were repressed upon agonist treatment specifically in
wild-type cells. Two other genes found to be repressed by ag-
onists in human MDMs were not regulated (Ccl8) or not
expressed (Enpp2) in murine BMDMs, while the canon-
ical target genes Pdk4 and Angptl4 showed the expected
PPAR"/#-dependent induction. These observations con-
firm the PPAR"/# dependence of agonist-mediated regu-
lation, but also point to cell type (BMDM versus MDM)
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Figure 1. PPAR"/# expression and activity in differentiating human MDMs. Human monocytes were differentiated in R10 medium for 11 days and
analyzed at the indicated times after initiation of differentiation. (A) Expression of PPARD mRNA measured by RT-qPCR relative d1 (sample size = 3).
(B) Quantitation of immunoblot analyses of PPAR"/# protein expression in differentiating MDMs from four different donors relative to LDH (loading
control). The individual blots are shown in Supplementary Figure S1. Values were normalized to 1.0 on d6 (maximum expression). (C) Ligand-mediated
induction relative to DMSO of PDK4 determined by RT-qPCR. Cells (sample size= 3) were exposed to L165,041 for 1 or 3 days (+1 or +3) at the indicated
d (d0, d5, d8, d11). (D) PPAR"/# and RXR enrichment at the PDK4 enhancer at −12 kb from the transcription start site and an irrelevant control region
(Con) in human monocytes (ChIP analysis; sample size = 6). Statistical significance was tested relative to d0 (panel (A)) or DMSO (panel (C)).
and/or species-specific differences in the regulation of in-
verse PPAR"/# target genes.
To gain further insight into the diverse functions and reg-
ulatory mechanisms suggested by the data in Figure 1 we
separately analyzed canonically regulated and inverse tar-
get genes as described in the following.
Canonical PPAR!/" target genes in MDMs
ChIP-Seq analyses identified 1175 enrichment sites for
PPAR"/# associated with 3798 genes located within a dis-
tance of 50 kb, and 27 255 RXR enrichment sites associ-
ated with 32 720 genes (Figure 3A and B; Supplementary
Tables S4 and S5). The majority of overlapping binding
sites occurred at transcription start sites (within 1250 bp,
29.1%), within introns (31.6%) or upstream locations (5000
bp, 5.7%) (Figure 3C). A large fraction of the L165,041-
induced genes (n= 132; 46.3%) showed clear enrichment of
PPAR"/# in vivo, and most of these sites (n = 130; 98.5%)
were co-occupied byRXR (Figure 3A andB). Another frac-
tion of L165,041-induced genes were occupied by RXR,
but enrichment for PPAR"/# at the same genomic region
was less clear or not visible (n = 139; 48.8%; Figure 3A).
These include the strongly regulated (Supplementary Fig-
ure S4) and established (51) canonical PPAR"/# target gene
ANGPTL4, which shows readily detectable ChIP-Seq peaks
in other cell types under identical assay conditions (18,19).
This may be due to cell type-specific PPAR"/# transcrip-
tion complexes inmacrophages that limit accessibility to the
antibody. We therefore assume that the presence of RXR
on PPREs of L165,041-induced genes indicates canonical
PPAR"/# regulation. This is supported by the results of
the upstream regulator analysis of L165,041-induced genes,
which identified PPAR ligands and the PPAR coactivator
PPARGC1A as the top regulators (nine out of 10; Figure
3D).
Diseases and functions annotation of the canonical target
genes showed the strongest positive correlation (byP-value)
with lipid metabolism (Figure 3E). The identified genes in-
clude established PPAR target genes with functions in lipid
metabolism, such as ACADVL, ACAA2, ANGPTL4, CAT,
CPT1A, FABP4, ECH1, PDK4, SLC25A20 and PLIN2,
but also novel target genes, such as ETFB, ETFDH and
ISCA1, the products of which play important roles in elec-
tron transfer and iron-sulfur cluster assembly, respectively.
Other sets of canonical target genes were either positively
associated with cell movement or negatively correlated with
systemic autoimmune syndrome (Figure 3E). Consistent
with this finding, the canonical target gene set encompasses
a number of genes with functions in immune regulation,
e.g. CD1D, CD36, CD52, CD300A, LRP5, NLRC4 and
PHACTR1 (Table 1 and Figure 3B). Several of these exam-
ples were validated by RT-qPCRwithMDMs from three to
seven independent donors (Supplementary Figure S4).
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Figure 2. Genome-wide identification of PPAR"/# target genes in macrophages. (A) Overlap of genes induced by L165,041 and repressed by ST247 or
PT-S264 in MDMs cultured for 6 days followed by treatment with DMSO or ligands for 24 h. Data are derived from two independent experiments using
either R10 (L165,041, ST247) or XV0 (L165,041, PT-S264) medium. Genes with a logFC > 0.7 in one culture condition, a logFC > 0 in both media, an
FPKM ≥ 0.3 and a raw tag count of at least 50 were scored as positive. (B) Overlap of genes repressed by L165,041 and activated by ST247 in MDMs
(conditions as in (A)). (C) IPA ‘Diseases and Functions Annotation’ of L165,041-regulated genes (examples of functionally different clusters with low P-
values and high z-scores). (D) Overlap of L165,041-regulated genes linked to different functions (according to IPA ‘Diseases and Functions Annotation’;
all clusters with n > 30 genes). (E) IPA ‘Upstream Regulator Analysis’ of L165,041-regulated genes (top regulators by P-value). (F) RT-qPCR analysis
of target gene regulation by the PPAR"/# agonist GW501516 in BMDMs from wild-type and Ppard null mice differentiated for 6 days in the presence
of GM-CSF (sample size: 3 each). The data show the fold change (mean of triplicates) in response to the ligand relative to solvent treated wild-type and
Ppard null control cells.
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Figure 3. Genome-wide identification of agonist-induced direct PPAR"/# target genes in MDMs. (A) Overlap of genes associated with PPAR"/# and
RXRbinding sites inMDMs (ChIP-Seq; peaks filtered and associated with genes as described in theMaterials andMethods section) and L165,041-induced
genes (RNA-Seq). (B) Examples of RXR (green) and PPAR"/# (red) enrichment peaks at novel canonical target genes (ChIP-Seq data). Blue: control IgG.
(C) Locations of PPAR"/# sites identified by ChIP-Seq. tss: within 1250 bp of a transcription start site; upstream: within 5 kb upstream of a transcription
start site. (D) IPA ‘Upstream Regulator Analysis’ of L165,041-induced genes (top regulators by P-value). (E) IPA ‘Diseases and Functions Annotation’ of
L165,041-induced genes in MDMs.
Inverse PPAR!/" target genes in MDMs
As described above, our RNA-Seq also identified a large
fraction of genes repressed by the agonist L165,041, which
we subsequently refer to as ‘inverse target genes’. As shown
in Figure 4A, less than 9% of these genes (34 out of 385)
harbored a PPAR"/#-RXR binding site, which almost uni-
formly showed low enrichment compared to canonical,
agonist-induced PPAR"/# genes (Figure 4B). This could be
due to their regulation by a non-canonical mechanism in-
volving indirect chromatin recruitment, but these genomic
regions could also be fortuitous non-functional enrichment
sites.
Upstream regulator analysis of the inverse target gene set
identified exclusively cytokine signaling pathways (12 out
of 12) as top regulators (Figure 4C). In agreement with this
finding, published binding sites detected by ChIP-Seq for
IFN$ -induced STAT1 (41), LPS-induced NF%B-p65 (24),
BCL-6 (24) or LPS-induced P300 (43) were found in a sub-
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Table 1. Canonical and inverse PPAR"/# target genes with immune regulatory functions in MDMs (examples)
Canonical target genes
CD1D CD1D molecule
CD36 CD36 molecule (thrombospondin receptor)
CD52 CD52 molecule
CD300A CD300a molecule
CD300LB CD300 molecule-like family member b
DIXDC1 DIX domain containing 1
LRP5 Low density lipoprotein receptor-related protein 5
MME Membrane metallo-endopeptidase
NLRC4 NLR family, CARD domain containing 4
PHACTR1 Phosphatase and actin regulator 1
S100Z S100 calcium binding protein Z
SCARB2 Scavenger receptor class B, member 2
SLAMF9 SLAM family member 9
ST14 Suppression of tumorigenicity 14
Inverse target genes
ARG2 Arginase 2
BCL3 B-Cell CLL/Lymphoma 3
CASP5 Caspase 5, apoptosis-related cysteine peptidase
CCL13 Chemokine (C-C motif) ligand 13
CCL24 Chemokine (C-C motif) ligand 24





CXCL1 Chemokine (C-X-C motif) ligand 1
CXCL10 Chemokine (C-X-C motif) ligand 10
CXCL11 Chemokine (C-X-C motif) ligand 11
CXCL6 Chemokine (C-X-C motif) ligand 6
CXCL9 Chemokine (C-X-C motif) ligand 9
FCGR2B Fc fragment of IgG, low affinity IIb, receptor (CD32B)
IDO1 Indoleamine 2,3-dioxygenase 1
IDO2 Indoleamine 2,3-dioxygenase 2
IL10 Interleukin 10
IL8 Interleukin 8
NLRP12 NLR family, pyrin domain containing 12
TLR3 Toll-like receptor
TNF Tumor necrosis factor !
stantial fraction of the inverse PPAR"/# target genes (Fig-
ure 4D), with BCL-6 and LPS-induced P300 presumably
indicative of NF%B recruitment. These associations suggest
thatNF%Bplays an essential role in the regulation of inverse
target genes by PPAR"/# agonists. RNA-Seq analyses also
identified BCL3 as an inverse target gene (Supplementary
Table S2). Since BCL-3 can activate transcription via nu-
clear NF%B complexes (52), its repression by L165,041 po-
tentially contributes to the inhibition of NF%B target genes.
Proteasome inhibitors block the function of NF%B by
different mechanisms, including a blockade of I%B degra-
dation or an inhibition of NF%B precursor processing (53).
Consistent with the predicted role of NF%B in the regula-
tion of inverse PPAR"/# target genes, we found that the
‘bona fide’ (24) NF%B target genes APOBEC3A, BCL3,
CCL24, FCGR2B, IL10, S100A8 and S100A9were strongly
downregulated by the proteasome inhibitor MG132. The
only exception was IL8, which was strongly induced by
MG132, indicating a different mechanism of regulation,
consistent with published observations (54). A role of
NF%B in the agonist-mediated regulation of inverse tar-
get genes is supported by our observation that MG132 di-
minished the magnitude of repression of several of these
genes to a statistically not significant level in all cases but
APOBEC3A and BCL3. However, repression by L165,041
was not completely abrogated, pointing to the involvement
of other signaling pathways.
In contrast to the canonically regulated genes, the inverse
target genes aremostly associated with functions in immune
regulation as indicated by the diseases and functions an-
notation in Figure 4F. Strong negative correlations were
found for leukocyte migration/movement/homing, prolif-
eration and cell death, indicating an anti-inflammatory and
pro-survival agonist effect via inverse target genes.However,
positive associations with pro-inflammatory functions were
also observed (‘Inflammation of organ’ and ‘Colitis’).
The inverse target genes include cytokines, chemokines
and enzymes involved in immune regulation (Table 1).Most
of these genes are pro-inflammatory (e.g. IL8), but a small
number of immunosuppressive genes are also found among
the inverse target genes (e.g. IDO1), consistent with the
results of the diseases and functions annotation analysis
above.
Functional networks derived from genomic data
In view of the above findings, several functional networks
centered on NF%B (or its upstream regulator TNF!) or
biological functions relevant to immune regulation were
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Figure 4. Genome-wide identification of agonist-repressed (inverse) PPAR"/# target genes. (A) Overlap of genes associated with PPAR"/# and RXR
binding sites in MDMs with L165,041-regulated genes. Number in parentheses indicates low enrichment sites. (B) Cumulative read distribution for all
PPAR"/# binding sites separated into agonist induced and agonist repressed genes. Plotted is the percentage of reads with n or fewer reads in PPAR"/#
ChIP-Seq analyses. (C) IPA ‘Upstream Regulator Analysis’ of L165,041-repressed genes (top regulators by P-value). (D) Percentage of inverse PPAR"/#
target genes in MDMs (this study) with published binding sites (ChIP-Seq) for STAT1 (INF$ induced) (41), STAT3 (IL-10 induced) (42), NF%B-p65 (24),
BCL-6 (24) (43) or P300 (LPS-induced). (E) Effect (fold change) of MG132 (10 &M), L165,041 or a combination of both compounds on inverse target
genes with ‘bona fide’ NF%B binding sites (24-h treatment) in MDMs from five donors. T-tests of the corresponding groups in the two L165,041 panels
against each other showed a statistical significance for CCL24 (P < 0.05). (F) IPA ‘Diseases and Functions Annotation’ of L165,041-repressed genes in
MDMs.
studied in further detail. It is obvious from the pathways
depicted in Figure 5 that numerous L165,041-regulated
genes impact on various aspects of inflammation and/or
immune modulation. Anti-inflammatory, agonist-mediated
mechanisms include inhibition of the NALP1 inflamma-
some through modulation of caspase 5 and multiple mem-
bers of the NOD-like receptor (NLR) family (Figure 5A),
reduced TLR signaling (Figure 5B) and diminished NF%B
activation (Figure 5A).
In contrast, repression of indoleamine 2,3-dioxygenase
1 (encoded by IDO1; Figure 5B), which catabolizes tryp-
tophan to kynurenine, would be predicted to be immune
stimulatory, since both tryptophan depletion and kynure-
nine production have been linked to T cell suppression (55).
Moreover, CD274, which codes for the transmembrane gly-
coprotein PD-L1 (PD-1 ligand; B7-H1) and suppresses T
cell proliferation (56), is repressed by PPAR"/# agonists
(Figure 5B). L165,041 also impinges on the regulation of
macrophage activity by immunoglobulin binding to Fc re-
ceptors (Figure 5C). In this context, repression of the in-
hibitory FCGR2B gene encoding CD32B is of particular in-
terest and points to another immune stimulatory action of
PPAR"/# agonists.
In addition, different pathways of antigen presentation
are modulated by PPAR"/# agonists. These include both
MHCI and MHCII (HLA-DR, HLA-B27) complexes and
MHC-like CD1 proteins involved in the presentation of dif-
ferent lipid antigens (57). These are modulated either di-
rectly by PPAR"/# ligands, by ligand-regulated members
of the leukocyte immunoglobulin-like receptor (LIR) family
and/or by NF%B (Figure 5A and D). As the genes involved
are either canonically or inversely regulated by ligands, and
their encoded proteins include both inhibitory and stimula-
tory molecules, the immune modulatory effect of L165,041
on antigen presentation is likely to be context-dependent.
These predictions clearly point to a specific phenotype
triggered by PPAR"/# agonists that includes both positive
and negative effects on immune regulation, consistent with
the conclusions drawn from the functional annotation anal-
yses above (Figures 2–4).
Ligand-induced anti-inflammatory alterations in human
MDMs
To elucidate the phenotypic alterations induced by
PPAR"/# agonists in MDMs we first analyzed potential
morphological alterations triggered by the PPAR"/#
agonists during the 6-day differentiation period of MDMs.
For comparison, LPS with or without IFN$ (inducing M1
polarization) or IL-4 (triggering M2 polarization) were
added to separate cultures. Figure 6A–E shows a clear
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Figure 5. Effects of L165,041 on immune regulatorymodules. The scheme displays functionalmodules derived from the IPA ‘FunctionalNetworkAnalysis’
(Supplementary Table S6; modules 2, 3, 4 and 10). Pink symbols: genes upregulated by L165,041; green symbols: genes downregulated by L165,041. Dashed
lines: indirect effects or interactions. Encircled areas indicate functional units with pro-inflammatory (red), anti-inflammatory (blue) or context-dependent
(black) functions.
morphological resemblance between L165,041 (agonist)
and IL-4 treated cultures, while PT-S264 (inverse agonist)
induced a morphology reminiscent ofM1 cells. Very similar
results were obtained irrespective of the culture medium
(R10 in Figure 6; XV0 medium in Supplementary Figure
S5).
These morphological alterations are in agreement with
the observed downregulation of pro-inflammatory genes
by L165,041, exemplified by IL8 and CCL24 (Figure
4E), which was confirmed for GW501516 (Supplemen-
tary Figure S6). Consistent with this conclusion we
also found that L165,041 inhibited phagocytosis. As
shown in Figure 6F, L165,041 significantly decreased the
macropinocytotic/phagocytotic activity for FITC-dextran
upon PPAR"/# activation in six independent experiments,
as determined by the diminished uptake of fluorescent
FITC-dextran by MDMs.
Ligand-induced immune stimulatory alterations in human
MDMs
The functional networks in Figure 5 also predicted an
increased T cell activation by agonist-treated MDMs as
antigen-presenting cells. We tested this hypothesis by mea-
suring intracellular IFN$ in CD8+ T cells after coculture
with MDMs exposed to an antigen peptide mix (CEFT).
Figure 7A shows that L165,041 pretreatment of MDMs
(during the 6-day differentiation period) led to a clear in-
crease in the fraction of IFN$+CD8+ cells with samples
from five out of six donors.
The product of the inverse PPAR"/# target gene IDO1,
which suppresses T cell activation via the production of
kynurenine (55), may be involved in this effect. As shown
in Figure 7, the agonist-mediated transcriptional repres-
sion of IDO1 (Figure 7B) was paralleled by a decreased
protein level (Figure 7C; Supplementary Figure S7) and
a clearly diminished release of kynurenine into the super-
natant ofMDMcultures (Figure 7D). Importantly, the level
of kynurenine produced under these conditions was suf-
ficient to significantly inhibit polyclonal (CD3 antibody-
mediated) T cell activation (Figure 7E).
Another potentially important player in this scenario is
the CD274 gene. Figure 7F shows that the inverse regula-
tion of CD274 resulted in a reduced surface expression of
its encoded product, the PD-1 ligand, a key regulator of an
inhibitory T cell checkpoint (56). The agonist-mediated in-
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Figure 6. Inhibitory effects of PPAR"/# ligands on human MDMs. Human monocytes were differentiated in XV0 medium for 6 days in the presence
of the indicated additives. Cells were stained with Giemsa dye after treatment with (A) DMSO (solvent control), (B) L165,041 (agonist), (C) IL-4 (‘M2’
macrophages), (D) PT-S264 (inverse agonist) and (E) LPS (‘M1’macrophages). (F) Effect of L165,041 on FITC-dextran uptake (FACS analysis) byMDMs.
Data of six biological replicates with cells from four different donors are shown.
hibition of kynurenine production may thus cooperate with
downregulation of PD-1 ligand expression to stimulate T
cell activation.
Our bioinformatic analyses also pointed to immune stim-
ulatory effects via the agonist-mediated repression of the
FCGR2B gene. FCGR2B codes for CD32B, a low affinity
Fc$ receptor that inhibits the phagocytosis of opsonized
antigens (58). In contrast to FCGR2B, FCGR2A was only
weakly repressed by L165,041 and not significantly affected
by the inverse agonists ST247 (Figure 7G). FCGR2B repres-
sion led to downregulation of CD32B protein as determined
by flow cytometry (Figure 7H). FCGR2B thus represents
a PPAR"/# target gene potentially mediating an agonist-
triggered immune stimulatory event.
The functional annotation and networks analysis (Figure
2C; Supplementary Table S3) also predicted an inhibition of
cell death of immune cells by L165,041 (Figure 2C), which
could be relevant under the stressful conditions of inflam-
mation. We therefore tested this prediction in the context of
hypoxia and found a clear pro-survival effect of L165,041,
while PT-S264 exacerbated hypoxia-induced cell death, as
indicated by the fraction of healthy cells and cell debris in
Supplementary Figure S8A. A similar effect was seen in
MMT-based viability assays of the adherent cell fraction
(Supplementary Figure S8B). Propidium iodide uptake as-
says showed a time-dependent pro-survival effect of both
PPAR"/# agonists tested (L165,041, GW501516) peaking
on day 4 (Figure 7I). As MDMs do not proliferate under
the culture conditions used here, a ligand effect on prolifer-
ation could not contribute to these observations.
Finally, time-lapse video microscopy revealed a slight,
but statistically significant inhibitory effect of L165,041 on
the motility of MDMs (Supplementary Figure S9), as pre-
dicted by the functional annotation analysis in Figure 2C.
Comparison of the PPAR!/" agonist-induced transcriptome
with defined MDM activation states
A recent study (3) defined a spectrum of macrophage
activation/polarization states extending theM1/M2-model
based on microarray data derived from MDMs exposed to
an array of different stimuli (28 plus baseline). In an at-
tempt to define the PPAR"/# agonist-induced MDM phe-
notype more precisely we compared the L165,041-induced
transcriptome to the 143 comparable microarray data sets
provided by the quoted study (3), as outlined in Figure 8A.
Toward this end, we first identified overlaps between the
PPAR"/# target gene set and the 49 modules representing
coregulated gene sets as defined by Xue et al. (3). Five mod-
ules yielding P-value <0.001 by hypergeometric test were
identified and further analyzed (modules 8, 15, 16, 21 and
43; Figure 8B). For each gene in the overlap between amod-
ule and the L165,041 regulated set, we determined the di-
rection of regulation by L165,041 (as in Supplementary Ta-
ble S2) and the 28 non-baseline stimuli. The heatmap in
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Figure 7. PPAR"/# ligand-induced immune stimulatory alterations in human MDMs. (A) Effects of L165,041 on T cell activation by the recall antigen
peptide mix CEFT. MDMs from six different donors differentiated in the presence of agonist or DMSO (solvent control) were analyzed for their ability to
stimulate CEFT-peptide induced INF$ production by co-cultured autologous T cells. The fraction of CD8+IFN$+ cells was determined by FACS. The
experiment was performed with six independent donors (Do1–Do6) showing a CEFT-directed response. (B) RT-qPCR analysis of IDO1 by L165,041 (24 h)
in MDMs from three donors relative to DMSO control. Each dot represents the average of technical triplicates. (C) Quantitation of immunoblot analyses
of IDO-1 protein expression in L165,041-treated (24 h) MDMs from five different donors relative to DMSO control. Blots are shown in Supplementary
Figure S7. (D) Kynurenine production by MDMs from three different donors treated with L165,041 for 24 h relative to DMSO control. (E) Effect of
L165,041 on polyclonal T cell activation relative to DMSO control (four different donors). (F) FACS analysis of CD274 expression onMDMs treated with
L165,041 or solvent (DMSO) during differentiation (four different donors). (G) RT-qPCR analysis of FCGR2A and FCGR2B expression onMDMs treated
with L165,041 or ST247 during differentiation relative to DMSO control (four donors as in (F)). (H) FACS analysis of CD32A and CD32B, conditions as
in (F). (I) Effect of PPAR"/# ligands on the time course of hypoxia-induced cell death. MDMs were cultured in XV0 medium at <1% oxygen for up to 5
days in the presence or absence of L165,041 or GW501516 and analyzed for propidium (PI) uptake by flow cytometry. Data represent the mean of three
biological replicates with cells from different donors. Horizontal lines in panels (B–H) and error bars in panel (I) indicate the average.
Figure 8B represents gene subsets regulated in the same or
opposite direction in red and blue, respectively. It is evi-
dent that for most stimulation conditions the five module-
specific subsets show divergent directions of regulation. For
instance, the classical inducers of alternative macrophage
polarization (M2), IL-4 and IL-13, regulate genes in mod-
ules 15 and 43 in the same direction as L165,041, but in the
opposite direction in module 16. Pro-inflammatory stim-
uli, like TNF!, IFN$ and LPS (stimulation conditions 10,
19–29), predominantly yield opposite patterns (modules 8
and 16), but also show a weak coordinate regulation within
modules 15 and 43, consistent with a predominantly, but
not exclusive anti-inflammatory effect exerted by L165,041.
On the other hand, lipid-triggered (conditions 14–18) and
agonist-induced patterns are similar in modules 15, 21 and
43. These data are in good agreement with our conclusion
that PPAR"/# induces a unique activation phenotype with
components of anti-inflammatory, pro-inflammatory and
fatty acid-mediated activation states.
Common and cell type-specific PPAR!/" target genes
Finally, we compared the PPAR"/# cistrome and the
ligand-responsive transcriptome with those obtained with
the human myofibroblastic cell line WPMY-1 (18) and the
human breast cancer cell lineMDA-MB-231 (19). TheVenn
diagrams in Figure 9A indicate a clear overlap of genes with
PPAR"/# binding sites in all three cell types (n= 129; Sup-
plementary Table S7). Diseases and functions annotation
revealed a statistically highly significant overlap with energy
production and lipid metabolism (P = 4.3 × 10−9). In con-
trast, there was no inverse target gene common to all three
cell types (Figure 9B). Our genomic studies in conjunction
with the RT-qPCR analyses thus led to three conclusions:
(i) a subgroup of canonical target genes are common tar-
get genes, including those with functions in intermediary
metabolism (Figure 9A); (ii) another subgroup of canon-
ical target genes are cell type-specific, such as CD52 and
LRP5, which are ligand-responsive only inMDMs (Supple-
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mentary Figure S4 and Supplementary Table S2) compared
to WPMY-1 and MDA-MB-231 cells (Figure 9C); and (iii)
inverse target genes, such as IDO1 and IL8, are not regu-
lated in WPMY1 and MDA-MB-231 cells (Figure 9C) as
opposed to the clear ligand regulation in MDMs (Figures
4E and 7B; Supplementary Table S2).
DISCUSSION
Our data show that PPAR"/# target genes in normal
macrophages (MDMs) fall into two major classes. The
first class represents canonical genes with PPAR"/#–RXR
binding sites (PPREs), induced by agonists and repressed
by inverse agonists. The second class is composed of genes
lacking direct PPAR"/# contact sites that are repressed by
agonists, which we have termed inverse regulation. Impor-
tantly, inverse regulation was also seen in murine BMDMs
for several target genes, and was impaired in cells with dis-
rupted Ppard alleles, unequivocally demonstrating the de-
pendence of non-canonical, ligand-mediated repression on
functional PPAR"/#. Clear evidence for the high selectivity
of one of the ligands (GW501516) used in our study is also
provided by published microarray data (36) obtained with
differentiating murine BMCs, as depicted in the evaluation
in Supplementary Figure S10.
Canonical and inverse target genes
A considerable fraction of canonical PPAR"/# target
genes have roles in lipid metabolism shared with other
cell types. These include the known PPAR target genes
with functions in fatty acid oxidation (ACADVL, ACAA2,
CAT, CPT1A, ECH1, PDK4, SLC25A20) or other as-
pects of lipid metabolism (ANGPTL4, FABP4, PLIN2),
but also genes not previously described as PPAR"/# tar-
gets, such as ETFDH and ISCA1. Another large fraction
of direct PPAR"/# target genes are associated with non-
metabolic functions, in particular immune regulation, such
as CD300A, CD52, LRP5, NLRC4 and PHACTR1, and
most of these genes are cell type-selective with respect to
agonist-mediated regulation.
In contrast, inverse target genes are almost exclusively
regulated by PPAR"/# ligands in a cell type-specific
fashion, at least for the three cell types analyzed, i.e.
macrophages, myofibroblastic cells and breast cancer cells.
Consistent with this finding, a large fraction of these genes
are associated with pro-inflammatory functions exerted by
macrophages, including immune cell activation, migration,
chemotaxis and cellular survival, exemplified by a number
of cytokine and chemokine genes (e.g. IL8, CCL24). How-
ever, several inverse target genes have immune suppressive
rather than pro-inflammatory functions, for example IDO1,
CD274 (PD-1L) and CD32B, which play essential roles in
the inhibition of T cell activation. This data strongly sug-
gested that the response to PPAR"/# agonists is mainly
anti-inflammatory, but also has immune stimulatory com-
ponents.
Bioinformatic analyses showed that many of the inverse
target genes are controlled by NF%B and STAT1 signaling
pathways. This finding is consistent with the reported up-
regulation of inflammatory signaling through these path-
ways in adherent monocytic cells (49,50), which appar-
ently is attenuated by PPAR"/# agonists. PPAR"/# has
been reported to impinge on NF%B signaling by physi-
cally and/or functionally interacting with p65 in endothe-
lial cells, cardiomyocytes, smooth muscle cells and ker-
atinocytes (14,20,59,60) or though ERK1/2 signaling in
adipocytes (22). However, in most cases the precise un-
derlying mechanisms are not entirely clear. In mouse
macrophages, a cell type selective mechanism involving the
transcriptional repressor BCL-6 has been identified (23).
BCL-6 is a repressor of NF%B target genes, which is se-
questered by PPAR"/# in the absence of PPAR"/# ago-
nists.
Our own data are consistent with the conclusion that
PPAR"/# agonists repress a subset of NF%B-regulated
genes in macrophages, based on the observation that
MG132 diminished the L165,041 effect on several NF%B
target genes previously identified by ChIP-Seq in mouse
macrophages (24). This effect of MG132 is presumably
due to the inhibition of I%B degradation or a block-
ade of proteasome-dependent processing of p105 to p50
(53). Both effects would lead to the loss of regulation by
NF%B and agonist-mediated regulation, as observed in
our experiments, independent of a potential role of BCL-6
and/or other signaling pathways impinging on NF%B regu-
lation. Obviously, proteasome inhibitors also target numer-
ous other signaling pathways and transcription factors that
might contribute to the observed effect, as exemplified by
IL8, which has been suggested to be induced by protea-
some inhibitors via reactive oxygen-mediated AP-1 activa-
tion (54).
The involvement of PPAR"/# in modulating STAT ac-
tivity is even less understood with all published evidence
restricted to STAT3 (61–64). The identification of strongly
regulated inverse target genes in the present study paves the
way for addressing these open questions using individual
genes as experimental models and for elucidating the mech-
anisms underlying the crosstalk betweenPPAR"/#and pro-
inflammatory signaling cascades.
Effects of PPAR!/" agonists on inflammatory pathways
‘Functional Annotation and Networks Analysis’ indicated
that inflammatory signaling is targeted by PPAR"/#
agonists at two different levels. First, several genes en-
coding pro-inflammatory cytokines (e.g. IL8, IFNG)
and chemokines (e.g. CCL3/MIP1A, CCL8/MCP2,
CCL11/eotaxin, CCL13/MCP4) are downregulated as in-
verse target genes with predicted anti-inflammatory effects.
In addition, a few anti-inflammatory cytokine genes (e.g.
IL10, IL13) are similarly affected, suggesting that agonist
effects on immune cells are not exclusively inhibitory.
Second, our RNA-Seq analyses identified several key
components of NALP inflammasomes as novel PPAR"/#
targets (Figure 5C). These include the canonical target
gene NLR4C and the inverse target genes NLRP1, NLRP3
and CASP5. NLR family proteins act as a sensor of
pathogenic signals and promotes inflammasome assembly,
leading to caspase-1 activation and inflammatory cytokine
(IL-1", IL-18) production (65).NLR4C encoded CARD12
is activated by microbial proteinaceous ligands, while
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Figure 8. Comparison of the PPAR"/# transcriptome with a spectrum of defined MDM activation states. (A) Scheme outlining the basis for the com-
parative analyses. (B) Relationship of PPAR"/# target genes to expression data obtained with 29 different stimuli grouped into 49 coexpression modules
(3). Overlaps between PPAR"/# target genes and each module were determined by hypergeometric test. Modules yielding P-values <0.001 (modules 8,
15, 16, 21 and 43) were further analyzed by determining for each gene the direction of regulation by L165,041 (Supplementary Table S2) compared to
all 29 stimuli (3). Results are displayed for each subset of genes (defined by specific stimulation conditions within individual modules) as a heatmap. The
color code is based on a directional score reflecting the number of genes regulated in the same direction (red) or in opposite directions (blue; for details see
the Materials and Methods section). GC, glucocorticoid; HDL, high density lipoprotein; IC, immune complexes; LA, lauric acid; LiA, linoleic acid; OA,
oleic acid; P3C, Pam3CysSerLys4; PA, palmitic acid; SA, stearic acid; sLPS, standard lipopolysaccharide; TPP, TNF!+PGE2+P3C; upLPS, ultrapure
lipopolysaccharide.
NLRP1 recognizes muramyl dipeptide and diverse stimuli
(e.g. crystalline material, peptide aggregates, bacterial
toxins) can trigger NLRP3 activation (65). Non-canonical
inflammasome activation by Gram-negative bacteria can
involve the additional recruitment of caspase 5, encoded
by another inverse PPAR"/# target gene. Taken together,
these findings indicate that PPAR"/# agonists can have
pro- and anti-inflammatory effects on specific inflamma-
some functions and suggest that the precise outcome is
stimulus-dependent.
Our data confirm and extend a previous study identi-
fying CD300A as a PPAR"/# target gene in macrophage-
like cells derived from the human leukemia cell line
THP-1 (35). In mice, disruption of the Cd300a gene
resulted in pro-inflammatory activation of peritoneal
macrophages, identifying CD300a-mediated inhibitory sig-
naling in macrophages as a critical regulator of intestinal
immune homeostasis (35). CD300E, coding for an activat-
ingCD300 subtype, is repressed byL165,041 (Figure 5D) si-
multaneously with the induction of the inhibitory CD300A
gene, consistent with an immunosuppressive agonist func-
tion via regulation of CD300 family members.
We also identified PHACTR1 as a novel canonical
PPAR"/# target gene. This gene encodes phosphatase and
actin regulator 1, which is involved in the G-actin mediated
control of actomyosin assembly (66) and may thus play a
role in modulating macrophage migration and phagocyto-
sis. However, the agonist-mediated induction of PHACTR1
appears to be inconsistent with the observed inhibition of
phagocytosis/macropinocytosis of FITC-dextran, suggest-
ing that other genes contribute to this effect. An example
isDIXDC1, another canonical PPAR"/# target gene impli-
cated in cell migration by modulating the WNT and PI3K
signaling pathways (67,68).
Immune stimulatory effects of PPAR!/" agonists
As shown by our functional studies, PPAR"/# agonists
stimulate CD8+ T cell activation. Based on our bioinfor-
matic analyses at least two mechanisms may be involved
in this effect, i.e. the IDO-1 mediated catabolism of tryp-
tophan and synthesis of PD-1 ligand (CD274). The in-
hibitory effect of agonists on CD274 and IDO1 transcrip-
tion resulted in a decreased expression of both proteins and
synthesis of the IDO-1 product kynurenine. The latter is a
known suppressor of T cell activation (55), which we con-
firmed for the concentrations achieved in our experimental
system. Repression ofCD274 by PPAR"/# agonist has pre-
viously also been described for human myofibroblastic cells
(69), emphasizing the potential relevance of this regulatory
effect of PPAR"/#. CD274/PD-L1 engagement of the PD-
1 receptor on T cells activates a key checkpoint restraining
T cell activation (56), which constitutes a key component of
immune suppression in the tumor microenvironment. We
also found several genes with functions in antigen presenta-
tion to be modulated by PPAR"/# agonists. Whether these
changes play a role in the observed stimulation of T cell ac-
tivation remains to be investigated.
Pro-survival effects of PPAR!/" agonists
Another clear biological effect of PPAR"/# agonists is the
suppression of macrophage cell death under hypoxia, which
is frequently associated with inflammation (70) and im-
poses environmental stress on the resident inflammatory
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Figure 9. Identification of common and cell type-specific PPAR"/# target genes. (A) Overlap of PPAR"/# binding sites in WPMY-1 myofibroblast-like
cells, MDA-MB-231 breast cancer cells and MDMs. Common target genes (n = 129) were analyzed by IPA Diseases and Functions Annotation. The box
shows the top term by p-value of overlap. (B)Overlap of agonist-repressed genes. (C)RT-qPCR validation of common and macrophage-specific PPAR"/#
target genes in WPMY-1 and MDA-MB-231 cells. Values were normalized to 1 for untreated cells (solvent only) individually for each gene and cell line.
Statistical significance was tested relative to DMSO-treated cells.
cells. This biological effect of PPAR"/# agonists is mirrored
by the observed changes in gene expression. Thus, several
transcription factor genes with death promoting functions
(e.g. ID3 and MYC) are downregulated by agonists, while
genes with pro-survival effects are upregulated (e.g. EGR3
andVDR). Our functional annotation analyses also showed
a strong overlap of PPAR"/# target genes associated with
the inhibition of inflammation and cell survival, suggesting
a functional link. This group indeed harbors a number of
inverse target genes with both pro-inflammatory and death-
promoting functions, for example the cytokines TNF! and
IL-1". In these cases, the downregulation of the same genes
by PPAR"/# agonist may thus contribute to both an atten-
uation of the inflammatory response and a promotion of
cell survival.
A specific macrophage activation state induced by PPAR!/"
agonists
The bioinformatic analyses and biological data described
above clearly indicate that PPAR"/# agonists have a pre-
dominantly, but not exclusively, anti-inflammatory effect on
MDMs. A recent study (3) reporting the transcriptomes for
MDMs exposed to 28 different stimuli provided a resource
to characterize the phenotype of agonist-stimulatedMDMs
in further detail. The authors used these data to define 49
modules of coregulated genes and determined the extent to
which each of these modules was associated with the dif-
ferent stimulation conditions, resulting in the development
of a spectrum model of macrophage activation. Compari-
son of these modules with the transcriptomes of L165,041-
stimulated cells unraveled highly significant overlaps with
activation states triggered by IL-4/IL13, TNF!/INF$ and
fatty acids. These observations clearly confirm the hypothe-
sis that PPAR"/# induces a unique activation phenotype
with components of anti-inflammatory, immune stimula-
tory and lipid-triggered activation states.
CONCLUSIONS
Numerous literature reports have documented an anti-
inflammatory effect of PPAR"/# agonists with few dis-
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crepant findings. However, the molecular mechanisms un-
derlying the regulation of immune cells by PPAR"/#
are only partially understood. In the present study,
we have determined the PPAR"/# transcriptome and
PPAR"/#-RXR cistrome in human MDMs to establish
the global PPAR"/#-regulated signaling network in hu-
man macrophages. This study showed that genes with im-
mune regulatory functions are regulated by PPAR"/# ag-
onists in a macrophage-selective fashion by at least two
mechanisms: (i) canonical regulation, analogous to ubiqui-
tous PPAR"/# target genes withmetabolic functions, which
involves transcriptional induction by agonists and direct
DNA contacts of PPAR"/#-RXR heterodimers, and (ii) re-
pression by agonists (inverse regulation) in the absence of
PPAR"/# DNA binding. The latter mechanism affects to
a large extent NF%B and STAT1 target genes, resulting in
the inhibition of multiple pro-inflammatory mediators in
line with the known anti-inflammatory effect of PPAR"/#
activation. However, consistent with the results of differ-
ent bioinformatic approaches, we also identified specific im-
mune stimulatory effects exerted by PPAR"/# agonists. Be-
sides a pro-survival effect onmacrophages and inhibition of
CD32B surface expression, the most prominent example in
this context is the stimulation of T cell activation. The lat-
ter is presumably linked to the repression of the CD274 and
IDO1 genes, resulting in a diminished surface expression
of PD-1 ligand and a decreased production of the immune
suppressive kynurenine. Consistent with these observations,
the PPAR"/# agonist-regulated transcriptome shows a sig-
nificant overlap with coexpression modules triggered by ei-
ther the anti-inflammatory IL-4 and IL-13 cytokines or the
pro-inflammatory mediators TNF! and IFN$ . These find-
ings clearly indicate that PPAR"/# agonists induce a novel
and unique macrophage activation state with strong anti-
inflammatory but also specific immune stimulatory compo-
nents. Collectively, these findings suggest that contrary to
the prevailing opinion PPAR"/# exerts context-dependent
rather than merely inhibitory functions in immune regula-
tion.
It is obviously of great interest to analyze the effects of
PPAR"/# ligands on macrophages in the context of other
immune cells in vivo. However, the identification of a mouse
model suitable to recapitulate the global role of PPAR"/# in
the human immune system is associated with problems that
cannot easily be solved, if at all. Thus, as suggested by our
own data obtained with murine BMCs, murine BMDMs
and human MDMs, the effect of PPAR"/# ligands on the
transcriptome of myeloid cells appears to be influenced by
their differentiation and/or activation state, and perhaps
also by species-specific effects. This suggests that data ob-
tained with human MDMs may not be easily transferable
to a mouse model. Testing the relevance of our findings in
a physiological setting therefore remains a major challenge
of future studies.
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Figure S2 – Re-ChIP analysis of PPARβ/δ-RXR complexes at the PDK4 enhancer in 
MDMs. After differentiation for 7 days, MDMs (sample size = 5) were fixed with 
formaldehyde, and sequential ChIP (ChIP re-ChIP) was carried out with sc-7197 anti-
PPARβ/δ  (Santa Cruz), sc-553 anti-RXR (Santa Cruz) or rabbit IgG I5006 (Sigma-
Aldrich). For re-ChIP, chromatin complexes were eluted with 50 µl of 1X TE 
containing 2% SDS, 15 mM DTT and protease inhibitors for 30 min at at 37 °C with 
agitation. After centrifugation, the supernatant was diluted 30X with dilution buffer (50 
mM Tris pH 8.0, 200 mM NaCl, 5 mM EDTA, 0.5% NP40). The second round of IPs 
was carried out as described in the Methods section. DNA was analyzed by qPCR 
with primers for the PDK4 upstream enhancer and an irrelevant control region as in 
Figure 1D. The control primers had the following sequences: 








Figure S3 – Expression of the macrophage surface markers CD32, CD64, CD86, 
CD206 and HLA-DR and intracellular CD68 on differentiating MDMs (biological 
replicates with cells from 3 different donors; experimental setup as in Figure 1). 
Staining and FACS analysis were performed as described in Materials and Methods. 
























Figure S4 – RT-qPCR analysis of target gene regulation by L165,041 (agonist; blue 
dots) and ST247 (inverse agonist; red dots). Each dot represents a biological 
replicate with cells from a different donor (n = 4-9). Horizontal lines indicate the 







Figure S5 – Effects of PPARβ/δ ligands on the morphology of human MDMs. Human 
monocytes were differentiated in R10 medium for 6 d in the presence of the indicated 
additives. Cells were stained with Giemsa dye after treatment with (A) DMSO 
(solvent control), (B) L165,041 (agonist), (C) PT-S264 (inverse agonist), (D) LPS 








Figure S6 – RT-qPCR analysis of target gene regulation by GW501516 in MDMs 
compared to L165,041. The data represent 3 experiments performed with cells from 
two different donors; error bars show the standard deviation. *P<0.05; **P<0.01; 







Figure S7 – Immunoblot analysis of IDO-1 expression in MDMs treated with DMSO 
or L165,041. The blot shows the data for cell from five different donors (as in Figure 
7C). L165: L165,041, LDH: lactate dehydrogenase (loading control). IDO-1 bands 
were quantified (ChemiDoc MP) and adjusted to LDH band intensities. Expression 




Figure S8 – Survival of MDMs exposed to hypoxia and L165,041 or PT-S264 for 4 d. 
(A) Photomicrographs of MDMs subjected to hypoxia for 2 days beginning on day 7 
of differentiation in the presence of the indicated ligands or solvent. (B) Viability of 
adherent cells was determined by MTT assay with MDM from 7 different donors as 
follows: After the incubation period, cells were treated with 1.2 mM MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma Aldrich) for four hours 
at 37 °C followed by a three-hour lysis in 0.005 mM HCl and 5% SDS (final 
concentration) at the same temperature. Measurements were performed with a 











Figure S9 – Quantification of the MDM motility by time-lapse video microscopy. Cells 
on day 6 of  differentiation (R0 medium) were treated with DMSO or 1 µM L165,041 
for 2 h and images were captured by life cell video microscopy for 30 min at the 
same conditions as in regular cell culture incubator (37 °C, 5% CO2). Recording was 
carried out with an Axiovert microscope (Zeiss) equipped with a 10x differential 
interference contrast (DIC) objecticve and a CO2 incubator. Images were captured 
every 5 min. Cells were tracked with the Image J / Fiji Plugin "Particle Tracker 
2D/3D" with a chosen radius of 11, a cutoff of 0,0 a percentile between 1-2, a link 
range of 5, a displacement of 60 and Brownian dynamics (Sbalzarini and 
Koumoutsakos, 2005). The data shown are derived from 5 independent experiments, 




Sbalzarini, I.F. and Koumoutsakos, P. (2005) Feature point tracking and trajectory analysis 

























Figure S10 – Specificity of GW501516. Mouse bone marrow cells from wt and Ppard 
null mice were cultured for 2 days in GM-CSF, yielding a mixed population of 
granulocytes and immature monocytic cells at different stages of differentiation, as 
described in ref. 36. These cells were treated for 1 day with 1 µM GW501516 or 
solvent (DMSO) in the presence of GM-CSF. RNA was analyzed by microarrays as 
published (36). The Venn diagrams show the number of genes induced (A) or down-
regulated (B) by the ligand in either wt (blue) or null (red) mice (fold change >1.5).  
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Tumors frequently exploit homeostatic mechanisms that suppress expression of IL-12, 
a central mediator of inflammatory and anti-tumor responses. The p40 subunit of the 
IL-12 heterodimer, encoded by IL12B, is limiting for these functions. Ovarian carcinoma 
patients frequently produce ascites which exerts immunosuppression by means of 
soluble factors. The NFκB pathway is necessary for transcription of IL12B, which is 
not expressed in macrophages freshly isolated from ascites. This raises the possibility 
that ascites prevents IL12B expression by perturbing NFκB binding to chromatin. Here, 
we show that ascites-mediated suppression of IL12B induction by LPS plus IFNγ in 
primary human macrophages is rapid, and that suppression can be reversible after 
ascites withdrawal. Nuclear translocation of the NFκB transcription factors c-REL and 
p65 was strongly reduced by ascites. Surprisingly, however, their binding to the IL12B 
locus and to CXCL10, a second NFκB target gene, was unaltered, and the induction 
of CXCL10 transcription was not suppressed by ascites. These findings indicate that, 
despite its reduced nuclear translocation, NFκB function is not generally impaired by 
ascites, suggesting that ascites-borne signals target additional pathways to suppress 
IL12B induction. Consistent with these data, IL-10, a clinically relevant constituent of 
ascites and negative regulator of NFκB translocation, only partially recapitulated IL12B 
suppression by ascites. Finally, restoration of a defective IL-12 response by appropriate 
culture conditions was observed only in macrophages from a subset of donors, which 
may have important implications for the understanding of patient-specific immune 
responses.
Keywords: IL12B, NFκB, REL, p65, ascites, ovarian carcinoma, macrophages, immunosuppression
2Unger et al. Macrophage IL12B Suppression by Ascites
Frontiers in Immunology | www.frontiersin.org June 2018 | Volume 9 | Article 1425
1. INTRODUCTION
Solid tumors are frequently accompanied by large numbers of 
tumor-associated macrophages (TAMs), and their abundance 
is correlated with poor prognosis in several tumor types (1, 2). 
Advanced ovarian carcinoma (OC) often coincides with consid-
erable accumulation of a malignant peritoneal effusion termed 
ascites which harbors large numbers of floating stromal and 
tumor cells. Its immunosuppressive properties are at least in part 
conferred by soluble mediators (3, 4). Like their counterparts 
from other tumor entities, TAMs isolated from OC ascites display 
an anti-inflammatory phenotype including high expression of the 
hemoglobin scavenger receptor CD163 (5). In follow-up studies, 
we found that the transcriptomes of ovarian carcinoma TAMs 
and those of peritoneal macrophages from non-tumor patients 
are very similar with the exception of a set of genes involved in 
extracellular matrix reorganization (6), which is a hallmark of 
wound healing and tumorigenesis. The expression of this gene 
set is correlated with poor survival (6, 7). On the other hand, 
elevated expression of an interferon (IFN)-inducible gene set in 
TAMs is correlated with improved survival (7). A recent meta-
analysis of TAM studies in OC patients (8) reflects the findings 
that CD163 expression correlates with worse prognosis, while 
pro-inflammatory macrophage polarization is positively associ-
ated with survival.
The ability of human macrophages to produce nitric oxide 
has been debated extensively (9–14). Apparently, their cytotoxic 
activity is rather exerted indirectly via secretion of cytokines, 
especially interleukin-12 (IL-12), which activates cytotoxic 
functions of T and NK cells (15–19). IL-10 is an immunosup-
pressive cytokine present in large amounts in OC ascites (20), 
and there is a strong negative correlation of its level with patient 
survival (5, 21). In the ovarian tumor microenvironment, IL10 
is expressed predominantly by TAMs (3, 21, 22). A critical func-
tion of IL-10 is to repress transcription of IL12B (23, 24), which 
encodes for the p40 subunit of IL-12 and IL-23 that is limiting 
for heterodimer formation. Antigen-presenting cells are the main 
producers of IL-12p40 (25). On the other hand, IL-12 represses 
IL10 transcription. This reciprocal blockade, “the IL-10–IL-12 
circuit” (26), is enforced by positive feedback of IL-10 and IL-12 
production, respectively (27). Mechanisms involved in these posi-
tive feedback loops are interdependent upregulations of IL-10 
and CD163 (28–30) or, vice versa, instigation of IFNγ production 
by T and NK cells upon exposure to IL-12 (31–33); in turn, IFNγ 
enables production of IL-12 by monocytic cells. Indeed, it was 
shown that IFNγ is capable of relieving suppression of IL-12 
production by OC ascites (7, 34) and is, therefore, required for 
the pro-inflammatory feedback loop. Taken together, switching 
between IL-10 and IL-12 production can toggle between the 
anti-inflammatory, immunosuppressive Th2 state, and pro-
inflammatory, tumoricidal Th1 activation (23). The large number 
of immunosuppressive TAMs relative to other hematopoietic cells 
in OC ascites provides them with a decisive, pro-tumorigenic 
role in the microenvironment which at least in part depends on 
efficient suppression of IL12B transcription (4).
IL12B transcription is induced cooperatively by STAT1 and 
the NFκB pathway (27). Stimuli that activate each of these have 
antitumorigenic effects in  vivo (7, 35). A critical role for the 
IFNγ pathway in IL12B expression is highlighted by mutations 
that cause autosomal Mendelian susceptibility to mycobacterial 
disease (MSMD). These were reported to occur in seven genes: 
IL12B, IL12RB1, IFNGR1, IFNGR2, IRF8, ISG15, and STAT1 
(36–38). IFNγ, if present during macrophage differentiation in 
OC ascites in vitro, can override suppression of IL-12 production 
(7, 34). Therefore, gene regulation by IFNγ and STAT1 is gener-
ally functional in macrophages exposed to ascites. Moreover, 
pretreatment of macrophages with IFNγ can prime them for 
stimulus-dependent IL-12 production (39), indicating that an 
IFNγ-mediated effect can limit the amplitude of the response.
The NFκB transcription factor c-REL (from now on abbrevi-
ated as REL), which is predominantly expressed in hematopoietic 
cells (40, 41), is crucial for IL12B expression (42, 43). The require-
ment for NFκB is underscored by the finding that mutations in 
NEMO/IKKG which disrupt induction of IL12B via CD40-IKKγ 
cause X-linked MSMD (37). Concomitant with diminished 
nuclear localization of p65, enhanced expression of p50 was 
observed in murine TAMs. Nuclear p50 may form heterodimers 
that contribute to Il12b suppression, and in TAMs lacking p50, 
Il12b inducibility was restored (44). IL-10 was shown to impinge 
on NFκB-dependent signaling by preventing nuclear transloca-
tion of p65 in human (45, 46) and rat macrophages (47) and of 
Rel in a mouse macrophage cell line (43). In summary, the pro-
tumorigenic and anti-inflammatory effect of ascites may depend 
on restrainment of NFκB function, and IL-10 may be required 
for this effect.
We speculated that ascites disables translocation and chro-
matin binding of NFκB effector transcription factors and, in 
consequence, induction of IL12B transcription. To test this hypo-
thesis, the impact of ascites on the induction of IL12B by the 
NFκB transcriptional activators REL and p65 was investigated. 
Our data show that cell-free OC ascites suppresses IL12B expres-
sion by primary human macrophages upon stimulation with LPS 
and IFNγ in vitro via a reversible mechanism. Both REL and p65 
translocation to the nucleus was strongly impaired by exposure 
to ascites. However, induction of CXCL10 mRNA by LPS and 
IFNγ was unaffected in the presence of ascites. High-throughput 
sequencing approaches after enrichment of several chromatin 
marks were used to map putative regulatory regions of the REL 
target genes IL12B and CXCL10. In the presence of ascites, REL 
and p65 were recruited to the IL12B and CXCL10 loci, indicating 
that their reduced nuclear levels are still sufficient for chromatin 
Abbreviations: APC, antigen-presenting cell; BMDM, bone marrow-derived mac-
rophage; CD, cluster of differentiation; C/EBP, CCAAT/enhancer binding protein; 
ChIP, chromatin immunoprecipitation; ENCODE, encyclopedia of DNA elements; 
GEO, gene expression omnibus; IFN, interferon; IKK, IκB kinase; IL, interleukin; 
IκB, inhibitor of κ light chain enhancer of activated B cells; JAK, Janus kinase; LPS, 
lipopolysaccharide; MDM, monocyte-derived macrophage; MFI, mean fluores-
cence intensity; MIRA, methylated CpG island recovery assay; MSMD, Mendelian 
susceptibility to mycobacterial disease; NFκB, nuclear factor κ light chain enhancer 
of activated B cells; NK, natural killer; OC, ovarian carcinoma; PBMC, peripheral 
blood mononuclear cell; pMDM, monocyte-derived macrophage from a patient; 
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Roswell Park Memorial Institute; RRID, research resource identifier; STAT, signal 
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binding. Furthermore, IL-10 contributes to but is not sufficient 
for full suppression of IL12B expression by macrophages in vitro. 
These data implicate an additional suppressive mechanism, 
mediated by ascites-borne soluble factors, which acts upstream 
of IL12B transcription.
2. MATERIALS AND METHODS
2.1. Ascites Collection and Isolation of 
TAMs From Ovarian Cancer Ascites
Ascites was collected from untreated high-grade serous ovarian 
carcinoma patients undergoing first-line surgery at the University 
Hospital Marburg. Informed consent was obtained from all 
patients according to the protocols approved by the institutional 
ethics committee. Mononuclear cells were isolated from ascites by 
Lymphocyte Separation Medium (Capricorn, no. LSM-A) density 
gradient centrifugation and subsequent enrichment by adherent 
cell positive selection in autologous ascites. Tumor-associated 
macrophages were directly harvested for chromatin immunopre-
cipitation, directly lysed for RNA isolation or cultivated in R5 
medium (RPMI 1640 (Life Technologies, no. 61870044) with 5% 
(v/v) human AB serum (human serum type AB (male), (Sigma 
no. H4522)), and 1 mM sodium pyruvate (Sigma, no. S8636)) or 
in 100% cell-free autologous ascites for 1–2 days with or without 
recombinant 50 ng/ml IFNγ (from E. coli; Biomol, no. 51564) as 
indicated.
2.2. Isolation and Culture of Monocyte-
Derived Macrophages
Buffy coats from healthy adult volunteers were kindly provided 
by the Center for Transfusion Medicine and Hemotherapy at the 
University Hospital Giessen and Marburg. Mononuclear cells were 
isolated from peripheral blood mononuclear cells from female 
healthy donors. Ficoll density gradient centrifugation was per-
formed with Lymphocyte Separation Medium (Capricorn), and 
the cells were further purified by adherent cell positive selection 
of healthy donor monocytes. Monocyte-derived macrophages 
(MDMs) were generated from monocytes (6–12 days differentia-
tion period) from healthy donors by cultivation in RPMI 1640 
(Life Technologies, no. 61870044) with 5% (v/v) human AB 
serum (human serum type AB (male), Sigma no. H4522) and 
1 mM sodium pyruvate (Sigma, no. S8636) (R5 medium) or in 
cell-free ascites from ovarian cancer patients, as indicated.
2.3. Cytokine Treatment
MDMs were stimulated with 100  ng/ml LPS (E. coli 0111:b4 
L4391; Sigma) and 20 ng/ml recombinant human IFNγ (from E. 
coli; Biomol, no. 51564) or 20 ng/ml recombinant human IL-10 
from HEK293 cells (Biomol, no. 97490) as indicated.
2.4. RNA Isolation and RT-qPCR
Total RNA from TAMs was extracted with TRIfast (Peqlab, 
no. 30-2020) or from MDMs with the NucleoSpin RNA kit 
(Macherey&Nagel, no. 740955) according to the manufacturer’s 
instructions. Complementary DNA synthesis was carried out with 
the iScript cDNA Synthesis Kit (Bio-Rad, no. 170-8891SP) according 
to the manufacturer’s instructions with 250–500 ng of purified 
RNA per sample. Quantitative PCR analyses were performed in 
three technical replicates per sample using ABsolute SYBR Green 
master mix (Thermo Scientific, no. AB-1158B) in Mx3000p and 
Mx3005 thermocyclers (Stratagene). The ribosomal protein 27, large 
subunit (RPL27) transcript was chosen for normalization after testing 
three housekeeping genes selected from our RNA-seq datasets with 
eight different TAM samples. RT-qPCR was carried out using the 
following primers: RPL27, AAAGCTGTCATCGTGAAGAAC 
and GCTGTCACTTTGCGGGGGTAG; IL12B, GCGAGGT 
TCTAAGCCATTCG and ACTCCTTGTTGTCCCCTCTG; 
CXCL10, AAGCAGTTAGCAAGGAAAGGTC and GACATA 
TACTCCATGTAGGGAAGTGA. Raw data were evaluated with 
the Cy0 method (48) or the MxPro 4.01 software from Stratagene 
for Ct value calculation as indicated.
2.5. IL-12p40 ELISA
Concentrations of p40 in cell-free supernatants of cultured cells 
were determined in three technical replicates per sample using an 
ELISA kit from Biolegend (no. 430706) according to the instruc-
tions of the manufacturer.
2.6. Flow Cytometry Analysis  
of Macrophages
MDMs were stained with APC-labeled α-CD206 (BioLegend Cat 
#321110 RRID:AB_571885) and PE-labeled α-CD163 (eBiosci-
ence no. 12-1639-42) as described previously (5). Isotype control 
antibodies were from BD Biosciences, Miltenyi Biotech, and 
eBioscience. Cells were analyzed by flow cytometry using a FACS 
Canto II cytometer and FACSDiva software (BD Bioscience), and 
results were calculated as percentage of positive cells and mean 
fluorescence intensities (MFI).
2.7. Subcellular Fractionation
Subcellular protein fractionation was performed after washing 
cells twice with ice cold PBS (Sigma). Cell pellets were subse-
quently lysed in hypotonic cytosol extraction buffer L1 (5 mM 
PIPES pH 8.0, 85 mM KCl, 0.5% (v/v) NP40, protease inhibitor 
mix (Sigma, no. P8340) 1:1,000) for 20–40 min on ice. Lysates 
were collected and centrifuged for 5  min at 2,000 × g, 4  °C. 
Cytosolic extract (CE) supernatants were collected, and nuclear 
pellets were washed once in L1 and subsequently lysed in RIPA 
buffer (10 mM Tris–HCl pH 7.5, 150 mM NaCl, 1% NP40 (v/v), 
1% sodium deoxycholate (w/v), 1 mM EDTA), 1:1,000 protease 
inhibitor Mix (Sigma), 25 U/ml benzonase (Merck Millipore, no. 
70746) for generation of nuclear extracts (NE) in a ratio of 5:1 of 
cytosol to nuclear extract.
2.8. Immunoblotting and Protein 
Quantification
Immunoblots were performed according to standard protocols 
using the following antibodies: α-c-REL polyclonal antibody 
(Cell Signaling Technology Cat #4727 RRID:AB_2178843); 
α-p65/RELA monoclonal antibody (Cell Signaling Technology 
Cat #8242 also 8242P, 8242S RRID:AB_10859369); α-
LDH polyclonal antibody (Santa Cruz Biotechnology Cat 
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#sc-33781 RRID:AB_2134947); α-acetyl-histone H3 poly-
clonal antibody (Millipore Cat #06-599 RRID:AB_2115283); 
α-β-actin (AC-15) monoclonal antibody (Sigma-Aldrich Cat 
#A5441 RRID:AB_476744); α-rabbit IgG, HRP-linked (Cell 
Signaling Technology Cat #7074 also 7074S, 7074V, 7074P2 
RRID:AB_2099233), and α-mouse IgG, HRP-linked (Cell 
Signaling Technology Cat #7076 also 7076S, 7076V, and 7076P2 
RRID:AB_330924). Imaging and quantification was done using 
the ChemiDoc MP chemoluminescence imaging system and 
Image Lab software version 5 (Bio-Rad).
2.9. RNA Interference
Small interfering RNA transfection was performed according to 
the manufacturer’s protocol using the TransIT-X2 reagent from 
Mirus (no. 6000) or the Viromer GREEN reagent (Lipocalyx, 
no. 230055). The following equimolar mixtures of three siRNA 
oligonucleotides each from Sigma were used for transfection of 
macrophages: REL SASI-Hs01-00064620, SASI-Hs01-00064621, 
SASI-Hs01-00064622. Set of four Upgrade ON-TARGETplus 
from Dharmacon was used for RELA (LU-003533-00-0002), con-
taining four siRNA oligonucleotides. MISSION siRNA Universal 
Negative Control #2 from Sigma was used as a control siRNA 
(si-ctrl). Cells were harvested 48 h after transfection.
2.10. Generation of Murine Bone Marrow-
Derived Macrophages, Il12b Quantitative 
RT-PCR, and Il-12p40 ELISA
BMDMs were generated by cultivation of 2 × 106 bone marrow 
cells/well derived from wild-type and Rel−/− mice in RPMI 1640 
medium supplemented with 10% heat-inactivated FCS and 10 ng/ml 
macrophage colony-stimulating factor (PeproTech) in six-well 
plates. After one week of cell culture, purity was tested by FACS 
staining for CD11b. Subsequently, BMDMs were stimulated 
with either LPS alone (100 ng/ml) or with LPS (100 ng/ml) in 
combination with recombinant IFNγ (10  ng/ml). 24  h after 
stimulation of BMDMs, supernatants from cell cultures were 
harvested. Murine Il-12p40 was measured with an ELISA kit 
(BD Biosciences, no. 555165) according to the manufacturer’s 
protocol. Total RNA was extracted from BMDM-derived cell 
pellets using the High Pure RNA Isolation Kit (Roche, no. 
11828665001). cDNA was synthesized using the RevertAid First 
Strand cDNA Synthesis Kit (Thermo Scientific, no. K1621). 
Gene expression was analyzed with a 7500 Fast Real-Time PCR 
System (Applied Biosystems). The gene expression of Hprt1 was 
measured as an internal control. The following primer sets were 
used: Hprt1, CTGGTGAAAAGGACCTCTCG and TGAAGTAC 
TCATTATAGTCAAGGGCA; Il12b, ATGTGTCCTCAGAAG 
CTAACCATC and CGTGTCACAGGTGAGGTTCACT.
2.11. Chromatin Immunoprecipitation  
and MIRA
After adherence selection in Greiner tissue culture flasks (no. 660175) 
in autologous ascites, TAMs were washed with PBS twice. MDMs 
were differentiated as indicated. Fixation was performed with 1% 
formaldehyde in PBS for 10 min at room temperature followed by 
quenching with 125 mM glycin for 5 min. Cells were washed with 
ice-cold PBS twice and harvested using a cell scraper. The pellet was 
lysed in hypotonic buffer L1 (5 mM PIPES pH 8.0, 85 mM KCl, 
0.5% (v/v) NP40) with protease inhibitor mix (Sigma, no. P8340, 
1:1,000) for 20–40 min on ice. Nuclei were resuspended in ChIP 
RIPA buffer (10 mM Tris–HCl pH 7.5, 150 mM NaCl, 1% NP40 
(v/v), 1% sodium deoxycholate (w/v), 1 mM EDTA) supplemented 
with 1:1,000 protease inhibitor mix (Sigma), incubated on ice for 
10–20 min and sheared with a Branson S250D Sonifier (Branson 
Ultrasonics) using a microtip in 1 ml aliquots in 15 ml conical tubes. 
52 pulses of 1 s, 4 s pause, 20% amplitude were applied with cooling 
of the sample in an ice–ethanol mixture or in a 15 ml tube cooler 
(Active Motif, no. 53077). A 15 min 20,000 × g supernatant was 
precleared with 10 µg of IgG coupled to 100 µl of blocked sepharose 
slurry (see below) for 45 min at 4 °C with agitation. IP was carried 
out with 300 µl of precleared chromatin, equivalent to 3–8 × 106 
cells. For MIRA, an aliquot of the sample was reverted as described 
below, purified on a Qiagen PCR purification column (no. 28106), 
and 250 ng of DNA were used according to the manufacturer’s 
instructions (Methylcollector Ultra, Active Motif, no. 55005). 
ChIP was performed and evaluated as described using 4 µg per 
sample of the following antibodies: IgG pool, (Sigma-Aldrich Cat 
#I5006 RRID:AB_1163659) or normal rabbit IgG (Cell Signaling 
Technology Cat #2729S RRID:AB_1031062); α-c-REL (Santa 
Cruz Biotechnology Cat #sc-70 RRID:AB_2178727 and Santa 
Cruz Biotechnology Cat #sc-71 RRID:AB_2253705, 1:1 mixture); 
α-p65/RELA (Diagenode Cat #C15310256 RRID:AB_2721009); 
α-p65/RELA (Cell Signaling Technology Cat #8242 also 8242P, 
8242S RRID:AB_10859369); α-H3K27me3 (Diagenode Cat #pAb-
069-050 also ENCAB000ARJ RRID:AB_2616049); α-H3K4me3 
(Diagenode Cat #pAb-003-050 also ENCAB000BKU, C15410003-
50, C15410003-10 RRID:AB_2616052); α-H3K27ac (Diagenode, 
Diagenode, Cat #C15410174, RRID:AB_2716835); α-H3K4me1 
(Diagenode Cat #pAb-037-050, RRID:AB_2561054); α-H3K9me3 
(Diagenode Cat #pAb-056-050, RRID:AB_2616051); α-H3K36me3 
(Abcam Cat #ab9050, RRID:AB_306966); α-C/EBPβ (Santa Cruz 
Biotechno logy Cat #sc-150, RRID:AB_2260363). For precipitation, 
a mixture of protein A and protein G sepharose (GE Healthcare 
life sciences, no. 1752800 and no. 1706180) was washed twice with 
ChIP RIPA buffer and blocked with 1 g/l BSA and 0.4 g/l sonicated 
salmon sperm DNA (Life Technologies no. 15632011) overnight. 
50 µl of blocked bead slurry (1:1 volume ratio with liquid phase) were 
used per IP. Samples were washed once in buffer I (20 mM Tris pH 
8.1; 150 mM NaCl; 1% (v/v) Triton X-100; 0.1% (w/v) SDS; 2 mM 
EDTA), once in buffer II (20 mM Tris pH 8.1; 500 mM NaCl; 1% 
(v/v) Triton X-100; 0.1% (w/v) SDS; 2 mM EDTA), twice in buffer 
III (10 mM Tris pH 8.1; 250 mM LiCl; 1% (v/v) NP40; 1% (w/v) 
sodium deoxycholate; 1 mM EDTA) on ice, and twice in Qiagen 
buffer EB (no. 19086) at room temperature. Immune complexes 
were eluted twice with 100 mM NaHCO3 and 1% SDS (w/v) under 
agitation. Eluates were incubated overnight at 65 °C after adding 
10 µg of RNase A and 20 µg of proteinase K in the presence of 
180 mM NaCl, 35 mM Tris–HCl pH 6.8, and 9 mM EDTA. An 
input sample representing 1% of the chromatin used per IP was 
reverted in parallel. Samples were purified using the Qiagen PCR 
purification kit according to the manufacturer’s instructions, except 
that DNA-binding lipids were removed by washing the matrix twice 
with pure methanol as described (49) previous to the final washing 
step with the buffer included in the kit. ChIP-qPCR was performed 
in three technical replicates per sample with the ABsolute SYBR 
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Green master mix (Thermo Scientific, no. AB-1158B) in Mx3000p 
and Mx3005 thermocyclers (Stratagene) using the following 
primers: IL12B −1,200  bp CCATCCCTGCTCTCGACCT and 
GAAATCTGCGCCCGCCTAAA; IL12B TSS, AGTGCTTA 
CCTTGCTCTGGG and TACCAGCAACAGCAGCAGAA; 
IL12B +20  kbp, ACGCCGCCCTAGAAGAAG and TCCC 
TTTCACCTTCTCTGGA; CXCL10 −5,000  bp, AGCTGGTG 
CAGAATATGCCTT and CACTGTGAGCTCGGGGAATC; 
CXCL10 TSS, GAAGTCCCATGTTGCAGACTC and AACAGT 
TCATGTTTTGGAAAGTGA. Data were evaluated using the 
MxPro 4.01 software from Stratagene for Ct value calculation. 
Relative recoveries were determined as percentage of input using 
a ΔCt method (50).
2.12. Library Preparation and High-
Throughput Sequencing
Libraries were synthesized from 1–2 ng of genomic DNA using 
the MicroPlex kit (Diagenode, no. C05010011) according to 
the manufacturer’s instructions. Samples were sequenced on an 
Illumina Hi-Seq 1000 (single-ended, 50 bp).
2.13. Statistical Tests
Paired t-tests were used to calculate p-values.
2.14. Bioinformatics and Data Deposition
Mapping of ChIP-Seq reads and peak calling were carried out as 
described (49). Peaks were filtered for at least 30 deduplicated 
tags and a fold change (FC) over IgG of ≥2 (normalized total 
read counts). All genomic sequence and gene annotation data 
were retrieved from Ensembl revision 74. ChIP-seq data were 
deposited at ArrayExpress (no. E-MTAB-6297).
3. RESULTS
3.1. Suppression of IL12B in Monocytic 
Cells From Ovarian Carcinoma Patients Is 
Mediated by Soluble Factors From Ascites
We initially assessed whether the inability of TAMs to produce 
IL-12p40 is reversible in our experimental setups. Ex vivo TAMs 
were in autologous ascites or in normal medium (RPMI 1640 sup-
plemented with 5% adult human serum, “R5”) for 1 day or 2 days 
and stimulated with LPS and IFNγ 24 h prior to harvesting. IL12B 
expression was induced on both mRNA (Figure 1A; RT-qPCR) 
and protein levels (Figure 1B; α-p40 ELISA) in cells from four out 
of eight patients cultivated in ascites. After cultivation in autolo-
gous ascites for 2 days, the transcript and the protein were induc-
ible to a lesser extent; LPS and IFNγ were added to the cultures 
24 h prior to harvesting. The presence of IFNγ for the whole time 
of cultivation in 2 days samples led to increased induction. We 
conclude that suppression of IL12B in TAMs happens primarily 
at the transcriptional level, and suppression can be counteracted 
by IFNγ, as it was shown by others (34). Furthermore, we found 
that expression was inducible without IFNγ pretreatment in some 
samples (Figure 1). It is important to note that we added IFNγ 
in parallel with LPS to non-pretreated cultures, while the afore-
mentioned study used LPS as a single stimulus after pretreatment 
with IFNγ (34). Apparently either a subpopulation of the cells 
from these patients is responsive to LPS and IFNγ ex vivo, or the 
autologous ascites samples are less capable of IL12B suppression. 
Strikingly, TAMs cultivated in normal medium in the absence of 
IFNγ were able to induce IL12 transcription to similar levels as 
TAMs cultivated in ascites in the presence of IFNγ (Figure 1A). 
Cultivation in normal medium led to detectable transcripts in all 
donors analyzed (N = 8), while cultivation in the presence of IFNγ 
had this effect only in five out of eight donors. Taken together, this 
suggests that ascites-mediated suppression of IL12B induction is 
reversible, and this may depend on differences between ascites 
samples as well as cells from individual donors. Presumably due 
to biological heterogeneity, differences between the induced and 
non-induced conditions regarding p40 protein levels were not 
statistically significant when analyzing supernatants from TAMs 
cultivated in ascites (Figure 1B).
IL12B expression data from TAMs cultivated in normal 
medium or in ascites supplemented with IFNγ suggest that these 
cells are generally capable of inducing this transcript. Its induction 
in the presence of ascites could be due to an effect on monocytic 
cells that were freshly recruited to the tumor microenvironment 
and thus not yet strongly affected by ascites, or the effect of ascites 
on IL12B could be of a reversible nature. We, therefore, conducted 
the following experiments in MDMs differentiated from healthy 
donor monocytes in vitro in normal medium (R5) or in ascites as 
described previously (7)—this culture system allows for controlled 
differentiation as well as short-term treatment of cell populations 
that are less heterogeneous than TAM isolates. High levels of 
IL-12p40 can be produced by MDMs, and this is suppressed by 
ascites but overcome in the presence of IFNγ (7, 34). Priming of 
MDMs differentiated in R5 with IFNγ prior to stimulation with 
LPS and IFNγ did not potentiate IL-12p40 production (Figure S1 
in Supplementary Material), indicating that our culture condi-
tions do not limit expression of p40 in this regard.
3.2. Suppression of IL12B Can Be 
Reversible Upon Ascites Withdrawal
When MDM differentiation was carried out in normal medium 
for 6 days and followed by exposure to ascites for 1 day (short-term 
exposure, which was applied simultaneously with LPS and IFNγ), 
IL12B (Figure 2A, N =  5), and IL-12p40 (Figure 2B, N =  8) 
induction was efficiently suppressed. The effect was reverted in 
all MDM samples on RNA level by ascites withdrawal for 1 day 
after short-term exposure (Figure 2A), which was statistically 
significant; however, cells from most donors produced little or no 
p40, while others produced considerable levels (3/8; Figure 2B). 
This further point to a highly variable effect due to heterogeneity 
between biological samples, which could be due to the use of dif-
ferent ascites samples, different healthy donors, or both.
To clarify whether long-term exposure to ascites has lasting 
effects on the capacity of MDMs to express IL12B, monocytes 
from three healthy donors were differentiated either in R5 or in 
each of five different cell-free ascites samples from OC patients 
for 12 days (long-term exposure) in order to mimick the cellular 
state after differentiation in the ovarian tumor microenviron-
ment. IL12B induction by LPS and IFNγ was markedly reduced 
AB
FIGURE 1 | IL-12 production by tumor-associated macrophages from ovarian carcinoma patients is suppressed by ascites in vitro. (A) Ex vivo TAMs (N = 8) were 
cultivated in autologous ascites in the presence or in the absence of IFNγ or in normal medium (R5) as indicated, and non-cultivated ex vivo TAMs served as an 
additional control. LPS and IFNγ or their respective solvents (vehicle) were added to the culture supernatants for 24 h prior to harvesting, and IL12B expression  
was measured by RT-qPCR. (B) Secreted IL-12p40 from these TAMs was measured by ELISA (N ≥ 6). Cell-free autologous ascites was used as additional control. 
Each dot denotes a biological replicate. Median values are indicated by horizontal bars. Colors encode individual patients, and colors are consistent between panels 
within this figure. Statistical significances were calculated with paired t-tests. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
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in ascites-differentiated MDMs vs. MDMs differentiated in 
R5 medium on both mRNA (Figure  2C) and protein levels 
(Figure 2D). Although, suppression was not complete in some 
cultures, and this depended on both the donor cells and the 
ascites samples. MDMs differentiated in ascites for 6 days clearly 
induced IL12B expression after ascites withdrawal for 6 days 
(Figures 2C,D), albeit to lower levels than MDMs cultivated 
in normal medium for 12 days. Importantly, this happened in 
MDM cultures from all three donors in combinations with dif-
ferent ascites samples; p40 was detected in all but two combina-
tions of donor cells with ascites samples. Induction after ascites 
withdrawal was elevated, but the effect did not reach statistical 
significance except for one comparison (Figure  2D, upper 
right panel). This can be attributed to the limiting number 
of samples analyzed and, importantly, to biological variation. 
Some ascites samples exerted suppressive effects that resulted 
in no or lesser reversibility, and MDMs from individual donors 
were susceptible to suppression by different ascites samples in 
a differential manner. We conclude that suppression of IL12B 
expression by OC ascites is reversible by ascites withdrawal 
in principle. On RNA level, reversal was more effective after 
short-term exposure. Since suppression was functional when 
ascites was added simultaneously with LPS and IFNγ, these 
data suggest that a suppressive mechanism acts immediately 
at the level of transcription and can affect MDMs which were 
differentiated in the absence of ascites (Figure 2A). Additional 




FIGURE 2 | Ascites-mediated suppression of IL12B in monocyte-derived macrophages is reversible upon ascites withdrawal. IL12B expression induced by LPS 
and IFNγ in MDMs (differentiated as indicated) was measured by RT-qPCR (A,C) or in culture supernatants by ELISA (B,D). Cells were stimulated for 24 h prior to 
harvesting, or the respective solvents (vehicle) were added, respectively. (A,B) Each dot denotes a biological replicate (healthy donor; N ≥ 5) randomly combined 
with different ascites samples encoded by color. (C,D) Colors encode ascites samples from five different patients; shapes encode different healthy donors (N = 3). 
Median values are indicated by horizontal bars. Statistical significances were calculated with paired t-tests. *P < 0.05; ns, not significant.
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The observation that IL12B suppression by ascites is rapid and 
reversible suggests that at least some of the mechanisms involved 
do not elicit a stable macrophage polarization state. In order to 
systematically characterize the state of MDMs upon suppression 
of IL12B expression by ascites in vitro, monocytes were differenti-
ated in normal medium, in ascites in the presence of recombinant 
IFNγ, or in normal medium for 6 days followed by ascites for 
1 day (short-term exposure). Under these conditions, we found 
that ascites leads to increased expression of the markers CD163 
and CD206, indicating alternative polarization (Figure S3 in 
Supplementary Material). Upon cultivation in ascites in the pres-
ence of IFNγ, induction of these markers was partially reversed, 
concomitant with a restoration of IL12B inducibility. It can, there-
fore, not be excluded that an altered macrophage differentiation 
state might contribute to the blockade of IL12B transcription in 
TAMs. This notion would be consistent with the observed stable 
IL12B suppression by a prolonged exposure of MDMs to ascites.
3.3. Ascites Reversibly Suppresses 
Nuclear Translocation of REL and p65
Since suppression of IL12B induction by ascites is immediate 
and acts on the level of transcription, an obvious assumption is 
that NFκB function is compromised due to high levels of IL-10 
in ascites. Nuclear translocation of REL was detected after both 
1 and 2.5  h of stimulation with LPS and IFNγ in our MDM 
culture system in cells differentiated in normal medium (Figure 
S2B in Supplementary Material), and the latter time point coin-
cided with measurable synthesis of IL12B mRNA (Figure S2A 
in Supplementary Material). This is in line with the regulation 
of “second wave” NFκB target genes such as IL12B (51). For 
subsequent analyses, LPS and IFNγ were added to the culture 
supernatants 2.5 h prior to harvesting.
According to our mass spectrometry data, REL, p65, and p50 
are the main NFκB transcription factors expressed in TAMs (52). 
Nuclear translocation of the transcriptional activators REL and 
p65 was assessed by subcellular fractionation of MDMs after 
short-term (24 h) or long-term exposure to ascites (differentiation 
for 6 days or more). Representative immunoblots are shown in 
Figures S4B,C in Supplementary Material. Long-term exposure 
abrogated measurable REL translocation in six out of nine donors 
(Figure 3A) and translocation of p65 in all three donors analyzed 
(Figure 3C). Short-term exposure was less effective; detectable 
REL translocation was lost in two out of six donors (Figure 3B) and 
that of p65 in one out of three (Figure 3D). Although, exposure 
to ascites strongly reduced nuclear translocation in cells from all 
donors. Strikingly, ascites withdrawal for 1 day reinstalled nuclear 
localization of both REL (Figure 3B) and p65 (Figure 3D) in 
MDMs exposed to ascites for 24 h, which, however, did not reach 
the same levels as those of MDMs not exposed to ascites. In cells 
from the same donors used for short-term exposure experiments, 
reinstallation happened only in two out of three donors for REL 
(Figure 3A) and in one out of three donors for p65 (Figure 3C) 
after long-term exposure and 6 days of ascites withdrawal. Taken 
A B
C D
FIGURE 3 | Ascites impairs inducible nuclear translocation of REL and p65 in monocyte-derived macrophages. MDMs were differentiated in R5 medium or in 
ascites and cultivated consecutively as indicated. Cells were incubated with LPS and IFNγ for 2.5 h or their respective solvents (vehicle), harvested, and subcellular 
fractionation was performed. After immunoblotting, chemoluminescence was measured, nuclear levels of REL were calculated relative to the R5 control population 
after long-term ascites exposure with (N = 9) or without (N = 3) ascites withdrawal (A) or after short-term exposure (B), respectively (N = 6 or N = 3 as plotted). 
Nuclear p65 levels were analyzed in a subset of the same samples (N = 3) accordingly (C,D). Each color denotes a biological replicate (combination of healthy 
donor and randomly chosen ascites sample). Dots mark samples which were probed for both REL and p65 nuclear translocation. The code is consistent between 
panels within this figure. Median values are indicated by horizontal bars. Statistical significances were calculated with paired t-tests; ns, not significant (P > 0.05).
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together, this demonstrates that impairment of REL and p65 
nuclear translocation by ascites is rapid, and the effect can be 
reversible upon ascites withdrawal.
Nuclear localization of the NFκB transcriptional activators 
is controlled by IκB proteins, and their involvement in IL-10-
mediated impairment of NFκB function is well documented 
(46, 53). We, therefore, measured the levels of IκBα, Iκβα, and IκBε 
proteins after stimulation of MDMs with LPS and IFNγ (Figures 
S5A–C in Supplementary Material; representative immunoblots 
are shown in Figure S4A in Supplementary Material) and found 
that, despite nuclear localization of REL, cellular IκBα levels 
were increased upon stimulation in all cell populations analyzed 
(Figure S5A in Supplementary Material). The levels of IκBβ 
and IκBε were strongly decreased upon stimulation under all 
conditions (Figures S5B,C in Supplementary Material). This is 
in line with the described positive feedback mechanism of IκBα 
after its initial rapid degradation, which subsequently leads to 
enhanced protein levels (53). Inducible Iκβα degradation was 
more pronounced in cells differentiated in ascites (Figure S5B 
in Supplementary Material). In conclusion, we did not observe a 
correlation between the levels of IκB proteins and the diminished 
capacity of IL12B transcription in MDMs exposed to ascites 
relative to non-exposed cells.
3.4. Induction of CXCL10 Expression Is 
Not Prevented in the Presence of Ascites
Because nuclear translocation of REL and p65 is diminished in 
the presence of ascites, we speculated that transcription of target 
genes other than IL12B may be affected. CXCL10/IP10 is a bona fide 
REL (54–56) and p65 target gene (57) which, however, is expressed 
in TAMs (7). A subset of cDNA samples shown in Figure 2 was 
used to test ascites-mediated effects on the induction of CXCL10 
expression. We found that the levels of this highly inducible 
transcript—ΔCy0 ≥  10 in most sample combinations, which is 
equivalent to >1,000-fold induction—were weakly reduced after 
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short-term exposure, reaching statistical significance, and signifi-
cantly elevated after short-term exposure and ascites withdrawal 
(Figure S6A in Supplementary Material). However, mean CXCL10 
levels (calculated for a total of six samples from three individual 
donors) were unaffected in MDMs stimulated with LPS and IFNγ 
after long-term exposure and ascites withdrawal (Figure S6B in 
Supplementary Material). CXCL10 expression was uniformly high 
upon induction after both short-term and long-term exposure to 
ascites (Figures S6A,B in Supplementary Material). In some MDM 
populations, transcript levels were inducible to even higher levels 
compared to the control sample after long-term exposure (Figure 
S6B in Supplementary Material). In summary, this argues against a 
direct effect of ascites on CXCL10 transcription. Therefore, our data 
do not show that mRNA synthesis of CXCL10 is prevented in the 
presence of ascites. This argues against a general ascites-dependent 
perturbation of the function of REL and p65 provided that CXCL10 
is a direct target gene.
3.5. Chromatin Marks and Regulatory 
Elements at the IL12B Locus
Since translocation of REL and p65 is impaired in the presence 
of ascites, and IL12B mRNA induction is prevented, while that 
of CXCL10 is not, an obvious hypothesis is that these transcripts 
are subject to gene-specific regulation. In order to address ascites-
mediated effects on NFκB target genes, which are possibly locus-
specific, we sought to map histone modifications and regulatory 
elements at these REL and p65 target genes in primary macrophages 
in an unbiased approach. To this end, ChIP-seq was performed in 
ex vivo OC TAMs with antibodies against the histone modification 
marks H3K4me1 (histone H3 lysine 4 monomethylation), 
H3K4me3, H3K9me3, H3K27me3, H3K27ac (H3K27 acetylation), 
H3K36me3, as well as the transcription factor C/EBPβ. Genome 
browser snapshots of the IL12B locus (Figure 4A) indicate that 
H3K4me1, which marks enhancer sequences, was detected at 
four sequence stretches within 25  kbp from either end of the 
coding region. These stretches are distinguished by the following 
features: (I) C/EBPβ binds to a region 11  kbp upstream of the 
IL12B transcription start site (TSS); (II) a region 7 kbp upstream 
of the TSS is decorated with H3K27ac, which marks active positive 
regulatory elements; (III) a local enrichment of H3K4me3 is 
localized 1,200 bp upstream of but not at the TSS itself, where 
this mark is usually found at active and poised genes (58); (IV) a 
region 4,500 bp downstream of the gene (20 kbp downstream of 
the TSS) harbors H3K27me3-modified nucleosomes, indicative of 
the Polycomb repressive complex 2 (58).
All four designated regions harbor highly conserved sequ-
ences, and none of them carry the heterochromatin mark 
H3K9me3. Consistent with minute or absent expression of 
IL12B transcripts in ex vivo OC TAMs (7), the coding region 
is devoid of the transcription elongation marker H3K36me3. 
Poorly annotated transcripts originate from regions III and IV. 
These long non-coding RNAs generally correlate with regulatory 
roles of the respective DNA sequences (59). Region II possibly 
is in spatial proximity to region I, since a minor but noticeable 
enrichment was caused by the C/EBPβ antibody at this site, 
which could be due to indirect crosslinking. We assume that 
regions I and II do not mediate repression due to the presence 
of the activating H3K27ac mark at region II and the absence of 
repressive marks at both regions.
The unusual configuration of the H3K4me3 mark appearing 
at a −1,200 bp upstream site (region III) but not at the TSS seems 
to be a hitherto undescribed characteristic of a set of cytokine-
encoding genes: in our dataset, we observed similar distances 
at, for instance, CXCL10/IP10 (−5,000 bp) and IL2 (−2,000 bp), 
which both are REL target genes (42, 54–56, 60). Genome 
browser snapshots of both loci are shown in Figures S9A,B in 
Supplementary Material. CXCL10 is expressed in OC TAMs as 
well as in peritoneal macrophages from tumor-free patients (6, 7), 
while IL2 is not a transcribed gene in macrophages and hence is 
devoid of active marks but apparently harbors H3K4me3- and 
H3K4me1-modified nucleosomes within 2,000  bp of its TSS. 
We excluded the possibility that these H3K4me3 upstream shifts 
relative to the TSSs are due to mapping artifacts; moreover, these 
observations were confirmed in published datasets such as those 
from ENCODE (ChIP-seq tracks for H3K4me3; GSM1003536 
and GSM945225 for monocytes; and GSM788075 for PBMCs) 
and an early ChIP-seq study in the Jurkat human T cell line (61).
Strikingly, a weak enrichment of region IV was also caused 
by the H3K4me3 antibody, which strongly enriches region III. 
Reciprocally, reads from the α-H3K27me3 ChIP, which are 
most prominent at region IV, are more densely spaced in an 
extended stretch, which encompasses region III and the TSS 
of IL12B, relative to the coding region. Taken together, region 
IV may be in proximity to region III in OC TAMs, since each 
region’s more prominent of these two histone marks is, to a lesser 
extent, mirrored at the other region, presumably due to indirect 
crosslinking. The presence of both H3K4me3 and H3K27me3 at 
the same locus is reminiscent of the bivalent state which allows 
for stable repression and comparably fast induction of expression 
that was first described for developmental genes (58); however, 
bivalent genes carry the marks at or close to their TSSs.
To investigate whether cytosine methylation is involved 
in repression of IL12B in TAMs, we used MIRA (methylated 
CpG island recovery assay)-seq (62). CpG island methylation 
was not detected at the promoter region of IL12B, while robust 
signals originated at the penultimate exon and a region 9  kbp 
upstream of the TSS (Figure 4A). Importantly, the promoter as 
well as conserved sequences upstream (region I) and downstream 
of the coding region, 20 kbp from the TSS (region IV), harbor 
CpG islands according to DBCAT analysis (63), but were not 
enriched by MIRA. The human Jurkat T cell line and other cell 
lines analyzed show an enrichment of methylated CpG sequences 
at the promoter and region IV according to ENCODE datasets 
(with GEO accession numbers; Jurkat: GSM999367, HeLa-S3: 
GSM999337, H1: GSM999379, HepG2: GSM999338, HL-60: 
GSM999386, GM12878: GSM999376, K562: GSM999341, 
HUVEC: GSM999364, Ovcar-3: GSM999393). This potentially 
means that methylation of region IV and the promoter regulates 
cell-type specific expression of IL12B.
In summary, the next-generation sequencing analyses led to 
the hypothesis that suppression of IL12B in TAMs is mediated 
by an H3K27me3-dependent mechanism and involves the 




FIGURE 4 | Chromatin marks at the IL12B locus. (A) A genome browser snapshot, including ChIP-seq tracks for α-H3K4me3, α-H3K4me1, α-H3K9me3, 
α-H3K27me3, α-C/EBPβ, α-H3K27ac, α-H3K36me3, IgG (unspecific polyclonal rabbit IgG pool) chromatin immunoprecipitations, and MIRA from a TAM sample 
freshly isolated from ovarian carcinoma ascites. Regions of interest are highlighted by rectangles. (B–D) ChIP-qPCR analyses of the indicated histone marks in an 
independent TAM sample at the indicated genomic locations amplified by specific primers are indicated. The error bars denote SDs from technical PCR replicates. 
(E–G) ChIP-qPCR analyses of the indicated histone marks in MDMs from three different pooled donor populations (N = 3; N = 4 for IgG and α-H3K27me3 samples) 
differentiated in normal medium, in ascites, or in normal medium followed by ascites for 1 day. Cells were stimulated with or without LPS and IFNγ (+) or their 
respective solvents (−) 2.5 h prior to harvesting. Genomic regions were amplified by specific primers are indicated. Each dot denotes a biological replicate; for each 
replicate, MDMs from six donors were pooled after harvesting of the cells for each experiment. Median values are indicated by horizontal bars. Colors encode 
ascites samples from individual patients, and colors are consistent between panels within this figure, Figure 5 and Figure S9 in Supplementary Material. Statistical 
significances were calculated with paired t-tests. **P < 0.01; all other analyses did not show significance (P > 0.05).
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20 kbp downstream of the TSS. For further analyses, we focused 
on elements that harbor repressive marks (regions III: −1,200 bp 
and IV: +20 kbp) as well as the TSS. The observed enrichment of 
H3K4me3 and H3K27me3 at these elements was confirmed by 
ChIP-qPCR in a different TAM sample (Figures 4B–D).
Using ChIP-qPCR, analysis of the chromatin marks H3K4me3, 
H3K27ac, and H3K27me3 was performed in MDMs differentiated 
in normal medium, in ascites, or in normal medium followed by 
exposure to ascites for one day in order to measure possible changes 
upon short-term and long-term suppression (Figures 4E–G). Cells 
were stimulated with LPS and IFNγ 2.5 h prior to fixation; at this 
time point, REL and p65 were detected in the nucleus (Figure 3; 
Figure S2B in Supplementary Material), and IL12B transcripts 
were detectable shortly thereafter (Figure S2A in Supplementary 
Material). The observed relative levels of the analyzed histone 
modifications generally mirrored the observations made in TAMs 
(Figures 4B–D), with absolute recoveries in MDMs being higher 
due to lower cell numbers that were obtained from MDM cultures 
in comparison to TAMs from large volumes of ascites. H3 lysine 
4 trimethylation levels did not change consistently; at the TSS, 
levels were low but uniformly increased upon stimulation with 
LPS and IFNγ. At the IL12B TSS, the H3 lysine 27 acetylation 
signal increased consistently (Figure 4F) upon stimulation, and 
this was statistically significant in the short-term ascites-exposed 
population. Mean H3K27me3 signals at the TSS of IL12B were 
slightly elevated in MDMs exposed to ascites. The difference did 
not reach statistical significance. Upon stimulation, α-H3K27me3 
signals were slightly diminished at the IL12B TSS (Figure 4F). 
This might reflect a decreased interaction between the TSS and the 
downstream putative silencer element at +20,000 bp, where robust 
enrichment of H3K27me3 was detected (Figure 4G). In summary, 
it seems plausible that the region IV downstream site and the 
TSS/−1,200 bp regions are in spatial proximity to each other, and 
H3K27me3 at the TSS might possibly be elevated after exposure to 
ascites. However, we cannot rule out that H3K27me3-dependent 
mechanisms are dispensable for suppression of IL12B due to the 
observation that enrichments by α-H3K27me3 at the TSS was 
only mildly elevated in MDMs exposed to ascites relative to the 
control population. The identified putative regulatory elements at 
the IL12B and CXCL10 loci are candidate regions for assessing 
binding of transcription factors that regulate IL12B expression.
3.6. Inducible REL and p65 Binding to 
Chromatin Is Not Impaired in MDMs 
Exposed to Ascites
REL and p65 binding was measured (Figures 5A–C) in the same 
samples as in Figures 4E–G (identical data for IgG samples are 
shown). An enrichment with antibodies against each transcrip-
tion factor was induced in the control population after stimulation 
at IL12B −1,200 bp (Figure 5A). Surprisingly, in the short-term 
ascites exposed population, REL and p65 were recruited to a 
similar extent at the −1,200 bp site of IL12B, while long-term 
exposure to ascites led to reduced but measurable recruitment. 
No recruitment was observed at the TSS and at +20,000  bp 
(Figures  5B,C). This indicates that chromatin binding of the 
NFκB transcriptional activators is functional in the presence of 
ascites despite their strongly impaired translocation (Figure 3). 
Notably, at the CXCL10 locus, where REL and p65 recruitment 
was detected at both the TSS (Figure  5D) and an upstream 
element (Figure 5E), recruitment was enhanced by short-term 
ascites exposure but was unchanged after long-term exposure. 
These data show that, unexpectedly, nuclear REL and p65 levels 
are not measurably limiting for their binding to chromatin in 
MDMs exposed to ascites.
3.7. The Role of REL in the Induction  
of IL12B Expression
In order to clarify whether RNAi-mediated depletion of REL 
and p65 affects expression of IL12B, we employed knockdown 
approaches using siRNA in MDMs differentiated in normal 
medium. Functionality of the siRNA oligonucleotides was validated 
on protein level (Figure S8 in Supplementary Material). However, 
we were unable to achieve high knockdown efficiencies in pri-
mary macrophages, resulting in apparent protein levels of 60% 
relative to the control population or less. Knockdown of REL 
resulted in slightly diminished induction of IL-12p40 (Figure S7 
in Supplementary Material). In a murine Rel knockout model, 
induction was largely dependent on Rel (42). However, the effects 
we observed after RNA interference are mild, which we attribute 
to incomplete depletion of the target proteins and to the effect that 
transfection with control siRNA also led to a strong reduction of 
p40 expression in most experiments. We could not find an efficient 
transfection reagent that did not elicit this effect, even in the absence 
of siRNA oligonucleotides (data not shown). In one of the MDM 
populations analyzed, IL12B expression was affected neither by 
REL knockdown nor by p65 knockdown (blue dots, Figure S7 in 
Supplementary Material) despite a measurable reduction of their 
protein levels, and in another sample, induction was increased 
after knockdown of p65 (black dots, Figure S7 in Supplementary 
Material). This prompted us to use a different experimental system 
in which Rel is genetically deleted. When we stimulated murine Rel 
knockout bone marrow-derived MDMs (BMDMs) with LPS and 
IFNγ, induction of Il12b (Figure 6A) as well as p40 (Figure 6B) 
was reduced to about 20% of the levels generated by wild-type 
cells, as it was similarly shown by others previously. These data 
suggest that REL is important but not necessary for IL12B induc-
tion. Indeed, it was observed previously by others that Rel-deficient 
murine antigen-presenting cells can produce IL-12p40 to a highly 
varying extent depending on the tissue they were isolated from 
Ref. (64). The function of REL is conceivably supplemented by and 
partially redundant with that of p65, as it was noted before (42, 65). 
The mild effects we observed after siRNA-mediated partial deple-
tion are in line with the notion that levels of REL and p65 are not 
limiting for target gene induction in MDMs.
3.8. IL-10 Is Not Sufficient to Suppress 
Il12b Expression
The inability of MDMs to synthesize IL-12p40 after exposure 
to ascites could be explained by the negative effect of IL-10 on 
the translocation of REL and p65 (45–47) as well as its indirect 
actions via the induction of STAT3 target genes (23, 24, 66–68). 




FIGURE 5 | Continued
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with recombinant IL-10 from human cells in parallel with LPS and 
IFNγ did not recapitulate full suppression of IL-12p40 produc-
tion (Figure 7B) and was unable to shut off IL12B transcription 
(Figure  7A) in cells from all but one donor. Importantly, the 
effects of partial suppression were highly significant on both 
mRNA (Figure 7A) and protein levels (Figure 7B), indicating 
A B
FIGURE 6 | The role of Rel in the induction of Il12b expression. Murine Rel 
knockout BMDMs or wild-type BMDMs (N = 2 each) were differentiated 
in vitro and stimulated with LPS or LPS and IFNγ for 24 h. Cells were used 
for RT-qPCR analysis of Il12b (A), and Il-12p40 was measured in 
supernatants by ELISA (B); n.d., not detected.
E
FIGURE 5 | Inducible REL and p65 binding at the IL12B and CXCL10 loci in MDMs. (A–E) ChIP-qPCR analyses of REL and p65 binding in chromatin preparations 
from MDMs differentiated in normal medium, in ascites, or in normal medium followed by ascites for 1 day were conducted. Cells were stimulated with or without 
LPS and IFNγ (+) or their respective solvents (−) 2.5 h prior to harvesting. Genomic regions were amplified by specific primers are indicated. The same samples 
were used as in Figure 4 (N = 4). Each dot denotes a biological replicate; for each replicate, MDMs from six donors were pooled after harvesting of the cells. 
Median values are indicated by horizontal bars. Colors encode ascites samples from individual patients, and colors are consistent between panels within this figure, 
Figure 4 and Figure S9 in Supplementary Material.
13
Unger et al. Macrophage IL12B Suppression by Ascites
Frontiers in Immunology | www.frontiersin.org June 2018 | Volume 9 | Article 1425
that the recombinant IL-10 was functional. MDMs from some 
individual donors were affected more than others, demonstrating 
that the amplitude of suppression is donor-dependent to a large 
extent. We conclude that other ascites-borne factors are necessary 
for full suppression of IL12B.
4. DISCUSSION
Our data suggest that (1) suppression of IL12B transcription 
by ovarian carcinoma ascites acts immediately and on dif-
ferentiated macrophages, and it is reversible upon ascites 
withdrawal; (2) although ascites impinges on REL and p65 
nuclear translocation, binding of these factors to chromatin is 
not diminished; and (3) IL-10 can only partially recapitulate 
suppression. This implicates that soluble factors in ascites may 
act combinatorially to achieve rapid, gene-specific suppression 
of IL12B transcription.
4.1. Reversibility and Immediacy of 
Ascites-Mediated IL12B Suppression
Immediately after ascites exposure, IL12B transcription was 
largely abrogated in MDMs simultaneously stimulated with LPS 
and IFNγ (Figure 2A). IL12B mRNA inducibility was partially 
restored in cells from all donors after ascites withdrawal. These 
data indicate that, while suppression is rapid, its effects are not 
permanent in cells exposed to ascites for 24 h. Additional post-
transcriptional mechanisms negatively affecting p40 synthesis are 
likely (Figure 2B). Importantly, some MDM cultures retain the 
ability to secrete measurable amounts of p40 in the presence of 
ascites, and this apparently depends on both the donor and the 
ascites used. Ascites withdrawal further attenuates suppression 
(Figures 2A–D).
In line with reversibility of IL12B suppression, the transcript 
was detected in most ex vivo TAM samples in the absence of ascites 
(Figure 1A). IL12B expression reached levels similar to those in 
TAMs cultivated in ascites in the presence of IFNγ. Furthermore, 
exposure to ascites does not immediately induce macrophage 
M2 marker expression in MDMs (Figure S3 in Supplementary 
Material), an observation which is compatible with a model of 
transient suppression by ascites.
As mentioned before, our data indicate that biological varia-
tion is high among both donor cells and ascites samples, which 
agrees with our finding that, on transcriptome level, TAMs from 
OC patients can be clustered into two groups which differ in the 
expression levels of interferon-responsive genes. Higher expres-
sion of these genes is positively correlated with patient survival 
(7). From a therapeutical perspective, it might be beneficial to 
determine genetic predispositions and environmental factors 
involved in ascites-mediated suppression of IL12B.
4.2. Restrainment of NFκB by Ascites  
Is Not Complete
Ascites-exposed MDMs show strongly reduced REL and p65 
nuclear translocation (Figure  3), yet chromatin binding of 
A B
FIGURE 7 | IL-10 is not sufficient to suppress IL12B induction in MDMs. MDMs were differentiated in R5 medium for 6–7 days and stimulated with LPS and IFNγ, 
with recombinant IL-10 from human cells, or both for 24 h. (A) IL12B expression was measured by RT-qPCR (N = 11). (B) IL-12p40 in culture supernatants (N = 9) 
was measured by ELISA. Each square denotes a biological replicate (individual healthy donor). Colors encode individual healthy donors, and colors are consistent 
between panels within this figure. Median values are indicated by horizontal bars. Statistical significances were calculated with paired t-tests. **P < 0.01; ***P < 0.001.
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these factors is functional (Figure 5). Additionally, after short-
term ascites exposure, REL and p65 translocation was not fully 
impaired in most samples (Figures 3B,D). In conclusion, nuclear 
REL and p65 levels after stimulus-dependent translocation 
are sufficient for saturation of their binding sites at the IL12B 
and CXCL10 loci regardless of ascites-mediated reduction of 
nuclear translocation. Consistent with this, siRNA-mediated 
partial depletion of REL or p65 did not significantly influence 
IL12B induction (Figure 6A). However, it cannot be excluded 
that reduced binding of REL proteins to sites with lower affinity 
than at the IL12B and CXCL10 loci has an indirect impact on 
IL12B transcription, e.g., by affecting the expression of a gene-
specific coactivator.
Interestingly, IL-10 was reported to selectively inhibit expres-
sion of a subset of LPS-inducible genes in murine macrophages 
in the absence of endogenous IL-10, and Il12b was among the 
most strongly downregulated transcripts (69). Gene-specific 
mechanisms offer a conclusive explanation why other NFκB 
targets such as CXCL10 are not suppressed by ascites (Figure 
S6 in Supplementary Material). Unaltered occupancy of REL 
and p65 at both the IL12B and CXCL10 loci in the presence 
of ascites (Figure 5) strongly suggests that these gene-specific 
mechanisms do not affect NFκB chromatin binding. Induction 
of CXCL10 expression depends on IFNγ, its receptor and STAT1 
(70, 71), and also on NFκB (72). These factors are likewise 
required for IL12B expression. Induction of IL12B by LPS and 
IFNγ is not functional in MDMs exposed to ascites (Figure 2), 
while induction of CXCL10 is (Figure S6 in Supplementary 
Material). CXCL10 is expressed in ex vivo TAMs, while IL12B 
is not (7). The two genes are presumably not regulated by differ-
ential NFκB and STAT1 recruitment to chromatin in the pres-
ence of ascites. Gene-specific posttranslational modifications 
of transcription factors, availability of coactivators, regulation 
of DNA looping involving the region IV putative silencer ele-
ment, or a repressor which does not affect the marks we used 
to characterize the chromatin state of IL12B may be involved 
in suppression.
4.3. The Role of IL-10 in IL12B 
Suppression
A plethora of studies ascribe a major role to IL-10 in the 
maintenance of homeostasis, including the prevention of IL-12 
production via multiple mechanisms (23, 24, 39, 43, 45–47, 67, 
68, 73). Our observation that IL-10 does not fully recapitulate 
ascites-mediated suppression of IL12B in  vitro in cultures 
from most donors suggests that additional suppressive factors 
might be lacking. In addition to IL-10, prostaglandin E2 (73), 
phosphatidylserine (74), adenosine (75, 76), lysophosphatidic 
acid (33), polyunsaturated fatty acids (77), and α-fetoprotein 
(78, 79) were described to downregulate IL-12 production. 
Potential targets of soluble factors could be upstream signaling 
components, transcription factors, or cofactors.
In murine alveolar macrophages, the E3 ubiquitin ligase Trim29 
was found to negatively regulate the host response after bacterial 
infection. Trim29, which is exclusively expressed in alveolar mac-
rophages, can induce degradation of the Ikk regulatory subunit 
(80). This highlights a paradigm for tissue-specific regulation 
of the pro-inflammatory response. Analogously, the expression 
of a regulator impinging on IKK function could conceivably be 
modulated by soluble factors from ascites. A corepressor which 
suppresses Il12b expression in murine macrophages is Smrt (81). 
The study elucidates that the closely related proteins Ncor and 
Smrt can differentially repress sets of target genes. Il12b was 
repressed by Smrt exclusively, and Smrt could be displaced from 
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the locus by IFNγ treatment. It is conceivable that ascites-borne 
soluble factors stablize SMRT or another gene-specific corepres-
sor at the IL12B locus, since the expression of CXCL10 is not 
suppressed by ascites. Transcription factors described to repress 
IL12B expression such as Nfil3 in mice (24) or c-MAF (82) might 
contribute to the establishment of a locus-specific repressive 
complex.
Intriguingly, the levels of IL-10 as well as those of arachidonic 
acid in ascites are negatively correlated with patient survival 
according to our previous studies, and IL-10 and arachidonic acid 
levels are synergistically correlated with poor prognosis (21). This 
suggests that IL-10 alone is not sufficient to exert its full pro-tumo-
rigenic effect in vivo. We postulate that other factors are required in 
addition to IL-10 for the suppression of a pro-inflammatory, anti-
tumorigenic macrophage phenotype that includes expression of 
IL-12p40. Imbalances of this postulated interplay which are inte-
grated into deregulated IL12B expression might be involved not 
only in tumorigenesis but could also contribute to diseases with an 
autoimmune component (26, 27). Future studies will investigate 
putative combinatorial suppressive mechanisms using a panel of 
purified factors.
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Supplementary Material:
Chromatin binding of c-REL and p65 is not limiting
for macrophage IL12B transcription during
immediate suppression by ovarian carcinoma
ascites
FIGURE CAPTIONS
1. Pretreatment with IFNγ does not lead to elevated p40 synthesis by MDMs cultivated in RPMI
supplemented with adult human serum. MDMs were differentiated for 6–7 d in RPMI 1640 media
supplemented with 5 % adult human AB serum (R5) and treated with IFNγ for the indicated periods of
time prior to stimulation with LPS and IFNγ together or with vehicle for 24 h. IL-12p40 concentrations
in culture supernatants were measured by ELISA. Two biological replicates denoted by colored
symbols are shown.
2. Kinetics of IL12B induction and REL nuclear translocation in MDMs. MDMs were differentiated
for 6–7 d in R5 media and incubated with vehicle or LPS and IFNγ for the indicated periods of time.
(A) RT-qPCR was used to measure IL12B transcript levels (N=2). Dots represent mean values. (B)
REL localisation was detected by immunoblotting after subcellular fractionation. LDH and acetylated
histone H3 were used as both loading and fractionation controls. CE, cytoplasmic extract; NE, nuclear
extract.
3. Macrophage M2 surface markers do not reflect immediate suppression of IL12B by ascites. MDM
cultures (N=6) were differentiated in R5 media, in ascites, in ascites in the presence of 50 ng/ml
recombinant for 7 d, or in R5 media for 6 d followed by ascites for 1 d. Cells were analysed by flow
cytometry using α-CD163 (A) and α-CD206 (B) as probes. Data were plotted as percentage of positive
cells or MFI (mean fluorescence index) as indicated. Each color denotes an individual donor, and donor
MDMs were randomly combined with different ascites samples. Horizontal bars denote median values.
4. Degradation and translocation of NFκB pathway components (representative immunoblots). MDMs
were differentiated in R5 media or in ascites and cultivated consecutively as indicated. Cells were
incubated with vehicle or LPS and IFNγ for 2.5 h. (A) Whole-cell lysates were blotted, and membranes
were probed with antibodies against IκB proteins as indicated. β-actin was used as a loading control.
Relative calculated protein amounts are included in the panel. One representative blot is shown. (B,C)
Cellular fractions were blotted, and membranes were probed with antibodies against REL or p65. LDH
and acetylated histone H3 were used as both loading and fractionation controls. Relative calculated
protein amounts are included in the panel. One representative blot is shown. CE, cytoplasmic extract;
NE, nuclear extract.
5. Stimulus-dependent protein levels of IκBα, β and ε are not differentially affected upon exposure to
ascites. (A–C) MDMs were differentiated in R5 media or in ascites and cultivated consecutively as
indicated. Cells were incubated with or without LPS and IFNγ for 2.5 h, harvested and lysed. After
immunoblotting of whole cell lysates, levels of IκB family members α (A, two biological replicates),
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β (B, three biological replicates) and ε (C, three biological replicates) relative to the corresponding
unstimulated sample were determined. Mean values are indicated by horizontal bars.
6. Induction of CXCL10 expression is not prevented in the presence of ascites. CXCL10 expression was
measured by qRT-PCR in a subset of samples shown in fig. 2. MDMs were differentiated in R5 media
or in ascites and cultivated consecutively as indicated. Stimulation was with LPS and IFNγ for 24 h
prior to harvesting. Each symbol denotes a biological replicate (MDM donor). (A) Induction after
differentiation in normal media, after short-term exposure to ascites, and after short-term exposure
and withdrawal as indicated (N=4), samples correspond to fig. 2A. (B) Induction after differentiation
in normal media, after long-term exposure to ascites, and after long-term exposure and withdrawal
as indicated (N=3; cells from each donor were exposed to 1–3 different ascites samples as indicated;
samples correspond to fig. 2C). Colors encode ascites samples from four (panel A) or three (panel
B) different patients; shapes encode different healthy donors. The code is consistent with fig. 2A,C.
Median values are indicated by horizontal bars. Statistical significances were calculated with paired
t tests; *, p<0.05; ns, not significant.
7. MDMs differentiated in R5 media for 6–7 d (N=3) were transfected with siRNA as indicated, incubated
for 24 h, stimulated with or without LPS and (+) or their respective solvents (vehicle; −) for an
additional 24 h, and IL12B expression was measured by RT-qPCR. Black dots, Viromer transfection
reagent; blue and green dots, Trans-IT X2 transfection reagent. Median values are indicated by
horizontal bars. Each dot denotes a biological replicate. Statistical significances were calculated with
paired t tests; ns, not significant (p>0.05).
8. Functionality of siRNA sequences on protein level (representative immunoblots). MDMs were
differentiated for 6–7 d in R5 media. Cells were transfected with siRNA as indicated and incubated
for 48 h. After immunoblotting of whole cell lysates, relative REL and p65 levels were calculated
using LDH as a loading control. Relative calculated protein amounts are included in the panel. One
representative blot is shown.
9. Chromatin marks at the IL2 and CXCL10 loci in TAMs and MDMs. (A,B) Genome browser snapshots
including ChIP-seq tracks for α-H3K4me3, α-H3K4me1, α-H3K9me3, α-H3K27me3, α-C/EBPβ,
α-H3K27ac, α-H3K36me3, IgG (unspecific polyclonal rabbit IgG pool) and MIRA from a TAM
sample freshly isolated from ovarian carcinoma ascites encompassing the IL2 (A) and CXCL10 (B)
genes. Regions of interest are highlighted with rectangles. (C,D) ChIP-qPCR analyses of the indicated
histone marks in MDMs differentiated in normal media, in ascites, or in normal media followed by
ascites for 1 d (the same samples as in figs. 6 and 7 are shown). Primers for the CXCL10 5000 bp
upstream region (C) or the CXCL10 TSS (D) were used, respectively. Each dot denotes a biological
replicate (N≥3); for each replicate, MDMs from six donors were pooled after harvesting of the cells.
Median values are indicated by horizontal bars. Colors encode ascites samples from individual patients,
and colors are consistent between panels within this figure and figs. 6 and 7.
10. Original immunoblot images used for compilation of fig. 3. Please note that some of the blots are also
shown in fig. S4. MDMs were differentiated in R5 media or in ascites and cultivated consecutively as
indicated. Cells were incubated with vehicle or LPS and IFNγ for 2.5 h. Cellular fractions were blotted,
and membranes were probed with antibodies against REL or p65. LDH and acetylated histone H3 or
lamin B were used as both loading and fractionation controls. Relative calculated protein amounts are
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Figure S10: Original immunoblot images used for compilation of fig. 3.
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